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Chapter 1 
Introduction 
 
1.1 Nanotechnology for bioanalytical applications 
Nanotechnology is a well-established and fast growing discipline that has generalized 
applications in health, environmental and social field. In the last decade, nanotechnology 
has become extraordinarily important because manages to combine materials, properties 
and purposes to develop multimaterial, multimodal and multitarget nanoplatforms to 
overcome present unresolved problems.1   
In particular, the advent of nanotechnology enables modern medicine to have great 
improvements in strategies that merge both diagnosis and therapeutics,2,3 referred to as 
theranostics.4,5 In this context, the design of devices suitable for in vivo applications must 
carefully consider some requirements, such as stability, toxicity,6 time of clearance and 
output signal reliability.7 It is possible to achieve these last parameters by using 
exogenous chemical contrast agents (CA), allowing non-invasive imaging approaches that 
are valuable in diagnostics and in medical treatments such as drug delivery and therapy 
monitoring;8 consequently, the development of new contrast agents with increased 
sensitivity and specificity is a crucial issue for in vivo imaging.9  
Nanoprobes that are suitable for targeting and compatible with different imaging 
techniques have emerged as promising tools in recent research.10-13 Modern medical 
imaging techniques - such as magnetic resonance imaging (MRI),14 computed X-ray 
tomography (CT),15 positron emission tomography (PET),16 single-photon emission 
computed tomography (SPECT)17 and ultrasound imaging (US)18 - have already a large 
clinical application and differ in basic peculiarities such as costs, time of analysis and 
resolution (Table 1.1). Synergy between the various techniques (by using multimodal 
approaches) appears to be the best solution to overcome limitations in getting 
comprehensive imaging, since each individual method has its pros and cons.19  
Among the various techniques listed above, we will focus particularly on Optical (OI)13 and 
photoacoustic imaging (PAI)20, which have limited clinical applications nowadays but are of 
considerable scientific interest21,22 because of their high sensitivities and short time of 
measurements, accompanied by low operating costs. In addition, compared to other 
imaging techniques, OI displays a reduced resolution, but it has the advantage of being 
suitable not only for diagnostic purposes but also for therapeutic treatments, such as the 
Photodynamic (PDT)  and Photothermal (PTT) therapy.23-27  
OI and PAI show low investigation depth (< 20 mm for OI and ~ 60 mm for PAI), which is 
their main limitation for in vivo applications in the Ultraviolet-Visible (UV-Vis) spectral 
range; indeed, in such a range absorption, autofluorescence and scattering of tissues limit 
the propagation of the excitation and, when relevant, emission radiation. It is possible to 
2 
 
partially overcome these problems using probes that exploit near-infrared (NIR) light, 
especially in the spectral range between 700 and 1000 nm.28,29 To better analyze this 
concept, it is useful to know that hemoglobin and water are the major photon absorbers in 
living tissues. The highest absorption coefficient for hemoglobin is present within Vis 
wavelengths, while for water is present within UV and infrared wavelengths. In contrast, 
hemoglobin, water, lipids and other endogenous chromophores, such as melanin, have 
their lowest absorption coefficient within the NIR spectrum which allows increased photon 
depth penetration into tissues.28-30 
 
Table 1.1 Main imaging techniques and their fundamental features, as in reference 19. 
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1IT=imaging techniques. Colors were used to indicate the clinical translation of main imaging techniques. 
Green=yes; yellow=no; red=partial. 2Spatial resolution in experiments with small anaimals. In the case of 
clinical applications a resolution decrease of a factor varying from 2 to about 10 usually takes place. 3IO=Iron 
Oxide; 4H=High; M=Medium; L=Low. 
 
Between the huge variety of new materials that nanotechnology has suggested in recent 
decades, nanoparticles are, without doubt, those that are most used and versatile. 
Moreover, self-organizing synthetic strategies managing to implement these 
nanoplatforms, produce materials suitable for complex functions.31-36 For these reasons, 
nanoparticles will have a key role in the course of this thesis, as will be explained in the 
next section. 
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1.2 Aim of the work 
The aim of this thesis is to design, synthesize and characterize systems based on 
luminescent nanoparticles to be exploited as chemosensors or as labels for 
bioapplications.  
A chemosensor is a device that combines three different components: (i) a recognition site 
(or receptor), able to molecular recognize the analyte; (ii) a signaling unit, apt to transform 
the molecular recognition into a detectable signal37-39 and, in most cases, (iii) a linker to 
separate spatially the receptor and the analyte. A label is a device that provides a 
detectable signal, leading to the spatial and temporal collocation of an analyte.40-42 Unlike 
the previous case, the signaling unit does not depend on the recognition event (Figure 
1.1). 
 
 
Figure 1.1 Schematic representation of a luminescent chemosensor (A) and label (B). 
 
Between the different imaging approaches suitable for bioanalytical applications, 
luminescence - and, especially, fluorescence - based techniques are particularly of interest 
to collect molecular level information about biologically relevant processes, because of 
their versatility, capacity to allow spatial and temporal resolution and low costs.37,43-45 In 
the next section the basics of fluorescence will be introduced, focusing on the essential 
parameters to be considered for the design of fluorescent nanoprobes. 
 
 
B A 
Analyte
Receptor
Linker
Signaling unit
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1.3 Fluorescence 
1.3.1 Photophysical processes 
Light excitation with a photon (hν) of suitable energy leads to the promotion of a molecule 
from its ground state (A) to an electronically excited state (A*) (Figure 1.2).  
 
 
Figure 1.2 Schematic representation of essential steps of the light-molecule interaction. 
 
Due to their high-energy content, electronically excited states are metastable and in a 
short period of time are subjected to deactivation; this process takes place following three 
main pathways: 
1) Photochemical reaction: it is a reaction induced by the light that leads to the formation of 
other species (P). 
2) Nonradiative deactivation: the excess energy is dissipated as heat due to collision with 
other surrounding molecules, especially those of the solvent. 
3) Radiative deactivation: the return of the molecule to its ground state is accompanied by 
the emission of a photon. 
An energy diagram, commonly known as Jablonski diagram, is used to represent the 
photophysical processes which affect the ground and the excited states of a molecule 
(Figure 1.3). 
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Figure 1.3 Schematic representation of simplified Jablonski diagram for a generic organic 
fluorophore. 
 
In such a diagram, the electronic states are depicted as thick horizontal lines and their 
relative energies are positioned in vertical order. The transitions between states are 
depicted as vertical lines and occur in a time (about 10-15 s) too short for noticeable 
displacement of nuclei, as inferred from the Franck-Condon principle. Vibrational levels are 
shown by thin lines while, for clarity, rotational levels are not indicated. Radiative 
transitions, relative to the absorption or emission of a photon, are shown by straight 
arrows, while radiationless transitions are represented by wavy arrows.  
The ground state is assumed to be a singlet and depicted as S0, as for many organic 
fluorophores, while S1 and S2 are the excited states with its same spin multiplicity. For 
clarity, only the first tripled excited state, T1, is shown.  
Light absorption commonly generates the excited state in a high vibrational level. The 
molecules tend to dissipate their excess vibrational energy by collisions with surrounding 
molecules in a very fast process (about 10-12 s) called vibrational relaxation. Radiationless 
transitions among states of equal spin multiplicity (S2 and S1, for example) are called 
internal conversion, that generally occur within 10-12 s or less and are immediately followed 
by vibrational relaxation.  
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The excited molecule can return to the ground state following the internal 
conversion/vibrational relaxation pathway, or through a radiative transition associated with 
the emission of a photon, known as fluorescence. Given that fluorescence is a slower 
process (10-9-10-6 s) than those previously cited, it can generally be observed only from 
the lowest vibrational level of S1 (Kasha’s rule):46 it follows that fluorescence spectrum is 
typically the mirror image of the of the S0    S1 transition. Because of the loss of energy due 
to vibrational relaxation, the energy of the emission is less than that of absorption: 
consequently, fluorescence typically occurs at lower energies (or longer wavelengths). 
Molecules in the S1 state can also be subjected to a spin conversion to the first triplet state 
T1, through intersystem crossing, i.e., a non-radiative transition between states of different 
spin multiplicity; this transition is theoretically forbidden by the spin electron rule but can be 
promoted, through the spin-orbit coupling, in molecules containing halogens47-49 or in 
transition metal complexes.50-52 Emission from T1 is termed phosphorescence (10-2-102 s) 
and is commonly shifted to longer wavelength compared to fluorescence; however, it is 
rare to observe phosphorescence at room temperature due to the predominance of 
accessible non-radiative pathways. 
 
1.3.2 Fluorescent nanoparticles 
Luminescence is a very sensitive technique that allows the detection down to single 
molecule detection and offers submicron visualization and sub millisecond temporal 
resolution. Systems that used luminescence-related techniques13,53-55 to collect molecular 
level information about biologically relevant processes could overcome many of the typical 
limitations of conventional luminophores - organic dyes (Figure 1.4) - such as poor 
photostability and water solubility, low quantum yield and aggregation under physiological 
conditions. 
 
 
 
A B C 
C D E 
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Figure 1.4 Chemical structures of (A) rhodamine-B, (B) cumarine, (C) squaraine, (D) 
cyanine, (E) BODIPY and (F) fluorescein derivatives. 
In this context, nanotechnology leaded to the design of platforms taking advantage of 
many classes of nanoparticles - organic, inorganic and metallic - which are currently used 
as fluorescent emitters, each presenting its own pros and cons. Luminescent dye-doped 
latex nanoparticles56,57 or intrinsically luminescent nanomaterials,12 like quantum dots 
(QDs) are broadly studied.58-67  
In particular, dye-doped silica nanoparticles are a very successful example, and in the next 
paragraph we will describe their principal features and bioanalytical applications. 
 
1.4 Dye-doped silica nanoparticles  
Dye-doped silica nanoparticles (DSNPs) offers all the necessary features to develop 
impactful tools for diagnostic and theranostic applications;13,32,37,42,68-72 indeed, their 
synthetic versatility leads to the achievement of multifunctional targeted nanosystems 
(Figure 1.5). A fine control of functionalization can produce important consequences: (i) 
the improvement of specific binding by the target sites;73,74 (ii) the decrease in nonspecific 
interactions;9,75 (iii) the enhancement of internalization by cells that overexpress the target 
receptor;76 (iv) the limitation of capture by macrophages of the reticuloendothelial system 
(RES),77 increasing the blood circulation times.78  
The advantages of DSNPs are due to their convenient use as fluorescent probes for 
applications ranging from biosensors38,79 to interfacial interaction studies such as 
immunoassays,80 multiplexed nucleic acid analysis81,82 and drug delivery.83  
 
 
Figure 1.5 Schematic representation of DSNPs as multifunctional system for 
nanomedicine as in reference 59. 
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The methods to synthesize DSNPs are very versatile - allowing the control over the 
architecture of the resulting materials - and share fundamental features such as simplicity, 
low costs and trouble-free disposal; a more detailed description of the synthetic methods 
will be performed in Chapter 2. 
Materials suited to bioanalysis must be non-toxic, (photo)chemically stable and 
biocompatible. For the reasons expressed above, the toxicity of SNPs is a key topic that is 
inserted into the more general issue of the potential risks, for both humans and the 
environment, associated with nanomaterials. The uptake, persistence, transformation and 
excretion of silica-based nanoparticles are under investigation nowadays.84 The lack of 
complete understanding of their in vivo toxicity and distribution makes human clinical trials 
not very common, despite the fact that these nanomaterials are of increasing interest in 
bioapplications. To confirm this trend, most SNPs-based systems for drug-dye delivery are 
still in the preclinical development stage. Appropriate answers to these problems require a 
thorough analysis of several parameters - such as different design, dimensions and 
charges70,85,86 - which can result in a different toxicity; for this reason the accurate 
characterization of SNPs is a prerequisite for the toxicity assessment.87 In vitro assays are 
widely used to assess the toxicity, as they are inexpensive, easy and reliable;88,89 on the 
contrary, in vivo tests90-93 are much less frequently reported, making the study of long-term 
effects, retention and excretion incomplete.40,54,70,94,95 However, in this complicated 
scenario we can say that the evidence obtained so far demonstrated that (i) silica does not 
show intrinsic toxicity and is not subjected to microbial attack and (ii) DSNPs does not 
exhibit appreciable toxicity in different relevant cell models.40 These data support the safe 
use of these nanoplatforms for diagnostic and therapeutic applications. 
To be more specific regarding the features possessed by luminescent silica nanoparticles, 
we should start from the intrinsic properties of silica, which is photophysically inert; 
therefore, the photophysical properties of the final platforms are given by the doping and/or 
the capping agents. Each DSNP may contain many dyes and consequently shows 
extremely high extinction coefficient, since its total value is equal to the sum of those of the 
individual chromophore.31,32,37 In addition to that, the inclusion in the silica matrix supplies 
a constant chemical environment to active species and protects from external chemicals, 
leading to (i) the decrease in the probability of unwanted photoreactions and (ii) the 
increase in the photostability of the system.96 Doping species are responsible for the 
emission properties of DSNPs, with effects due not only to their own features, but also to 
their potential cross-interactions. By means of classic photophysical techniques - such as 
fluorescence anisotropy and steady-state and time-resolved fluorescence - it is possible to 
obtain information on the distance and communication among the active species, on their 
rotational mobility and on the effect of signal amplification. These data, for example, are of 
interest to the evaluation of homo-energy transfer processes, as they can cause unwanted 
self-quenching phenomena; nevertheless, Genovese et al. showed that they can be 
exploited to make the excitation energy available for the final processes of interest, thus 
increasing the signal amplification effect.97 Otherwise, if DSNPs are loaded with different 
dyes, the possible hetero-energy transfer processes can be promoted to obtain 
nanoparticles suitable for multiplex Förster resonance energy transfer (FRET) bioassays, 
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because of a high fluorescence intensity, wide absorption and large Stokes shift,45,98 i.e., 
the difference among the first absorption band and the maximum of the fluorescence 
spectrum. On the other hand, with a convenient design, hetero-energy transfer processes 
can also be intentionally avoided, leading to ratiometric systems.99,100  
At the beginning of this section, we have presented the versatility of DSNPs as the starting 
point for exploring their promising developments. At this point, it is important to underline 
that versatility is intrinsic to luminescence spectroscopy; indeed, in addition to the 
luminescent parameters exploited for monitoring the target species43 - such as intensity, 
anisotropy, emission and excitation spectra and excited state lifetime - the different origins 
of the luminescent process can introduce another element of versatility. In particular, the 
generation of luminescence without photo-excitation leads to higher sensitivity due to the 
increased signal-to-noise ratio; the most commonly exploited techniques are those that are 
able to generate luminescence from electrogenerated species in solution, namely 
chemiluminescence (CL)101-103 and electrochemiluminescence (ECL).104,105 In this regard, 
it is important to note that ECL is regularly used for the quantification of biomolecules and 
ECL nanoprobes are quickly increasing in number and complexity.35,36,106 We also want to 
emphasize the promising prospects offered by thermochemiluminescence (TL), where the 
excited state is generated by the thermolysis of suitable molecules; it is a technique that, 
for the first time, has recently been used in combination with nanoparticles, providing 
encouraging results.34  
 
 
Figure 1.6 Schematic representation of derivatives used for: A) ECL, as in reference 106; 
B) TCL, as in reference 34. 
 
A more complete description of DSNPs will be discussed in the next chapter, concerning 
the common synthetic approaches to these materials. 
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Chapter 2 
Synthesis of luminescent silica nanoparticles 
 
2.1 Introduction 
The synthetic approaches in solution to perform silica nanoparticles (SNPs) are based on 
sol-gel processes, by using tetrahethoxysilane (TEOS) as their silica precursor.1 These 
methods share important features such as high versatility and reproducibility, low costs, 
mild synthetic conditions, control over the dimensional range of the resulting nanoparticles, 
and the possibility of choosing parameters such as catalytic conditions and the 
nanoparticle nucleation-growth confinement. 
These main synthetic methods are known as Stöber-Van Blaaderen, reverse 
microemulsion (also called “water in oil”)2-5 and direct micelles assisted methods2,6-8 and  
allow a great versatility in the design of SNPs. However, it is important to take into account 
the qualities and weaknesses of each synthetic strategy, since these features are 
transferred to the resulting nanostructures (Table 2.1).  
 
Table 2.1 Main fluorescent Silica nanoparticles synthetic methods: versatility (     = poor;  
            = very good). 
SNPs 
synthetic 
method 
Dimensional 
range 
Colloidal 
stability 
Dyes 
incorporation 
Surface 
modification 
Accessibility 
to hybrid 
systems 
Overall 
efficiency 
Stöber 
      
Reverse 
microemulsion 
      
Direct 
micelles 
      
 
In most cases the synthesis of luminescent SNPs relies on trialkoxysilane derivatized dyes 
which are covalently linked to the silica matrix, to avoid dye leaching in the external 
environment, to prevent dye toxicity and therefore to securely fix fluorescent emission due 
to SNPs in biological media.9,10 
The number of dyes which can be incorporated within a nanoparticle is a very important 
parameter: potential problems can be due to the dye solubility in the reaction medium, and 
to the difficulty of synthesis and purification of the trialkoxysilane derivatives. As a general 
indication, electrostatic interactions among the dyes and the silica core of SNPs promote 
the incorporation of positively charged molecules and inhibit the inclusion of negatively 
charged species. 
In the case of biomedical applications, the overall synthesis efficiency is an average of a 
large number of parameters such as the brightness of the system (concerning the dye 
incorporation), the surface derivatization (concerning the targeting, colloidal stability and 
behavior in biological environments), and the dimensional range. The spatial control over 
15 
 
nanoparticles components is often a priority to carry specific functions, especially in 
complex architectures. 
 
2.2 Stöber method 
This method exploits TEOS hydrolysis for the nanoparticle formation using ammonia as 
catalyst in an ethanol/water mixture. This synthetic procedure to obtain colloidal silica 
originates from a study of Kolbe and Stöber,11 then improved by Van Blaaderen using 
triethoxysilane (-Si) modified dyes, such as fluorescein isothiocyanate-Si9 and rhodamine 
B isothiocyanate-Si (Figure 2.1).10  
 
 
Figure 2.1 Synthesis of rhodamine B isothiocyanate-Si as in reference 10. 
 
With the Stöber-Van Blaaderen method, the achievable dimensional range - with one pot 
procedures - is quite large, spanning from 10 to several hundreds of nm. This approach 
requires mild conditions (Figure 2.2) and allows the control of dimensional range by 
varying concentrations and ratios of the components in the reactions mixture (TEOS, water 
and ammonia).12  
 
 
Figure 2.2 Schematization of the Stöber-Van Blaaderen method for the synthesis of SNPs 
as in reference 10. 
TEOS
NH3
EtOH
H2O
Purif.
Dye-Si(OEt)3 Targetting unit
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Alkoxysilane derivatized dyes are used in order to achieve the covalent doping of the 
SNPs, but some limitations may rise from their solubility in ethanol/water mixtures.10 The 
luminescence properties of these nanocolloidal systems are based on the mutual position 
of the dyes within the SNPs.13 Previous reports showed that alkoxysilane pyrene 
derivatives undergo to self-compartmentalization during NP nucleation and growth 
processes, which can lead to spontaneous core-shell structures (Figure 2.3).14 Two 
different modifications of the Stöber method have been developed:  
(1) the use of amino acids as the hydrolytic catalyst and a phase transfer approach to 
modulate the TEOS provision into the reaction medium.15 With this method it is possible to 
obtain very small nanoparticles (~ 10 nm) and multiple-shell monodisperse nanoparticles;  
(2) the strategy developed by Wiesner and co-workers, which exploit a heterogeneous 
nucleation process where dyes reach cores act as seeds in the nucleation process.16-18 
The luminescent silica NPs obtained in this way, called Cornell Dots (or C-Dots), have a 
core-shell structure that allows the control over NPs monodispersity and dimension and 
protect the dyes from the solvent, thus increasing their photostability.19-22 
 
 
Figure 2.3 Molecular structure of the pyrene derivative as in reference 14. 
 
Colloidal suspension obtained by the Stöber methods are stabilized by electrostatic 
repulsion, since the deprotonation of the Si-OH groups on the SNPs surface yield 
nanoparticles with very negative ζ-potential values. Furthermore, it is possible to 
functionalize these NPs by chemical modifications on Si-OH groups with additional 
alkoxysilane components for several applications; the occurrence of aggregation and 
incomplete passivation of the surface can make this process quite tricky. 
Purification steps are necessary to remove uncondensed dyes, catalysts, oligomers and, if 
necessary, to change suspending media. These processes may include precipitation-
centrifugation steps, ultrafiltration (UF), dialysis, size exclusion chromatography (SEC) and 
other instrumental techniques as FlFFF (Flow Field Flow Fractionation).23 The last three 
purification methods presented here are mild and contribute to preserve the SNPs 
monodispersity. 
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2.3 Reverse microemulsion method 
In this approach a Stöber process is carried out in a reverse microemulsion: a 
thermodynamically stable, isotropic, and transparent solution of hydrocarbon, water and 
surfactant. The water droplets in the reverse microemulsion act as nanoreactors in a 
continuous domain of hydrocarbon, where the hydrolysis and condensation processes, 
that form the SNPs, take place.24 Several synthetic protocols supply the nanoparticle 
synthesis and surface modification in the 15-200 nm dimensional range,2,25 which depend 
upon the surfactant type (Figure 2.4) and on the surfactant-to-water molar ratio.26 
Unfortunately, this approach is suitable for positively charged water soluble dyes (Figure 
2.5),3,27,28 which can be entrapped in the nanoparticle silica core by electrostatic 
interactions; this is a strong limitation for the incorporation of poorly water soluble or 
negatively charged dyes.  
 
 
Figure 2.4 Molecular structures of more common surfactants used in the reverse 
microemulsion synthesis of silica nanoparticles as in reference 2 (A, B, C and D) and in 
reference 3 (C). 
 
This approach is particularly useful for the synthesis of SNPs with a layer-by-layer 
structure, to develop hybrid structures by covering nanoparticles of other materials (Q-
Dots, metals, iron oxides, etc.) with a silica shell, and for the surface derivatization to 
increase the chemical stabilization or for bio-molecules targeting.29 
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Figure 2.5 Ru(II) complexes used in the reverse microemulsion synthesis of silica 
nanoparticles as in reference 2 (A) and in reference 3 (B). 
 
These derivatizations are obtained by subsequent addition of reactants within the 
microemulsion, without intermediate purification steps,2,25 which are necessary to remove 
the organic solvent and the surfactants from SNPs, and usually are carried through 
precipitation-centrifugation-sonication steps which can lead to irreversible aggregation 
among the nanoparticles (Figure 2.6).  
The addition of appropriate ratios of inert functional groups (e.g., methylphosphonate) to 
active functional groups (e.g., amino groups) to the surface of silica nanoparticles results 
in very negative ζ-potential values, which can minimize nanoparticles aggregation and 
nonspecific binding.25 
 
 
Figure 2.6 Schematization of the reverse microemulsion method for the synthesis of silica 
nanoparticles as in reference 3. 
 
2.4 Direct micelles assisted methods 
2.4.1 ORMOSIL nanoparticles 
With this approach the hydrolysis and condensation processes involving highly lipophilic 
silica precursors such as TEOS and organo-alkoxyilane take place in direct aggregates or 
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co-aggregates of surfactants in water. A large variety of dyes can be used to produce 
luminescent and very mono-disperse nanoparticles in water, with a dimensional range of 
10-60 nm; this features make this method versatile for the development of luminescent 
nanocolloids for in vivo and in vitro applications. 
This strategy has many advantages such as the possibility of using water as a solvent, and 
of lower surfactant (co-surfactant) quantities compared to the reverse microemulsion 
strategies. The direct micelles assisted methods differ from each other mainly in the 
molecular weight of the surfactant implicated in formation of the nanoparticles. Also in this 
case, SNPs purification procedures are necessary to remove silica oligomers, surfactants 
and dyes that have not been trapped in the particles. 
With this approach Prasad and co-workers have made many nanoparticles in the 20-30 
nm dimensional range that are often called ORMOSIL (Organic modified Silica), obtained 
using oil in water systems usually made by mixtures of surfactant, DMSO, 1-butanol and 
water.30-33 The hydrolysis of the lipophilic silica precursor triethoxyvinylsilane (VTES) is 
catalysed by addition of  (3-Aminopropyl)triethoxysilane (APTES) or ammonia, while the 
low molecular weight surfactants normally used are Tween 8034 or Bis(2-ethylhexyl) 
sulfosuccinate sodium salt (AOT).35-38 This SNPs have a certain degree of mesoporosity, 
due to the presence of the surfactant and to the low reticulation deriving from the 
trialkoxysilane precursor: for these reasons the covalent condensation of the doping 
agents (such as dyes39 and PDT agents35,40,41) is needed to avoid leaching from the 
particle.34,42 With the use of this strategy surface functionalization (-NH2, -COOH, -SH also 
together with polyethylene glycol (PEG) chains) is readily accessible and allows for 
conjugation with bioactive molecules (Figure 2.7).36,43,44 The incorporation of dyes, PDT 
agents, and the possibility of obtaining hybrid structures containing QDs45 and Fe3O4 
nanoparticles46 make the ORMOSIL particles very versatile platforms for multimodal 
imaging and the development of theranostic nanoprobes.  
 
 
Figure 2.7 Schematization of the direct micelles assisted method for the synthesis of 
ORMOSIL nanoparticles as in reference 40. 
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This last synthetic strategy can be used with high molecular weight surfactants, where the 
occurrence of entrapment-adsorption phenomena can cause the irreversible bond among 
the surfactant molecules and the silica matrix. Several groups took advantage of the 
template effect of high molar weight surfactants such as Pluronic F108 or Brij700 to obtain 
cross-linked micellar SNPs that have core-shell structures,7,47,48 or to tune the SNP size 
using an organic swelling agent, such as trimethylbenzene.49   
 
2.4.2 Pluronic F127 nanoparticles 
Our research group proposed a strategy to obtain luminescent core-shell silica-PEG 
nanoparticles6 which can be employed in several fields such as photophysical studies,50 
live cells fluorescence imaging,51 in vivo imaging,52 electrochemiluminescence (ECL) 
applications7,53 and chemical sensors development.54,55 This synthetic strategy relies on 
the formation of direct micelles of Pluronic F127 (Figure 2.8) in water.47,56 
 
 
Figure 2.8 Molecular structure of Pluronic F127 
 
Pluronic surfactants represent a family of non-ionic tri-block A-B-A copolymers, bearing a 
poly(ethylene glycol)x-poly(propylene oxide)y-poly(ethylene glycol)x (PEGx-PPOy-PEGx) 
structure, thus terminating in primary hydroxy groups.57 Specifically, Pluronic F127 has an 
average molecular weight of 12.6 KDa, (x = 100 and y = 65), and Pluronic F127 micelles 
have a PPO hydrophobic core and a more hydrophilic PEG shell.58,59 
When added to a Pluronic F127 aqueous solution, TEOS is able to diffuse and condensate 
in the hydrophobic PPO core: the central part of the micelle acts as a nanoreactor for the 
hydrolysis and condensation processes of TEOS and of triethoxysilane-derivatized dyes 
used as doping units. Hydrolysis-condensation processes are promoted by an acidic 
environment, using diluted acids such as HOAc51 or HCl47,57: in these conditions (pH < 4) 
hydrolysis has faster kinetics compared with the condensation rate, leading to the 
occurrence of Si-O-Si chains in the early stages of polymerization,60 that finally undergo 
cross-linking.61 In this way, the confinement of the silica matrix occurs exclusively in the 
micellar environment, together with the entrapment and adsorption processes of the 
surfactant to the silica core, leading to the nanoparticle surface modification in a single 
synthetic process (Figure 2.9). 
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Figure 2.9 Schematization of the direct micelles assisted method for the synthesis of F127 
nanoparticles. 
 
A terminating agent such as trimethylsilyl chloride (TMSCl) is added to the reaction mixture 
to stop the condensation of TEOS: TMSCl, in fact, supplies alkyl substituents for the end-
capping of the silica surface.62,63 
This synthetic strategy is useful to obtain luminescent core-shell silica-PEG nanoparticles 
with very high monodispersity and colloidal stability in water, bearing a silica core of about 
10 nm (Figure 2.10) and an overall hydrodynamic diameter (including the PEG shell) of  
 
 
Figure 2.10 TEM images of silica core/PEG shell nanoparticles (silica core size 
distribution, dc = 11 ± 3 nm). 
 
TEOS
HOAc
H2O
Purif.
Dye-Si(OEt)3 Targetting unit
Pluronic F127
TMSCl
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about 25 nm (Figure 2.11).64,65 This last feature, deriving from the entrapped Pluronic 
F127, together with the non-toxic properties of PEG are valuable characteristics able to 
confer stealth properties in biological environments.66,67 
This synthetic method is applicable to a vast variety of trialkoxysilane derivatized dyes, 
since it is quite independent from their solubility properties.68  
These core-shell silica-PEG nanoparticles can also act as labels modifying the Pluronic 
F127 hydroxy end groups (see Chapter 3, 6 and 8).52,69 These modifications are carried 
out in the pristine Pluronic F127 surfactant, then used in the nanoparticle synthesis in the 
desired amount, so that no post nanoparticle functionalization is needed to introduce 
chemical functionalities (-COOH, -NH2, -SH, -N3, alkynes, etc.) for targeting and bio-
molecule conjugation.70,71 It is also possible to obtain charge insertion through silica core 
functionalization using a suitable silane reagent, to provide SNPs in which the charges are 
hidden by the PEG shell surrounding the silica core.71 These features make SNPs highly 
adaptable for in vitro and in vivo imaging applications. 
 
 
Figure 2.11 Dynamic light scattering diameter distribution by volume and undersize curve 
for silica core/PEG shell nanoparticles (dH = 25 nm; PdI = 0.04, water, 25°C). 
 
2.5 Conclusions 
Luminescent silica nanoparticles in solution can be obtained mainly by Stöber, reverse 
microemulsion and direct micelles assisted methods. Every strategy has quite different 
characteristics, that can be exploited to tailor the final system to a specific application.  
The direct micelles assisted strategy using Pluronic F127 has proven to be suitable for the 
synthesis of silica-core/PEG-shell nanoparticles with high reproducibility, stability and 
monodispersity. This characteristics make them extremely versatile for in vitro and in vivo 
imaging applications. By modification of the surfactant hydroxy end groups, and by 
functionalization of the silica core, in a one-pot procedure it is possible to introduce 
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functional groups on the surface and on the silica core of these nanoplatforms, with the 
objective of using them as devices for bioanalytical applications.  
The possible use of the silica-core/PEG-shell nanoparticles as fluorescent labels will be 
shown in the next chapter. 
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Chapter 3 
Silica nanoparticles as fluorescent labels 
 
3.1 Introduction 
In this part we present Silica-based luminescent nanoparticles (SNPs) designed to display 
neutral, positive or negative charges on their surface will be presented. The main purposes 
of this experimental work were: to improve the cell adhesion and internalization efficiency 
of SNPs; to study the kinetics and mechanism of cell internalization as well as the 
persistence of SNPs-cellular fluorescence (mainly by flow cytometric analyses); to 
evaluate their cytotoxicity by using several cellular models.  
Nanoparticles are up-and-coming devices in nanomedicine nowadays,  because of their 
applicability in essential topics such as early diagnosis of several diseases and targeted 
therapy.1-8 However, a great limitation is that only a few types of multifunctional 
nanostructures have reached the stage of clinical trials.9 A parameter which must be taken 
into account in the design of nanoparticles is the uncertainty about their cellular uptake, as 
well as their potential cytotoxicity in different cell models.10-14 
In the field of nanomedicine, SNPs can provide very stunning solutions for several 
reasons.15 Firstly, luminescence measurements are highly sensitive (down to single 
molecule detection), smoothly carried out and very versatile, providing submicrom spatial 
resolution and sub-millisecond temporal resolution.16 This enables, in general, low 
detection limits, and could allow the tracking of biological events to show the origin and 
growth of various pathologies, including cancer. Theoretically, there are many different 
fluorescent nanocolloids that could represent a good alternative to SNPs, such as dye 
doped latex nanoparticles,17-19 or quantum dots (QDs), that are intrinsically luminescent 
nanomaterials.8,20,21 Nevertheless, SNPs can show unparalleled features for effective 
diagnostics and theranostic applications.8,13,20,22-27 In fact, from a chemical viewpoint, 
SNPs are very stable platforms to incorporate dyes, increasing the resistance to 
photobleaching as well as the protection against enzymatic degradation. Since many dyes 
can be contained inside a nanoparticle, it is possible to have an increase in the brightness 
and in the signal-to-noise ratio, with the possibility, when required, to tune the signals 
spectral range.12,28 
In conclusion, the main synthetic methods (see Chapter 2) share important features such 
as high versatility and reproducibility, low costs and mild synthetic conditions that can be 
tuned to a large number of applications.7,23 In this context, Prodi and co-workers recently 
developed a new one-pot synthetic approach for SNPs that starts from the preparation of 
Pluronic F127 micelles in water.24,29,30 The resulting SNPs dispersions are bright, 
photostable, highly monodisperse (d ~ 25 nm) and stable in water also in the presence of 
proteins, thus offering a valuable advantage compared to other nanostructures, which 
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require solvothermal approaches with the use of organic solvents, quite high temperatures 
and additional steps for surface stabilization and derivatization.15 
Moreover, it is noteworthy that the structure and versatility of these SNPs offer the 
possibility to load external species such as photoswitches,31 drugs,29 and chemosensors.32 
In the present study, the possibility to tune the external SNP charge was then investigated 
to improve the efficiency of SNP-cell binding/cell uptake processes. In particular, with the 
aim to translate these SNPs for in vivo applications, was assessed the potential cellular 
toxicity by using a variety of cellular models. Moreover, were analysed the kinetics and 
mechanism of cell internalization were, as well as the persistence of SNP-cellular 
fluorescence, mainly by flow cytometric quantitative approaches. The results obtained 
provide interesting evidences, opening up the possibility for several in vivo applications of 
these derivatized fluorescent SNPs.  
 
3.2 Result and discussion 
3.2.1 Synthesis and characterization of nanoparticles 
The surfactant Pluronic F127 was derivatized to obtain two derivatives: F127-carbo and 
F127-amino. These two compounds, along with the unmodified F127 (Table 3.1), were 
employed for the synthesis of SNPs having on their outer PEG shells negative, positive or 
neutral charges,30 respectively, yielding NP-PEG-carbo, NP-PEG-amino and NP-PEG, as 
shown in Fig. 3.2. All the SNPs were covalently doped with a triethoxysilane derivative of 
the Rhodamine B (RhodB-Si): the covalent linking of the dyes to the silica matrix limits dye 
leaching in the biological environment and circumvents dye toxicity. In addition, the 
photophysical properties of this derivatized dye allow visualizationby both flow-cytometry 
and fluorescence microscopy (Fig. 3.1).  
 
Figure 3.1 Molecular structure of RhodB-Si. 
In this context it is worth underlining that covalent linking of fluorophores to the NP silica  
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Figure 3.2 Schematic representation of the synthetic procedure and the main components 
of non-derivatized NP-PEG and derivatized NP-PEG-amino and NP-PEG-carbo. 
 
Table 3.1 Quantities of F127 surfactant and RhodB-Si used in SNPs preparations. 
NPs sample F127  
(mg) 
Derivatized F127 
(mg) 
RhodB-Si 
(mg) 
NP-PEG 200 - 2.9 
NP-PEG-carbo 140 F127-carbo     60 2.9 
NP-PEG-amino 140 F127-amino    60 2.9 
30 
 
matrix has manifold advantages, such as to circumvent dye toxicity, avoiding dye leaching 
in a biological environment, and therefore to securely fix fluorescent emission due to NPs 
in biological media.33 
These nanoparticles are characterized by an absorption coefficient of ε = 9.5 x 105 M-1 cm-
1
, with an average of ten RhodB-Si dye molecules inside each silica core. Furthermore, 
since a quantum yield of Φ = 0.52 was measured in all samples, these SNPs showed a 
remarkable brightness (B = 4.9 x 105 M-1 cm-1).24,34 These photophysical parameters 
showed that at this concentration RhodB-Si give rise to negligible ground state interactions 
and to very low self-quenching processes (Figure 3.3). 
 
Figure 3.3 Representative absorption and emission spectra of SNPs doped with RhodB-Si 
in water. 
 
From a morphological viewpoint, the hydrodynamic diameter (dH) measured by Dynamic 
Light Scattering (DLS) was less than 30 nm for NP-PEG and NP-PEG-carbo (dH = 25 and 
28 nm, respectively), with a very low polydispersity index (PdI = 0.04 and 0.08, 
respectively); higher values of dH and PdI were found for NP-PEG-amino (dH = 69 nm and 
PdI = 0.2): this was probably due to H-bonding interactions between the SNPs (Figure 3.4 
and Table 3.2). Morphological characterization by TEM images indicates a silica core 
diameter, dc = 12 ± 2 nm for NP-PEG-amino, dc = 11 ± 2 nm for NP-PEG-carbo and dc = 
11 ± 3nm for NP-PEG (Figure 3.5 and Table 3.2). 
 
Table 3.2 Mean silica core  (dc ± SD) determined by TEM analysis, DLS hydrodynamic 
values (dH  ± SD) and corresponding PdI for the SNPs described in this work. Standard 
deviation was calculated on five different measurements. 
Sample (dc ± SD) / nm (dH ± SD) / nm PdI 
NP-PEG 11 ± 3    25 ± 5 0.04 
NP-PEG-carbo 11 ± 2    28 ± 8 0.08 
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NP-PEG-amino 12 ± 2 69 ± 30 0.20 
 
 
 
Figure 3.4 Dynamic light scattering diameter distributions by volume and undersize curves 
for SNPs: (left) NP-PEG-carbo (dH = 28 nm; PdI = 0.08, water, 25° C); (right) NP-PEG-
amino (dH = 69 nm; PdI = 0.20, water, 25° C). For clarity, only results of experiments done 
with NP-PEG-carbo and NP-PEG-amino are shown. 
 
 
Figure 3.5 TEM images of SNPs NP-PEG-amino (silica core size distribution
 
= 12 ± 2 nm). 
For clarity, only results of experiments done with NP-PEG-amino are shown. 
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3.2.2 Evaluation of cell cytotoxicity 
The cytotoxicity of SNPs functionalized on their surface with different charges (NP-PEG, 
NP-PEG-amino and NP-PEG-carbo) (Table 3.3), was evaluated in different cell models.  
 
Table 3.3 Values of ζ-Potential ± SD (n=6) for SNPs samples. Conditions: [NPs] = 2 µM, 
[PB] = 1 mM, [KCl] = 1 mM, pH 7.4, 25° C. 
NPs sample ζ-Potential ± SD (mV) 
NP-PEG -4.3 ± 0.3 
NP-PEG-carbo -6.5 ± 0.5 
NP-PEG-amino -9.6 ± 0.4 
 
It is important to emphasize that in vitro cell toxicity of SNPs is a significant topic in 
nanomedicine which depends on numerous factors, such as the testing techniques and 
treatment modalities;35 previous studies reported that silica nanoparticles can have 
cytotoxic effects on diverse cell lines,35-37 while other reports showed the absence of 
toxicity.7,8,11,20,38 
In this work were used both tumor cell lines (leukemic JVM-2 cells and hepatocellular-
carcinoma Huh7 cells) as well as primary normal cell models (peripheral blood 
mononuclear cells, PBMC, and human umbilical vein endothelial cells, HUVEC). By means 
of the Trypan blue dye exclusion test it was possible to evaluate the effects of SNPs on the 
viability of cells growing in suspension, namely leukemic JVM-2 and normal PBMC cells: a 
slight decrease in the cell availability (10%), that was not connected with the surface 
charge of the various SNPs, was observed after 48 hours of exposure at the maximal dose 
of 100 nM (Figure 3.6).  
 
 
Figure 3.6 NP cytotoxicity evaluated on normal human PBMC and JVM-2 leukemic cells. 
Cells were cultured in the absence or presence of SNPs (100 nM). Cell viability was 
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calculated as a percentage with respect to the control vehicle cultures (set to 100% for 
each cell line). Data are reported as means ± SD of results from at least three independent 
experiments (different PBMC donors), performed in duplicate. 
 
Furthermore, the effects of SNPs on the viability of cells growing adherent to plastic, such 
as HUVEC (normal human umbilical vein endothelial cells) and hepatocellular-carcinoma 
Huh7 cells, were assessed using the xCELLigence real time cell analyzer (RTCA): the 
proliferation curves relative to the Cell Index of the cultures incubated with the NPs were 
comparable with those obtained using untreated cultures for both cell models investigated 
(Figure 3.7). In addition, it is interesting to note that the analysis of these proliferation 
curves show that cells treated with SNPs could maintain their morphology and viability 
even when treated for more than 48 hours with the highest concentration of SNPs (100 
nM).  
 
 
Figure 3.7 Adherent cell cultures (Huvec and Huh7) were exposed to SNPs used at the 
indicated concentrations. Cell proliferation/cytotoxicity was evaluated using the 
xCELLigence real time cell analyzer (RTCA) and was expressed as Cell Index. In parallel, 
the cell morphology was examined by using phase-contrast microscopy. In (A), cell 
proliferation/cytotoxicity was evaluated in endothelial primary cells (Huvec) seeded on pre-
fibronectin-coated wells. In (B), cell proliferation/cytotoxicity was evaluated in 
hepatocellular carcinoma cells (Huh7). Representative Cell Index graphs (expressed as a 
A 
B 
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mean of quadruplicates) and microscopy images (original magnification: 20) of cultures 
from at least three independent experiments are shown. For clarity, only results of 
experiments done with NP-PEG-amino are shown. 
 
This negligible cytotoxicity was further shown by comparison with the effects due to the 
treatment with the kinase inhibitor Sorafenib, used as an inducer of cell toxicity. The 
effects produced by the inhibitor were visible not only on the proliferation curves, but also 
on the cell morphology and cell number, as shown by microscopy images (Figure 3.8). 
 
 
Figure 3.8 Cytotoxic effects (Cell Index reduction as well as morphological changes) 
induced by treatment with Sorafenib are shown for comparison. Representative Cell Index 
graphs (expressed as a mean of quadruplicates) and microscopy images (original 
magnification: 20 ) of cultures from at least three independent experiments are shown. For 
clarity, only results of experiments done with NP-PEG-amino are shown. 
 
Taken together, our results clearly indicate that, even upon surface derivatization, the 
SNPs display a very low grade of cytotoxicity, evaluated as alteration of cell viability and 
cell proliferation capacity. Of note, our results were derived from assays performed on 
different and relevant cell models of both normal and cancer origins, strengthening the 
notion of a potential use of SNPs in several biomedical applications. 
 
3.2.3 Cell adhesion and internalization 
The study of the SNPs cellular uptake is of fundamental importance because it can provide 
precise indications about their possible use as cell labels for in vivo applications and as 
carrier for active species, such as photoswitches,31 drugs29 and chemosensors.32  
Firstly, the capacity of binding to the cells of the SNPs functionalized on their surface with 
neutral (NP-PEG), negative (NP-PEG-carbo) or positive (NP-PEG-amino) charges was 
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evaluated by means of incubation of leukemic JVM-2 cells with SNPs covalently doped 
with RhodB-Si for 30 minutes at 4° C, followed by washing with cold PBS before flow-
cytometry analysis. The shifts in the graphs of the Rhodamine-positive populations 
demonstrated that all SNPs previously described were able to adhere to the cells in a 
dose-dependent fashion (Figure 3.9A). Secondly, the endocytosis process was induced by 
increasing the temperature from 4° C to 37° C. In this case, the negatively charged SNPs 
(NP-PEG- carbo) were less efficient than neutral (NP-PEG) and positively charged (NP-
PEG-amino) SNPs in the overall process of binding and entry (Fig. 3.9A). These results 
showed that the highest efficiency of entry was verified for NP-PEG-amino, even at the 
lowest assessed concentration (10 nM) (Fig. 3.9A). It can be assumed that the better 
performance of NP-PEG-amino in this test can be due to electrostatic interactions among 
the cell membrane (negatively charged) and the amino groups (positively charged) present 
on the PEG shell of NP-PEG-amino, which facilitated the entry of attached SNPs.39 The 
persistence of NP-PEG-amino connected to the cells until 48 hours has been documented 
by flow-cytometric analyses of the Rhodamine signal; a reduction of mean fluorescence 
intensity subsequently was noticed after 72 hours, probably attributable cell duplication 
process (Figure 3.9B).  
 
 
Figure 3.9 Binding to cell surface and persistence during time of Rhodamine-labeled 
SNPs. Cells incubated with Rhodamine-labeled SNPs were analyzed by flow cytometry. In 
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(A), JVM-2 cells were incubated with Rhodamine-labeled SNPs (10 nM and 100 nM) 
characterized for having different surface charge, and analyzed after 45 min incubation at 
4°C and after washings and additional incubation over night at 37°C. Arrows indicate the 
best performing SNPs. In (B), kinetics analysis of the persistence of Rhodamine-labeled 
NP-PEG-amino signal into JVM-2 cells. Background signal from not-treated cells is in solid 
grey and specific Rhodamine signal is in color. Representative results out of three 
independent experiments are shown. The arrow indicates the loss of signal corresponding 
to a mean fluorescence intensity decrease after 72h, probably due to cellular duplication. 
In the histogram, flow cytometry analyses are expressed as Mean Fluorescence Intensity 
± SD. Asterisk, p < 0.05 with respect to 24 hours of cultures. 
 
The ability of the SNPs to enter into cells has been further confirmed by the confocal 
fluorescence microscopy observation of Huh7 cells treated with Rhodamine-loaded SNPs. 
Cells were counterstained with FITC-conjugated phalloidin to mark intracellular actin, 
predominantly distributed alongside cell perimeters in these cells (Figure. 3.10A and B). As 
shown in Fig. 3.10A, SNPs showed red fluorescence mostly in the form of dots. In 
particular, after incubation at 4° C the 3D distribution of fluorescence obtained from the z-
stack showed that the majority of SNPs were attached to the cell membrane, as evident 
from the arch drawn by the SNPs delineating the external border of the cells (Fig. 3.10B). 
Upon incubation at 37 °C, the SNPs were instead mostly localized inside the cells at the 
same depth of actin (Fig. 3.10B).  
 
 
Figure 3.10 Fluorescence microscopy analysis of SiNP entry. Huh7 cells were incubated 
with Rhodamine-labeled SNPs (red) at 37°C and then counterstained with FITC-
conjugated Phalloidin (to visualize intracellular actin, green). In (A), confocal 2D image of 
cells incubated with SNPs for 24 hours. A representative image merged of 21 sections is 
shown. Photographs were taken at a magnification of 60x. In (B), images of 21 subsequent 
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optical sections collected at 0.5 µm intervals (z-stack) were recorded and rearranged to a 
section view visualizing the 3D distribution of fluorescence inside the cells. A single 2D 
optical slice (horizontal median plane, XY panels) from the stack is in high magnification, 
while XZ and YZ panels show merged reconstruction of the stack along the Z axis (vertical 
plane originated from a slice through the stack, perpendicular to the XY image plane). The 
lines indicate the level at which the photographs were taken (X, Y, 5 µm). Examining the 
XZ and YZ panels, the arrows indicate the localization of SNPs delineating the external 
border of the cells after incubation at 4°C, while the SNPs show the same depth 
localization than intracellular actin indicating cell entry after incubation at 37°C. 
Photographs were taken at a magnification of 60x. 
 
To further validate these results and to define the mechanisms of SNP uptake, cells were 
pre-incubated with Genistein, a commonly used clathrin-independent caveolae-mediated 
endocytosis inhibitor40 before assessing quantitatively the entry of Rhodamine-labeled 
SNPs by flow cytometry. As shown in Figure 3.11, the pretreatment with Genistein was 
able to interfere with the SNP uptake, as underlined by a significant reduction of 
fluorescence intensity in two different cell models represented by leukemic JVM-2 cells 
(growing in suspension) and by hepatocarcinoma Huh7 cells (growing in adhesion). The 
inhibitory effect was significant but not complete, due to the involvement of additional 
endocytosis mechanisms not inhibited by Genistein.41 The multiparametric flow cytometry 
approach was preferred over that with confocal microscopy because it offered the 
advantage of analyzing a large population of cells (50000 in our study) instead of a small 
field of about 10-20 cells, and to rapidly quantify the inhibition of the entry. 
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Figure 3.11 SNP entry is blocked by endocytosis inhibition. JVM-2 and Huh7 cells 
incubated with Rhodamine-labeled SNPs in the presence or absence of Genistein (Gen) 
were analyzed by flow cytometry. Background histograms from untreated cells are in solid 
grey (uptake 0%), specific Rhodamine-labeled NP signals are black (100% uptake) or 
dotted (Genistein addition) empty histograms. Analyses are expressed as Mean 
Fluorescence Intensity ± SD. Representative results out of three independent experiments 
are shown. Asterisk, p < 0.05. 
 
3.2.4 In vivo experiments 
JVM-2 leukemic cells were loaded with Rhodamine-labeled NP-PEG-amino to evaluate not 
only the stability of SNPs inside the cells in the in vivo environment, but also  to use them 
for cell traceability and detection in whole organisms (Figure 3.12A). After that, the labeled 
JVM-2 leukemic cells, at a pre-determined number, were injected intravenously in SCID 
immune-deficient mice. Twenty-four hours post-injection, mice circulating total blood cells 
were analyzed by flow-cytometry, after gating on the live cell populations (Figure 3.12B). 
As shown in Fig. 3.12B, we were able to detect in the peripheral blood of the injected mice 
a population of circulating cells positive for Rhodamine and showing a side and forward 
scatter characteristic of labeled JVM-2 human leukemic cells, which accounted for 
approximately 6% of the total peripheral blood population (Fig. 3.12B). Such a population 
was not present in the blood of mice injected with unlabeled JVM-2, used as control (Fig. 
3.12B). In addition, the labeling with a FITC-conjugated antibody against human CD19 
(expressed by the JVM-2 cells) confirms that the Rhodamine fluorescence was associated 
with JVM-2, further excluding a leaking of the SNP out from the injected JVM-2 and/or the 
uptake by different circulating cells (Fig. 3.12B). 
There is growing interest in new methodologies which allow tracking of transplanted cells 
in animals and humans.42 In this context, our in vitro data document a stable and intense 
fluorescence of the SNPs, a good efficiency of cell labeling capacity, and a stability of the 
SNPs in the intracellular microenvironment: together with our preliminary in vivo results, 
they support the potential application of SNPs for cell labeling and monitoring in vivo. 
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Figure 3.12 Cells loaded with Rhodamine-labeled SNPs are traceable after in vivo 
administration. SCID mice were i.v. injected with 5x106 JVM-2 cells or with JVM-2 cells 
pre-loaded with Rhodamine-labeled SNP (NP-R). In (A), JVM-2 cells were incubated for 
24h with NP-R (100 nM) and before inoculation in mice the percentage of labeled cells 
was analyzed at flow cytometry. In (B), 24 hours post injection, mouse blood circulating 
cells were analyzed at flow cytometry for the presence of Rhodamine- positive and 
Rhodamine/hCD19-FITC double positive JVM-2 cells. A representative experiment is 
shown. 
 
3.3 Conclusions 
Among the several possible approaches related to bio-analytical and imaging applications 
based on the use of NPs, the ones employed in the present study offer several 
advantages.14,15 The possibility to obtain tiny NPs with a core-shell silica-PEG structure 
with a one pot synthesis is quite unique, moreover the synthetic approach is based on mild 
conditions in aqueous solution, is extremely reliable and it requires accessible and cheap 
components. The resulting SNPs are highly monodisperse, stable in physiological 
conditions and highly bright.24 Furthermore, the structure of the SNPs offers the possibility 
to load external species such as drugs (see Chapter 7)29 and chemosensors.32 We have 
derivatized silica core/PEG shell SNPs with modified surfactants to obtain NP-PEG-amino 
and NP-PEG-carbo, having a different external charge. With the aim to characterize the 
behaviour of these SNP preparations (covalently doped with a Rhodamine B derivative) for 
potential in vivo applications, we have first demonstrated that none of these preparations 
showed toxicity on either suspension or adherent cell models of normal or cancer cell 
types. Within these families of nanoparticles, NP-PEG-amino exhibited the most efficient 
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kinetics of cell adhesion and internalization, coupled with high levels of SNP cell 
associated fluorescence persisting for more than 48 hours. The endocytosis of SNPs by a 
caveolae-mediated pathway was then demonstrated through significant inhibition by 
Genistein. Proper SNP cell internalization allowed cell traceability in vivo (upon blood 
analysis) of leukemic cells, pre-loaded in vitro with SNPs and intravenously injected into 
SCID mouse model. 
It should be underlined that, although multiple approaches were used in order to 
investigate the different experimental aspects mentioned above, multiparametric flow 
cytometry offered a powerful tool to quantitatively evaluate aspects linked to the SNP 
adhesion and uptake by the cells as well as for the in vivo studies. We believe that our 
results strengthen the idea that derivatized fluorescent SNP are versatile non-toxic 
materials suitable for several in vivo applications, including cell labeling and monitoring. 
 
3.4 Notes and references 
The contents of this chapter are based on E. Rampazzo, R. Voltan, L. Petrizza, N. 
Zaccheroni, L. Prodi, F. Casciano, G. Zauli and P. Secchiero, Nanoscale 2013, 5, 7897- 
Reproduced by permission of The Royal Society of Chemistry. 
 (1) Kim, D. K.; Dobson, J. Journal of Materials Chemistry 2009, 19, 6294. 
 (2) Riehemann, K.; Schneider, S. W.; Luger, T. A.; Godin, B.; Ferrari, M.; Fuchs, H. Angewandte 
Chemie International Edition 2009, 48, 872. 
 (3) Shi, D. L. Adv. Funct. Mater. 2009, 19, 3356. 
 (4) Shi, J. J.; Xiao, Z. Y.; Kamaly, N.; Farokhzad, O. C. Accounts of Chemical Research 2011, 44, 1123. 
 (5) Cuenca, A. G.; Jiang, H. B.; Hochwald, S. N.; Delano, M.; Cance, W. G.; Grobmyer, S. R. Cancer 
2006, 107, 459. 
 (6) Doshi, N.; Mitragotri, S. Adv. Funct. Mater. 2009, 19, 3843. 
 (7) Gunasekera, U. A.; Pankhurst, Q. A.; Douek, M. Targeted Oncology 2009, 4, 169. 
 (8) Yong, K. T.; Roy, I.; Swihart, M. T.; Prasad, P. N. Journal of Materials Chemistry 2009, 19, 4655. 
 (9) Rai, P.; Mallidi, S.; Zheng, X.; Rahmanzadeh, R.; Mir, Y.; Elrington, S.; Khurshid, A.; Hasan, T. 
Advanced Drug Delivery Reviews 2010, 62, 1094. 
 (10) Kim, K.; Kim, J. H.; Park, H.; Kim, Y. S.; Park, K.; Nam, H.; Lee, S.; Park, J. H.; Park, R. W.; Kim, I. 
S.; Choi, K.; Kim, S. Y.; Kwon, I. C. Journal of Controlled Release 2010, 146, 219. 
 (11) Wang, M.; Thanou, M. Pharmacological Research 2010, 62, 90. 
 (12) Rosenholm, J. M.; Sahlgren, C.; Linden, M. Nanoscale 2010, 2, 1870. 
 (13) Benezra, M.; Penate-Medina, O.; Zanzonico, P. B.; Schaer, D.; Ow, H.; Burns, A.; DeStanchina, E.; 
Longo, V.; Herz, E.; Iyer, S.; Wolchok, J.; Larson, S. M.; Wiesner, U.; Bradbury, M. S. Journal of Clinical 
Investigation 2011, 121, 2768. 
 (14) Mahmoudi, M.; Hofmann, H.; Rothen-Rutishauser, B.; Petri-Fink, A. Chemical Reviews 2011, 112, 
2323. 
 (15) Reddy, L. H.; Arias, J. L.; Nicolas, J.; Couvreur, P. Chemical Reviews 2012, 112, 5818. 
 (16) Prodi, L. New Journal of Chemistry 2005, 29, 20. 
 (17) Gong, Y. K.; Nakashima, K. Chemical Communications 2001, 1772. 
 (18) Katz, L. C.; Burkhalter, A.; Dreyer, W. J. Nature 1984, 310, 498. 
 (19) Prilloff, S.; Fan, J. Y.; Henrich-Noack, P.; Sabel, B. A. Eur. J. Neurosci. 2010, 31, 521. 
 (20) Burns, A.; Ow, H.; Wiesner, U. Chemical Society Reviews 2006, 35, 1028. 
 (21) Medintz, I. L.; Uyeda, H. T.; Goldman, E. R.; Mattoussi, H. Nat. Mater. 2005, 4, 435. 
 (22) Bae, W.; Tan, W.; Hong, J.-I. Chemical Communications 2012, 48, 2270. 
 (23) Wang, L.; Wang, K. M.; Santra, S.; Zhao, X. J.; Hilliard, L. R.; Smith, J. E.; Wu, J. R.; Tan, W. H. 
Analytical Chemistry 2006, 78, 646. 
 (24) Bonacchi, S.; Genovese, D.; Juris, R.; Montalti, M.; Prodi, L.; Rampazzo, E.; Zaccheroni, N. 
Angewandte Chemie, International Edition in English 2011, 50, 4056. 
41 
 
 (25) Bonacchi, S.; Genovese, D.; Juris, R.; Montalti, M.; Prodi, L.; Rampazzo, E.; Sgarzi, M.; Zaccheroni, 
N. In Luminescence Applied in Sensor Science; Prodi, L., Montalti, M., Zaccheroni, N., Eds. 2011; Vol. 300, 
p 93. 
 (26) Rampazzo, E.; Bonacchi, S.; Genovese, D.; Juris, R.; Marcaccio, M.; Montalti, M.; Paolucci, F.; 
Sgarzi, M.; Valenti, G.; Zaccheroni, N.; Prodi, L. Coord. Chem. Rev. 2012, 256, 1664. 
 (27) Montalti, M.; Rampazzo, E.; Zaccheroni, N.; Prodi, L. New Journal of Chemistry 2013, 37, 28. 
 (28) Ambrogio, M. W.; Thomas, C. R.; Zhao, Y. L.; Zink, J. I.; Stoddartt, J. F. Accounts of Chemical 
Research 2011, 44, 903. 
 (29) Rampazzo, E.; Bonacchi, S.; Juris, R.; Montalti, M.; Genovese, D.; Zaccheroni, N.; Prodi, L.; 
Rambaldi, D. C.; Zattoni, A.; Reschiglian, P. Journal of Physical Chemistry B 2010, 114, 14605. 
 (30) Soster, M.; Juris, R.; Bonacchi, S.; Genovese, D.; Montalti, M.; Rampazzo, E.; Zaccheroni, N.; 
Garagnani, P.; Bussolino, F.; Prodi, L.; Marchio, S. International Journal of Nanomedicine 2012, 7, 4797. 
 (31) Genovese, D.; Montalti, M.; Prodi, L.; Rampazzo, E.; Zaccheroni, N.; Tosic, O.; Altenhoner, K.; May, 
F.; Mattay, J. Chemical Communications 2011, 47, 10975. 
 (32) Rampazzo, E.; Bonacchi, S.; Genovese, D.; Juris, R.; Sgarzi, M.; Montalti, M.; Prodi, L.; Zaccheroni, 
N.; Tomaselli, G.; Gentile, S.; Satriano, C.; Rizzarelli, E. Chemistry- A European Journal 2011, 17, 13429. 
 (33) Ohulchanskyy, T. Y.; Roy, I.; Goswami, L. N.; Chen, Y.; Bergey, E. J.; Pandey, R. K.; Oseroff, A. R.; 
Prasad, P. N. Nano Letters 2007, 7, 2835. 
 (34) Rampazzo, E.; Boschi, F.; Bonacchi, S.; Juris, R.; Montalti, M.; Zaccheroni, N.; Prodi, L.; Calderan, 
L.; Rossi, B.; Becchi, S.; Sbarbati, A. Nanoscale 2012, 4, 824. 
 (35) Fede, C.; Selvestrel, F.; Compagnin, C.; Mognato, M.; Mancin, F.; Reddi, E.; Celotti, L. Anal Bioanal 
Chem 2012, 404, 1789. 
 (36) Stępnik, M.; Arkusz, J.; Smok-Pieniążek, A.; Bratek-Skicki, A.; Salvati, A.; Lynch, I.; Dawson, K. A.; 
Gromadzińska, J.; De Jong, W. H.; Rydzyński, K. Toxicology and Applied Pharmacology 2012, 263, 89. 
 (37) Kunzmann, A.; Andersson, B.; Thurnherr, T.; Krug, H.; Scheynius, A.; Fadeel, B. Biochimica et 
Biophysica Acta (BBA) - General Subjects 2011, 1810, 361. 
 (38) Malvindi, M. A.; Brunetti, V.; Vecchio, G.; Galeone, A.; Cingolani, R.; Pompa, P. P. Nanoscale 2012, 
4, 486. 
 (39) Yeh, M.-K.; Hu, C.-s.; Chiang, C.-H.; Po-da, H. International Journal of Nanomedicine 2012, 4861. 
 (40) Vercauteren, D.; Vandenbroucke, R. E.; Jones, A. T.; Rejman, J.; Demeester, J.; De Smedt, S. C.; 
Sanders, N. N.; Braeckmans, K. Molecular Theraphy 2010, 18, 561. 
 (41) Reno, F.; Carniato, F.; Rizzi, M.; Olivero, F.; Pittarella, P.; Marchese, L. Nanotechnology 2013, 24, 
185101. 
 (42) Taylor, A.; Wilson, K. M.; Murray, P.; Fernig, D. G.; Levy, R. Chemical Society Reviews 2012, 41, 
2707. 
 (43) Kaijzel, E. L.; van der Pluijm, G.; Lowik, C. W. Clinical Cancer Research 2007, 13, 3490. 
 (44) McIntyre, J. O.; Scherer, R. L.; Matrisian, L. M. Methods in Molecular Biology 2010, 622, 279. 
 (45) Agostinis, C.; Biffi, S.; Garrovo, C.; Durigutto, P.; Lorenzon, A.; Bek, A.; Bulla, R.; Grossi, C.; Borghi, 
M. O.; Meroni, P.; Tedesco, F. Blood 2011, 118, 4231. 
 (46) Day, K. E.; Sweeny, L.; Kulbersh, B.; Zinn, K. R.; Rosenthal, E. L. Molecular Imaging and Biology 
2013, 15, 722. 
 (47) Ntziachristos, V.; Razansky, D. Recent Results in Cancer Research 2013, 187, 133. 
 (48) Byrne, W. L.; DeLille, A.; Kuo, C.; de Jong, J. S.; van Dam, G. M.; Francis, K. P.; Tangney, M. 
Journal of Controlled Release 2013, 172, 523. 
 (49) Schaafsma, B. E.; Mieog, J. S.; Hutteman, M.; van der Vorst, J. R.; Kuppen, P. J.; Lowik, C. W.; 
Frangioni, J. V.; van de Velde, C. J.; Vahrmeijer, A. L. Journal of Surgical Oncology 2011, 104, 323. 
 (50) Vahrmeijer, A. L.; Hutteman, M.; van der Vorst, J. R.; van de Velde, C. J.; Frangioni, J. V. Nature 
Reviews Clinical Oncology 2013, 10, 507. 
 (51) Helle, M.; Rampazzo, E.; Monchanin, M.; Marchal, F.; Guillemin, F.; Bonacchi, S.; Salis, F.; Prodi, L.; 
Bezdetnaya, L. ACS Nano 2013, 7, 8645. 
 (52) Burns, A. A.; Vider, J.; Ow, H.; Herz, E.; Penate-Medina, O.; Baumgart, M.; Larson, S. M.; Wiesner, 
U.; Bradbury, M. Nano Letters 2008, 9, 442. 
 (53) Ma, K.; Sai, H.; Wiesner, U. Journal of the American Chemical Society 2012, 134, 13180. 
 (54) Montalti, M.; Prodi, L.; Rampazzo, E.; Zaccheroni, N. Chemical Society Reviews 2014, DOI: 
10.1039/c3cs60433k. 
 (55) Lavis, L. D.; Raines, R. T. ACS Chemical Biology 2008, 3, 142. 
 (56) Gruber, H. J.; Hahn, C. D.; Kada, G.; Riener, C. K.; Harms, G. S.; Ahrer, W.; Dax, T. G.; Knaus, H.-
G. Bioconjugate Chemistry 2000, 11, 696. 
 (57) Vivero-Escoto, J. L.; Huxford-Phillips, R. C.; Lin, W. Chemical Society Reviews 2012, 41, 2673. 
 (58) Deen, W. M.; Lazzara, M. J.; Myers, B. D. American Journal of Physiology: Renal Physiology 2001, 
281, F579. 
42 
 
 (59) Voltan, R.; Secchiero, P.; Ruozi, B.; Forni, F.; Agostinis, C.; Caruso, L.; Vandelli, M. A.; Zauli, G. 
Clinical Cancer Research 2013, 19, 3871. 
 (60) Maeda, H.; Wu, J.; Sawa, T.; Matsumura, Y.; Hori, K. Journal of Controlled Release 2000, 65, 271. 
 (61) Rampazzo, E.; Voltan, R.; Petrizza, L.; Zaccheroni, N.; Prodi, L.; Casciano, F.; Zauli, G.; Secchiero, 
P. Nanoscale 2013, 5, 7897. 
 (62) Genovese, D.; Rampazzo, E.; Bonacchi, S.; Montalti, M.; zaccheroni, N.; Prodi, L. Nanoscale 2013, 
DOI: 10.1039/c3nr05599j. 
 (63) Genovese, D.; Bonacchi, S.; Juris, R.; Montalti, M.; Prodi, L.; Rampazzo, E.; Zaccheroni, N. 
Angewandte Chemie International Edition 2013, 52, 5965. 
 
 
43 
 
44 
 
Chapter 4 
NIR-emitting silica nanoparticles as fluorescent labels 
 
4.1 Introduction  
The field of biomedical imaging requires non-toxic, photostable and bright tools for 
fluorescence imaging. Optical imaging is actually broadly applied to obtain functional 
information in vivo over time for the preclinical assessment of protein expression, antibody 
binding, cell tracking and enzymatic activities. It represents, consequently, a rapidly 
improving technology that can be essential in a broad range of applications such as optical 
imaging that uses near-infrared (NIR) fluorescent light.1-6 This application has emerged as 
a tool also in the clinical context because it provides real-time, intraoperative, high-contrast 
delineation of both normal and pathologic tissues and can offer new possibilities for both 
general and oncologic surgery.7 Fluorescence-guided surgery has, certainly, the potential 
to improve cancer surgery outcomes and can also help surgeons in the identification and 
removal of malignant lesions. For these reasons, over the last years much effort has gone 
in clinical trials in this specific field.8 
Today several optical imaging approaches have been developed but, in spite of this, there 
is an increasing need of more effective optical imaging probes beyond the approved 
indocyanine green (ICG).7 A significant improvement in this field have led to a variety of 
fluorescent labeling probes based on nanomaterials (nanoparticles; NPs), which allow to 
store large payloads of imaging contrast agents and/or therapeutics within the NP core 
and “tissue specific targeting” molecules on NP surface.9 The versatility of synthetic NPs 
allows to provide contrast improvement, binding specificity, enhanced stability and 
prolonged blood half-life.10 Among the nanomaterials, fluorescent dye-doped NIR-emitting 
silica nanoparticles (NIR-SNPs) have demonstrated excellent potential for applications in 
advanced bioanalysis.9-12 NIR-SNPs represent a precious tool in bioimaging, because they 
provide sufficient brightness and photostability and consist of hydrophilic non-toxic 
materials.13-16 
Multiple dye-doped NIR emitting SNPs (m-NIR-SNPs) suitable for both time domain (TD) 
optical imaging and multiparametric flow cytometry analyses were developed. In order to 
characterize the optical properties and fluorescence imaging applications of these m-NIR-
SNPs, we have characterized their performance by analyzing their in vivo biodistribution in 
healthy mice as well as in lymphoma bearing xenografts, and their suitability as contrast 
imaging agents for cell labeling and tracking. 
 
4.2 Result and discussion 
4.2.1 Synthesis and characterization of m-NIR-SNPs 
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Following the synthetic approach already shown in Section 3.2.1 (see also Section 8.9), in 
this work we synthesized silica nanoparticles, characterized by both long-term stability and 
low adhesion properties toward proteins. This synthetic approach allows to bind covalently 
to the silica matrix a large number of dyes, ensuring in this way an increase of the 
nanoparticle absorption coefficeint ε. Furthermore, the silica matrix protects the dyes that 
are incorporated within the particles from the external chemicals, increasing their 
photostability and, frequently, their luminescence quantum yield Φ. Because of the 
reasons mentioned above, the SNPs are often characterized by high values of 
brightness.10,14  
SNPs were covalently doped by using increasing doping ratios of the triethoxysilane 
derivative of Cy 5.5 dye (Cy5.5-Si, Figure 4.1A, Fig. 4.2, Fig. 4.3 and Table 4.1) to obtain 
NP-1 and NP-2, nanoplatforms suitable for both multiparametric flow cytometry analyses 
and time-domain optical imaging.  
 
 
Figure 4.1 Molecular structure of: (A) Cy5.5-Si; (B) Cy7-Si. 
 
Cy5.5-Si was synthesized starting from 1,1,2-trimethylbenz[e]indole (1), that was alkylated 
with 1-Iodopropane in acetonitrile (MeCN) under reflux for two days to afford the 
compound (2), which was treated with malonaldehyde bis(phenylimine) 
monohydrochloride in acetic anhydride at 100°C for 1 h to obtain the hemicyanine 
intermediate (3). N-alkylation of (1) with 6-Bromohexanoic acid in MeCN under reflux for 
four days gave compound (4), which was treated with compound (3) to afford the 
compound (5).17,18 The triethoxysilane function of Cy5.5-Si was introduced via a coupling 
reaction between the carboxylic moiety of (5) and the amino group of (3-
Aminopropyl)triethoxysilane (Figure 4.2). Further details for this synthesis are given in 
Section 8.2. 
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Figure 4.2 Schematization of the synthesis of Cy5.5-Si. Reagents and conditions: i) 
MeCN, reflux, 2 d; ii) Ac2O, 100°C, 2 h; iii) MeCN, reflux, 4 d; iv) Pyridine, 40°C, 30 min; v) 
HATU, TEA, DCM, rt, 2 h. 
 
However, the dye showed a great tendency to aggregate, which has led to a scant loading 
of the dye within the silica matrix. This is also highlighted by the appearance of self-
quenching processes,15,16,19 which caused a decrease of the fluorescent quantum yield of 
the Cy5.5-Si dye inside the particles compared to the one noticed in solution. To overcome  
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Figure 4.3 Doping dyes (Cy5.5-Si and Cy7-Si) and schematization of the synthetic 
procedure used for the synthesis of the NIR-SNPs (NP-1 and NP-2) and m-NIR-SNPs  
(NP-3 and NP-4) samples described in this work. 
 
Table 4.1 Doping characteristics of the SNPs samples presented in this study. 
SNPs 
sample 
%Dyea TEOS 
          mmol 
Cy5.5-Sib 
µmol 
Cy7-Sib 
µmol 
NP-1 0.1 Cy5.5-Si  0.8 0.8  - 
NP-2 0.2 Cy5.5-Si  0.8 1.6  - 
NP-3 0.2 Cy5.5-Si- 
0.1 Cy7-Si 
 0.8 1.6  0.8 
NP-4 0.2 Cy5.5-Si- 
0.2 Cy7-Si 
 0.8 1.6  1.6 
aDoping ratio=[mol(dye)/mol(TEOS)]*100. bCy5.5-Si and Cy7-Si were introduced in the 
reaction mixtures using pristine dichloromethane solutions. 
 
these problems, the idea was to dope the SNPs with the alkoxysilane derivative of Cy5.5 
and an additional cyanine dye, to check whether the increase in the probability of 
aggregation with another dye could increase the number of Cy5.5 per nanoparticle and 
decrease the self-quenching processes. In addition, we also expected to have, at the 
same time, the beneficial effect of the presence of multiple signals.9,20 For this objective, 
different SNPs preparatives were synthesized by using the derivative Cy5.5-Si in 
combination with the IR813 alkoxysilane dye derivative Cy7-Si (Figure 4.1B; NP-3 and NP-
4, Fig. 4.3; Table 4.1, and Section 8.2) at two different Cy5.5-Si : Cy7-Si molecular ratios 
(2 : 1, 1 : 1) (Table 4.1).  As shown in Figure 4.4, SNPs doped with both dyes showed the 
typical absorption maxima of Cy5.5 (693 nm) and Cy7 (828 nm). Additional photophysical 
properties of the SNPs preparatives are reported in Table 4.2. 
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Figure 4.4 (A) Absorption spectra of aqueous suspensions of nanoparticles samples NP-3  
and NP-4 ([NP-3] = 0.4 µM; [NP-4] = 0.4 µM). (B) Emission spectra of aqueous 
suspension of nanoparticles samples NP-3 and NP-4 (λex = 640 nm). 
 
Table 4.2 Spectral and emission properties of nanoparticles samples. 
Sample Abs. 
max./nm 
Emi. 
max.a/nm 
Φem τb,d τc r  
(∆λ/nm) 
re 
(∆λ/nm) 
ηET 
(%) 
Cy5.5-Si 685 717 0.07 1.6 - - - - 
Cy5.5 f 683 707 0.2 1.4 - - - - 
Cy7-Si 819 860 0.03 - - - - - 
NP-1 645, 
688 
722 0.02 1.5 - 0.3 
(720-730)d 
- - 
NP-2 645, 
688 
722 0.03 1.4 - 0.008 
(720-730)d 
- - 
NP-3 645, 693,  
828 
724, 860 0.08 1.0 1.1 0.4 (720-730)e 0.4 
(850-870) 
38 
NP-4 645, 693,  
828 
724, 860 0.06 0.5 0.7 0.4 (720-730)e 0.1 
(850-870) 
70 
a λex = 650 nm; b λem = 724 nm; c λem = 860 nm; d λex = 640 nm; e λex = 650 nm; f Cy5.5 
commercial dye (Cy5.5 GE) was purchased from GE Healthcare. 
 
Morphological characterization by TEM images (Figure 4.5) showed a silica core diameter 
dc = 10  nm for NP-1, dc = 9 nm for NP-2, dc = 10.5 nm for NP-3 and dc = 11 nm for NP-4. 
The hydrodynamic diameter (dH) measured by dynamic light scattering (DLS) was very 
similar for NP-1, NP-2, NP-3 and NP-4 (dH = 25, 27, 25 and 27 nm, respectively), with 
relatively low polidispersity index (0.27, 0.27, 0.21 and 0.31, respectively) (Table 4.3). 
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Figure 4.5 TEM images and silica core size distribution of NP-4. dc = (11.0 ± 1.5) nm. For 
clarity, only results of experiments done with NP-4 are shown. 
 
Table 4.3 Mean silica core - dc ± SD - determined by TEM analysis and DLS 
hydrodynamic values (dH ± SD) for the SNPs described in this work. Standard deviation 
was calculated on five different measurements. 
Sample (dc ± SD) / nm (dH ± SD) / nm PdI 
NP-1 10 ± 2 25 ± 13 0.27 
NP-2 9 ± 2 27 ± 14 0.27 
NP-3 10.5 ± 1.5 24 ± 11 0.21 
NP-4 11.0 ± 1.5 27 ± 15 0.31 
 
All SNPs synthesized were assessed both by flow-cytometry and optical imaging. In 
particular, for flow-cytometry assays, SNP samples were used for cell labeling, as shown 
in Section 3.2. SNPs doped with both dyes (NP-3 and NP-4, respectively) displayed a 
signal detectable in the FL4 channel of the flow-cytometer; moreover, their mean 
fluorescence intensity (NP-3 = 130; NP-4 = 100) was increased compared to that obtained 
with nanoparticels doped with only Cy5.5-Si (Figure 4.6A-B). These results confirmed that 
the approach selected in this work was very effective in increasing the fluorescence 
quantum yield and the number of Cy5.5 per nanoparticle and, as a consequence, the SNP 
brightness.  
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Figure 4.6 Characterization of the flow-cytometric and optical imaging performance of the 
NIR-SNPs and m-NIR-SNPs. (A-B) Cells were incubated with the indicated SNP at 37°C 
for 18 hours, to allow SNP cell internalization, before analyses by flow cytometry. (A) The 
fluorescence intensity of the NIR-SNPs- and m-NIR-SNPs-labeled cells, detected 
selectively on the FL4 channel, is indicated by the light grey histograms. On the right 
panels, the overlays compare the fluorescence intensity of the double dye-doped NP-3 
[Cy5.5-Si+Cy7-Si] either with the unlabeled cells (Unlab.) or with the single dye-doped NP-
1 [Cy5.5-Si]. (B) Flow-cytometric analyses of SNP-labeled cells are shown as dot plots; 
percentages of the positive cells (into the lower right quadrant) are indicated. (C) 
Equimolar aliquots of the SNP preparatives were placed on a paper substrate before 
analysis of the fluorescence with a time-domain fluorescence imager Optix. Results are 
expressed as means ± SD (experiments performed in triplicate). (D) Comparison of 
absorption and emission spectra of the double dye-doped [Cy5.5-Si+Cy7-Si] samples NP-
3 and NP-4. (A-D) For each set of analyses, representative results out of three 
independent experiments are shown. 
 
By comparison of the fluorescence of the SNPs obtained with a small animal TD 
fluorescence imager, NP-3 sample exhibited the best result in terms of emission intensity. 
This performance was better compared to that obtained with NP-1 and NP-2, but also with 
respect to NP-4 sample, which had the same content of the Cy5.5-Si but the highest Cy7-
Si content: this result was due to the fact that NP-3 and NP-4 samples had very similar 
quantum yields (ΦNP-3 = 0.08 and ΦNP-4 = 0.06), but not the same energy transfer efficiency 
(38% and 70%, respectively) (Table 4.2 and Figure 4.6C).  
As can be seen from Figure 4.6D for the NP-3 sample, the lower Cy7 concentration 
promoted the increase in the Cy5.5 fluorescence intensity. On the other hand, the higher 
Cy7 concentration in NP-4 decreased the Cy5.5 fluorescence intensity, because the 
increased concentration of the energy acceptor Cy7 raised the energy transfer efficiency. 
For these reasons, NP-3 SNPs were chosen for the in vivo experiments relating to their 
biodistribution in healthy mice as well as in lymphoma bearing xenografts, and their 
suitability as contrast imaging agents for cell labeling and tracking. 
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Figure 4.9 also showed an irrelevant NIR fluorescence in the small intestine wall sections; 
nevertheless, this apparent contradiction of what ex vivo analysis of the organs underlined 
can be explained with the presence of the m-NIR-SNPs in the feces. It is of interest to note 
that the overall conclusions derived by whole-body and ex vivo analyses are consistent 
with the excretion of the silica based nanostructures by the hepatobiliary way.10 Finally, 
although a fluorescent signal was revealed by microscopic examination of kidneys 
sections, no fluorescence was detected in urine samples: this observation confirmed data 
previously reported showing that molecules with a hydrodynamic diameter greater than 8 
nm do not typically undergo to glomerular filtration.21 
 
4.2.3 In vivo tumor imaging and cell tracking 
With the aim to assess the possible tumor-targeting properties of SNPs, the JVM-2 human 
leukemic cells were injected subcutaneously in SCID mice (107 cells per mouse) to obtain 
the formation of a tumor of an average size of 0.6–0.7 cm diameter in 12–15 days after 
injection.22,23 After that, subcutaneous tumor-bearing mice were i.v. injected with the NP-3 
sample and monitored for up to 48 hours (Figure 4.10A). At 24 hours after injection, it was 
possible to note a clear accumulation of SNPs in the tumor site by the in vivo whole-body 
TD optical imaging. Previous observations were confirmed by the ex vivo analysis of the 
explanted tumor masses, which highlighted the localization of the m-NIR-SNPs 
fluorescence signal into the JVM-2-derived tumor mass (4.10B).  
 
 
Figure 4.10 Application of m-NIR-SNPs as contrast agent for in vivo tumor imaging. SCID 
mice (n=8) were subcutaneously injected with JVM-2 cells (107 cells/mouse) and, when 
xenograft tumors reached the size of 0.6-0.7 cm diameter, mice were either left untreated 
or i.v. injected with the m-NIR-SNPs. (A) Whole-body scan of a representative tumor-
bearing mouse. Fluorescence intensity images were acquired at the indicated time post-
injection; arrows indicate the tumor site. (B) Ex vivo imaging of the tumor mass explanted 
from mouse either left untreated or injected with m-NIR-SNPs. IHC analysis documents 
that the tumors derive from the s.c. injected CD20 + JVM-2 cells (original magnification 
x200). Representative results are shown. 
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At 48 hours after injection, although m-NIR-SNPs uptake was mainly in the liver, a 
fluorescence signal due to the SNPs was still noticeable. These results demonstrated the 
ability of the circulating SNPs to passively localize into solid tumors due to the enhanced 
permeability and retention (EPR) effect, which depends on numerous factors such as 
extensive angiogenesis and hence hypervasculature, defective vascular architecture and 
impaired lymphatic drainage/ recovery system.24 Of course, the tumor-targeting properties 
of m-NIR-SNPs could be useful for important applications such as tumor imaging (for 
diagnostic purposes and for intraoperative image guidance) and/or to deliver drugs 
physically entrapped in the silica matrix of the SNPs (See Chapter 7) to the tumoral sites. 
The possibility of using the SNPs for in vivo cell tracking of cells labeled with the SNPs 
was also investigated.10,25 For this study, which represented a combination of flow-
cytometry and optical imaging, JVM-2 cells were labeled with m-NIR-SNPs and the 
efficiency of the intracellular uptake was verfied by flow-cytometry, before s.c. injection in 
SCID mice (Figure 4.11). 
 
 
Figure 4.11 m-NIR-SNPs allow multiparametric analysis in flow-cytometry. Cells were 
either left untreated or incubated with m-NIR-SNPs at 37°C for 18 hours, to allow SNPs 
cell internalization, before analyses by flow cytometry in combination with antibodies (Ab) 
for cell surface antigens. JVM-2 cells were labelled with m-NIR-SNPs along with the B-cell 
specific CD19 Ab. Flow-cytometric analyses of multi-labeled cells were shown as two-
colours dot plots in which co-expression (of either 2 different antigens or antigen + NP) 
was documented by localization of the cells in the upper right quadrant. Irr., isotype-
matched control Ab. The results showed that m-NIR-SNPs fluorescence did not interfere 
with the fluorescence (FITC, PE) of Ab used for phenotypical cell characterization. 
Representative results out of three independent experiments are shown. 
 
Injected mice were then monitored daily by whole-body TD optical imaging. As can be 
noted from Figure 4.12A, a strong fluorescent signal was detectable in the injection site for 
3 days after cell inoculation and, although the signal decreased progressively over time, it 
JVM-2 
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was still visible for 12 days. It is important to note that the fluorescent signal was due to the 
to the m-NIR-SNPs-JVM-2 labeled cells, and not derived from cell-free nanoparticles, as 
demonstrated by two important evidences: (1) the co-localization of the fluorescence and 
of the human CD20 antigen (the marker of JVM-2 cells), respectively, was documented by 
ex vivo and IHC analyses of the explanted subcutaneous tissue (Fig. 4.12B); (2) a 
subcutaneous tumor mass became macroscopically detectable at the injection site from 
day 8 onward (Fig. 4.12C).  
 
 
Figure 4.12 In vivo cell tracking using m-NIR-SNPs as cell labeling probe. JVM-2 leukemic 
cells were either left untreated or incubated with m-NIR-SNPs at 37°C for 18 hours, to 
allow SNPs cell internalization, before s.c. injection in SCID mice (107 cells/mouse). (A 
and B) Whole-body scan of a representative mouse injected with m-NIR-SNPs-labeled 
JVM-2 and ex vivo imaging of the explanted subcutaneous tumor mass. Microscopic 
analyses of tumor sections stained with haematoxylin and eosin (H&E) and anti-human 
CD20 staining (original magnification x200) confirm the co-localization of the in vivo and 
ex-vivo fluorescence signal with the s.c. injected CD20 + JVM-2 cells. (C) At the indicated 
time post-injection of the labeled cells, fluorescence intensity images were acquired from 
whole-body scan of 5 mice and results are expressed as means±SD. 
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As a consequence, the tumor-forming capacity of m-NIR-SNPs- labeled cells can be a tool 
to monitor both the cell localization upon injection and the site of tumor development, with 
the possibility to anticipate and substitute eventual macroscopic manifestations or autoptic 
examinations in animal models. 
 
4.3 Conclusions 
In this work, a synthetic strategy based on the development of silica-core PEG-shell 
nanostructures doped with a donor-acceptor couple exhibiting a tunable intensity profile 
across the NIR spectrum was reported. This is a fundamental feature in view of 
applications such as whole-animal optical imaging and in vitro and in vivo cell labeling 
applications. In fact, this approach allows to increase the fluorescence signal in vivo, and 
to match in a versatile way the probe and instrumental setup spectral properties. 
Moreover - respect  to the single dye preparation - it will be possible a significant 
improvement of the signal-to-noise ratio of optical measurements, since large pseudo 
Stokes-shifts can be obtained exploiting efficient energy transfer processes within the 
particle.24,26-29 These features will be useful in designing new application for imaging 
agents based on silica nanoparticles for different experimental disease models. 
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Chapter 5 
Silica nanoparticles as agents for optoacoustic imaging 
 
5.1 Introduction 
In this work dye-doped near infrared-emitting silica nanoparticles (NIR-SNPs) were 
designed to study their potential application in the field of the optoacoustic imaging. 
Optical imaging proved to be an important method for bioanalytical applications, operating 
on contrast mechanisms which permit the visualization of cellular and subcellular function 
and structure.1 Optical imaging methods used different physical parameters of the 
interaction of light with tissue (Table 5.1). The image signal provided by these methods 
appears mainly as a function of internal contrast, which often shows a limited  information 
content. A recent technique, however, has gained great popularity, as it offers molecular 
specificity to in vivo imaging technologies: fluorescence imaging. In fluorescence imaging, 
the light that comes from an external source is absorbed and immediately re-emitted at a 
longer wavelength (see Section 1.3). This technique can be performed with different 
resolutions and depth of penetration, ranging from micrometers (intravital microscopy) to 
centimeters (fluorescence molecular tomography, FMT) (Table 5.1).  
 
Table 5.1 Optical in vivo imaging systems, as in reference 4. 
Methoda Constrastb Depth Commonly 
used λ 
Clinical 
potentialc 
A-Epi Ab, Fl 20 µm Visible 
 
A-Confocal Fl 500 µm Visible 
 
A-Two-photons Fl 800 µm Visible 
 
B-Opt. projection tomography Ab, Fl 15 mmd Visible 
 
B-Opt. coherence tomography Sc 2 mm Visible, NIR 
 
B-Laser speckle imaging Sc 1 mm Visible, NIR 
 
C-Hyperspectral imaging Ab, Fl, Sc <5 mm Visible 
 
C-Endoscopy Ab, Fl, Sc <5 mm Visible 
 
C-Polarization imaging Ab, Sc <1.5 cm Visible, NIR 
 
C-Fluor. reflectante imaging (FRI) Ab, Fl <7 mm NIR 
 
C-Diffuse opt. tomography (DOT) Ab, Fl <20 cm NIR 
 
D-Fluor. Resonance imaging (FRI) Ab, Fl <7 mm NIR 
 
D-Fluor. molecular tomography (FMT) Fl <20 cm NIR 
 
D-Bioluminescence imaging (BLI) Em <3 cm 500-600 nm 
 
aA=microscopic resolution; B=mesoscopic resolution; C=macroscopic resolution, intrinsic contrast; 
D=macroscopic resolution, molecular contrast. bAb=absorption; Em=emission; Sc=scattering; 
Fl=fluorescence. c =yes; =no; =experimental. d In cleared specimen. 
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The recent development of a strong variety of fluorescent tags, which can display 
functional and molecular processes in vivo, showed the fascinating benefits of 
fluorescence for the optical imaging.2    
In this context, the development of bright near-infrared (NIR) fluorescent probes, with 
excitation and emission spectra above 650 nm, allows more interesting applications,3 such 
as whole body animal imaging. Indeed, it gives high sensitivity imaging through several 
millimeters of tissue, because hemoglobin (that is the principal absorber of visible light), 
water and lipids (that are the principal absorbers of infrared light) have their lowest 
absorption coefficient in the NIR spectral region (650–900 nm).4  
Imaging in this wavelength range can have the additional advantage of minimizing tissue 
autofluorescence, thus increasing the signal-to-noise ratio.5 A great multiplicity of probes 
operating in the NIR region have been developed, from fluorescent dyes (that are able to 
preferentially accumulate in tissues of interest) to activatable photoproteins.3,6 
Furthermore, several nanoparticles with optical contrast, such as gold or carbon 
nanoparticles, can be derivatized for specific cell targeting and molecular imaging.7-10  
Conventional microscopy methods allow the visualization of in vivo imaging of optical 
reporter molecules, especially in cell monolayers or thin tissue slices. Over the last 
decade, in this field an increase in performance has occurred with the use of confocal and 
multiphoton microscopy for a deeper imaging than ever before in tissues.11,12 Confocal 
microscopy can succeed in reaching depths of up to 100-200 µm when imaging highly 
scattering tissues in vivo, while two-photon and multiphoton microscopy can achieve 300-
500 µm. However, these techniques, together with the Optical Projection Tomography 
(OPT)13 and Selective Plane Illumination Microscopy (SPIM)14 (which are very useful for 
volumetric imaging of low-scattering samples) are highly limited by tissue scattering.  
As previously described, it is necessary to use optical reporter agents that work in the NIR 
region to reach a detection through up to few centimeters in tissues. Photon scattering 
process in tissues, however, can make imaging more difficult to achieve, yielding a 
significant resolution loss. A solution can be macroscopic optical tomography, that can 
resolve optical contrast in three-dimensions using optical measurements through multiple 
illumination and detection projections around the tissue of interest and, finally, 
mathematically combining these measurements to have a three-dimensional 
reconstruction of optical contrast images inside the investigated object.15-17  
In recent years the accessibility to hybrid approaches, such as the combination with X-ray 
computed tomography (CT),18,19 magnetic resonance imaging (MRI)20 and optoacustic 
methods, leaded to improvements in macroscopic optical imaging performance, making 
these hybrid methods valuable and versatile for bioimaging. In this study, the interest has 
been directed to optoacoustic methods based on NIR-SNPs for imaging applications, with 
the aim to obtain a deeper penetration and higher spatial resolution that the ones achieved 
by optical microscopy. 
Optoacoustic (or photoacoustic) imaging relies on the generation of acoustic waves 
following the absorption of light pulses of ultrashort duration. The optoacoustic 
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phenomenon has been known for over a century,21 but only in the last decade has been 
used for bioanalytical applications.22-24 The increase in the use of this technique was due 
to the coupling of the commercially available pulsed laser technology in the nanosecond 
range with sensitive acoustic detectors, yielding the generation of optoacoustic responses 
from tissue and the visualization of subsurface blood vessels with high resolution.25-27  
In particular, MultiSpectral Optoacoustic Tomography (MSOT) is based on the spectral 
identification of chromophoric agents (such as molecules and particles) spread in tissue 
over background tissue absorption, and requires that the tissue of interest is illuminated 
with light pulses of time-shared multiple wavelengths of duration in the 1-100 ns range. 
The fast absorption of light pulses produces a response from photoabsorbing agents: 
indeed, the latter are designed to have an efficient and fast non radiative deactivation; this 
process leads to a thermoelastic expansion of the solvent around the dye that generates 
mechanical waves at ultrasonic frequencies. Acoustic detectors, placed in proximity to the 
illuminated tissue, can detect these waves. By modeling photon and acoustic propagation 
in tissues and using appropriate mathematical methods (inversion, or simply tomographic 
methods), it is possible to obtain images; if different dyes are present, it is also possible to 
spectrally separate their contribution to yield the biodistribution of all reporter molecules 
and tissue biomarkers (Figure 5.1). 
Each light wavelength can generate images separately, but multiwavelength illumination 
and spectral processing are necessary for the identification of the unique spectral 
signatures of optical reporter agents of interest in the presence of intrinsic tissue 
chromophores. MSOT imaging requires agents with absorption spectra that show 
characteristic differences from the absorption of background tissue; for this reason,  
 
Figure 5.1 Principle of MSOT operation. (A) Light pulses of different time-shared multiple 
wavelengths illuminate the tissue of interest and achieve transient photon fields in tissue. 
(B) The fast absorption of light pulses produces a thermoelastic expansion that generates 
acoustic responses, that are then detected using acoustic detectors. (C) Tomographically 
reconstructed and spectrally unmixed images depicting the photoabsorbing agent (NIR-
SNPs, in this case) and water signals detected by MSOT. 
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molecules or nanoparticles that have steep absorption changes are preferible, since it is 
easier to resolve them by scanning narrow spectral bands. Reporter agents with molecular 
specificity without characteristic spectral signatures - such as agents with slow varying, 
broad absorption spectra - can also be detected in MSOT, using single wavelength 
measurements. In this case baseline measurements must be available, and this method is 
appropriate for highly absorbing agents with fast distribution or expression dynamics.28  
Moreover, it is also necessary to evaluate the effects of light propagation in tissues 
accurately, to decompose the true probe concentration from variations of the optoacoustic 
signal due to light intensity variations in tissue. 
In summary, with this method the spectral signature of the reporter dyes is distinguished 
with specificity from the nonspecific background absorption by multispectral separation. 
Suitable photoabsorbing agents display different spectra compared to the background 
absorption spectrum: as a consequence, compounds that have high molar extinction 
coefficients and can be detected above the intrinsic tissue optoacoustic signal are 
important for molecular imaging applications.29 Previous reports showed that for these 
applications suitable agents could be conjugated plasmonic particles (e.g. gold 
nanorods),7,9,10,30,31 targeted particles (e.g. carbon nanotubes, quantum dots),8,32-34 
fluorochromes and organic dyes (conjugated for targeting)35,36 and agents used in other 
nonoptical imaging modalities (e.g. MRI) (Table 5.2).37 In the next section, the design and 
synthesis of NIR-SNPs will be shown to assess their potential application as 
photoabsorbing agents for optoacoustic imaging. 
 
Table 5.2 Optical Characteristics of Major Tissue Chromophores and Some Optoacoustic 
Molecular Contrast Agents. The actual values can change depending on the particular 
compound and its derivatization; therefore, representative examples are provided, as in 
references 8, 9, 28, 32, 34, and 36. 
Chromophore λexc  
(nm) 
εa  
(cm-1 M-1) 
Φem Concentration-normalized 
absorptivityb [cm-1/(mg/mL)] 
Oxygenated 
hemoglobin (HbO2) 
750 
550 
5.2 x 102 
58 x 103 
0 
0 
0.008 
0.9 
Eumelanin 
 
750 
550 
4.7 x 102 
1.2 x 103 
0 
0 
2.3 
5.8 
NIR- organic dyes 
(AlexaFluor750) 
750 2.5 x 102 0.12 169 
 
Red-shifted fluor. 
protein (mCherry) 
587 7.2 x 104 0.22 2.2 
Single-walled 
carbon nanotubes 
750 1.5 x 107 0 150 
Gold nanorods  750 9.4 x 108 0 72 
Activ. chromogenic 
assay (X-gal) 
650 104 0 24.5 
NIR-Quantum 
dots 
840 5 x 106 0.13 9.9 
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aThese numbers are provided per particle/molecule; bIt is an estimate of a contrast agent’s 
efficiency, with optical absorption coefficient in cm-1, created in the target volume by a 1 
mg/mL concentration of the contrast agent. 
 
5.2 Results and discussion 
5.2.1 Synthesis and characterization of NIR-SNPs 
In this work, dye-doped core-shell NIR-SNPs were synthesized using a one-pot synthetic 
approach (see Section 8.9), which starts from the preparation of surfactant Pluronic F127 
micelles in water.38-43 The resulting SNPs are photostable, showing high and durable 
monodispersity and colloidal stability,44-48 displaying low adhesion properties toward 
proteins and that make them suitable for in vitro and in vivo experiments.49,50   
Different dye-doped NIR-emitting silica nanoparticles (m-NIR-SNPs) were synthesized 
using increasing doping ratios of the triethoxysilane derivative Cy5.5-Si (Figure 5.2A) (see 
Section 4.2 and Section 8.2), utilized either alone (NPLP-2, -3, -4, -5 and -6, Figure 5.3) or 
together with the IR813 triethoxysilane dye derivative Cy7-Si (NP-3, -4 and -5, Fig. 5.2 and 
5.3) to evaluate their suitability as optoacoustic imaging probes (Figure 5.3, Table 5.3).  
 
 
Figure 5.2 Molecular structure of: (A) Cy5.5-Si; (B) Cy7-Si. 
 
M-NIR-SNPs presented the distinctive absorption bands of the two Cyanine derivatives 
(693 nm, Cy5.5-Si; 828 nm, Cy7-Si, Figure 5.4). As can be seen from Table 5.4, m-NIR-
SNPs with the highest Cy5.5-Si content (NPLP-5 and NPLP-6) exhibited the best results in 
terms of luminescence brightness, due to a higher fluorescence quantum yield and a 
higher molar absorption coefficient. This last property makes m-NIR-SNPs very promising 
tools for optoacoustic imaging. Additional photophysical properties of these SNPs are 
reported in Table 5.4. Moreover, from a morphological point of view, these nanoparticles 
have shown values comparable to those found in Section 4.2.1 (silica core diameter (dc) ~ 
A B 
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10  nm; hydrodynamic diameter (dH) ~ 25  nm), with relatively low polidispersity index (PdI 
~ 0.25). 
 
 
Figure 5.3 Doping dyes (Cy5.5-Si and Cy7-Si) and schematization of the synthetic 
procedure used for the synthesis of the m-NIR-SNPs (NPLP-2, -3, -4, -5 and -6; NP-3, -4 
and -5) samples described in this work. 
 
Table 5.3 Doping characteristics of the SNPs samples presented in this study. 
SNPs 
sample 
%Dyea TEOS 
          mmol 
Cy5.5-Sib 
µmol 
Cy7-Sib 
µmol 
NP-3 0.2 Cy5.5-Si- 
0.1 Cy7-Si 
 0.8 1.6  0.8 
NP-4 0.2 Cy5.5-Si- 
0.2 Cy7-Si 
 0.8 1.6  1.6 
NP-5 0.4 Cy5.5-Si- 
0.4 Cy7-Si 
 0.8 3.2  3.2 
NPLP-2 0.2 Cy5.5-Si-  0.8 1.6  - 
NPLP-3 0.5 Cy5.5-Si-  0.8 4  - 
NPLP-4 1 Cy5.5-Si-  0.8 8  - 
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NPLP-5 2 Cy5.5-Si-   16  - 
NPLP-6 5 Cy5.5-Si-   40  - 
aDoping ratio=[mol(dye)/mol(TEOS)]*100. bCy5.5-Si and Cy7-Si were introduced in the 
reaction mixtures using pristine dichloromethane solutions. 
 
 
 
Figure 5.4 (A) Absorption spectra of aqueous suspensions of nanoparticles samples NP-
3, NP-4 and NP-5 ([NP-3] = 0.4 µM; [NP-4] = 0.2 µM; [NP-5] = 0.1 µM ). (B) Emission 
spectra of aqueous suspension of nanoparticles samples NP-3, NP-4 and NP-5 (λex = 650 
nm). (C) Absorption spectra of aqueous suspensions of NPLP-6 ([LPSC-6] 0.1 µM. (D) 
Emission spectra of aqueous suspension of NPLP-6 (λex = 650 nm). 
 
Table 5.4 Spectral and emission properties of nanoparticles samples. 
Sample Abs. 
max./nm 
Emi. 
max.a/nm 
Φem τ
b,d
 τc r  
(∆λ/nm) 
re (∆λ/nm) 
Cy5.5-Si 685 717 0.07 1.6 - - - 
Cy5.5 f 683 707 0.2 1.4 - - - 
Cy7-Si 819 860 0.03 - - - - 
NP-3 645, 693,  
828 
724, 860 0.08 1.0 1.1 0.4 (720-730)e 0.4 
(850-870) 
NP-4 645, 693,  
828 
724, 860 0.06 0.5 0.7 0.4 (720-730)e 0.1 
(850-870) 
NP-5 645, 693,  
828 
724, 860 0.06 0.5 0.7 0.4 (720-730)e 0.006 
(850-870) 
NPLP-2 645, 688 722 0.03 1.4 - 0.008 
(720-730)d 
 
NPLP-3 645, 688 712 0.05 1.4 - 0.3  
(710-720)e 
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NPLP-4 645, 691 716 0.07 1.2 - 0.1  
(710-720)e 
 
NPLP-5 645, 691 720 0.07 1.2 - 0.2  
(714-724)e 
 
NPLP-6 645, 691 721 0.12 0.8 - 0.1  
(720-730)e 
 
a λex = 650 nm; b λem = 724 nm; c λem = 860 nm; d λex = 640 nm; e λex = 650 nm; f Cy5.5 
commercial dye (Cy5.5 GE) was purchased from GE Healthcare 
 
5.2.2 In vitro optoacoustic experiments 
In the first set of experiments, SNPs doped with both fluorophores (NP-3, NP-4 and NP-5) 
were analyzed to evaluate the possibility of obtaining a detectable optoacoustic signal. For 
this purpose water solutions of the three probes were placed into the scattering MSOT 
phantom (1.5% agar, 1% intralipid) to determine their optoacoustic spectra (Figure 5.5). 
 
 
Figure 5.5 Optoacoustic spectrum of NP-3, NP-4 and NP-5 samples. Water dilutions of 
the three probes were placed into a scattering MSOT phantom (1.5% agar, 1% intralipid) 
to determine their optoacoustic spectrum (insertion diameter: 3 mm). 
 
The MSOT optoacoustic spectrum resembled the absorption spectrum of analyzed SNPs 
with regard to peak wavelengths and signal strength at 690 nm, while the peak at 830 nm 
produced a weak optoacoustic signal.  
The analysis of tomographically reconstructed and spectrally unmixed images depicting 
NP-3, NP-4 and NP-5 samples detected by MSOT in combination with the MSOT 
quantification revealed that:  
• NP-3, NP-4 and NP-5 samples generated a signal detectable by means of MSOT 
imaging;  
• 2) the SNPs preparatives share very low lower limit of quantification (LLOQ) (NP-3 
= 9.1 nM; NP-4 = 18 nM; NP-5 = 19 nM) and high linearity between the optoacoustic 
signal and the concentration (Figure 5.6).  
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Figure 5.6 Tomographically reconstructed and spectrally unmixed images of m-NIR-SNPs 
and water signals detected by MSOT in single cross-sections for each dilution. A) Dilutions 
of NP-3, NP-4 and NP-5 samples in water (starting concentration 1 OD; OD = Optical 
Density) were inserted in a scattering agar phantom (1.5% agar and 1% Intralipid; 2 cm 
diameter) along with water as a control. MSOT acquisition was performed in five imaging 
planes (~800µm cross-section) with a 2 mm step size. B) MSOT quantifications of m-NIR-
SNPs. Regions of interest were drawn around the probe and water phantom insertions and 
the spectrally unmixed signal was quantified. Error bars: standard error o the mean of 5 
measurements. For clarity, only results of experiments done with NP-3 are shown. 
 
To further investigate the possibility to use the m-NIR-SNPs for in vivo evaluation, the 
photoacoustic spectrum of nanoparticles doped with Cy5.5-Si (NPLP-2, -3, -4, -5, -6) was 
acquired in the wavelength range from 680 to 970 nm using PBS spectrum as reference 
for background values (Figure 5.7). Higher values were in the wavelength range from 680 
to 730 nm. While NPLP-2 and -3 displayed spectra similar to the PBS, NPLP-4, -5 and -6 
samples showed greater photoacoustic intensity (PAI) values with NPLP-6 showing the 
highest signal.  
Similar results were obtained with spectra recorded after dilution with PBS (dilution factor = 
2), with NPLP-6 exhibiting the best result in terms of photoacoustic intensity.  
 
 Concentration (µM) 
OD NP-3 NP-4 NP-5 
1.0 4.6 2.4 2.4 
5.0x10-1 2.3 1.2 1.2 
2.5x10-1 1.2 5.9x10-1 5.9x10-1 
1.3x10-1 5.8x10-1 2.9x10-1 3.0x10-1 
6.3x10-2 2.9x10-2 1.5x10-1 1.5x10-1 
3.1x10-2 1.4x10-2 7.4x10-2 7.4x10-2 
1.6x10-2 7.2x10-2 3.7x10-2 3.7x10-2 
7.8x10-3 3.6x10-3 1.8x10-2 1.9x10-2 
3.9x10-3 1.8x10-3 9.2x10-3 9.3x10-3 
2.0x10-3 9.1x10-3 4.6x10-3 4.6x10-3 
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Figure 5.7 Optoacoustic spectrum of NPLP-2, -3, -4, -5 and -6 samples. A) and B) The 
phantom for the optoacoustic in vitro tests is a polyurethane tubing (outer diameter: 0.9 
mm; inner diameter: 0.6 mm) submerged in a vinyl and borax gel. C) The acquisitions 
were performed along the major axis of the tube, obtaining content tube axial sections 
images. D)  Comparison with PBS spectrum. [m-NIR-SNPs] = 20µM. 
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D 
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Figure 5.8 Optoacoustic spectrum of NPLP-4, -5, -6 samples after dilutions with PBS. 
Final [m-NIR-SNPs] = 10µM. 
 
The results showed an important decrease of photoacoustic intensity (PAI) values (~ 80%) 
that was not proportional to dilution (Figure 5.8). 
Subsequently, blood spectrum was recorded and compared with the NPLP-4, -5 and -6 
spectrum, showing that at the wavelength of interest for in vivo testing (range from 680 to 
730 nm) there was no interference from blood signal (Figure 5.9).  
 
 
Figure 5.9 Comparison between NPLP-4, -5, -6 samples and blood optoacoustic 
spectrum. [m-NIR-SNPs] = 20µM.  
 
Finally, LPNP-4, -5 and -6 were diluted with blood (dilution factors = 2 for NPLP-4, -5 and -
6; 3 and 3.5 for NPLP-6), displaying a decrease in the PAI signal that was again not 
proportional to dilution (Figure 5.10). As showed in Fig. 5.10, also after dilution with blood, 
the best results were obtained from the sample with the highest Cy5.5-Si content, 
suggesting its use in further experiments in vivo. 
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Figure 5.10 Optoacoustic spectrum of NPLP-4, -5, -6 samples after dilutions with blood. A) 
Final [m-NIR-SNPs] = 10µM. B) Final [NPLP-6] = 6.7µM and 5.7 µM. 
 
5.3 Conclusions 
In this work, we have reported a synthetic strategy to develop silica-PEG core-shell 
nanostructures doped with two cyanine dyes displaying a tunable intensity profile across 
the NIR spectrum.  
The synthetic approach shown in this chapter has enabled to synthesize SNPs suitable for 
in vitro optoacoustic imaging, as it permitted to increase the m-NIR-SNPs extinction 
coefficient value, resulting in a significant improvement of the photoacoustic intensity. 
Indeed, these SNPs showed a signal detectable by means of MSOT imaging, even when 
the samples were diluted with PBS and blood. These results represent an interesting 
starting point for the design of new platforms for optoacoustic imaging in vivo based on 
silica nanoparticles.  
A 
B 
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Furthermore, these results open the way for a possible use of these nanoparticles as 
sensitisers for phototherapeutic modalities for the treatment of solid tumours, such as the 
PhotoThermal Therapy (PTT).51,52 
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Chapter 6 
Silica nanoparticles as fluorescent chemosensors 
 
6.1 Introduction 
In this study dye-doped silica-core/PEG-shell nanoparticles (DSNPs) were designed to 
develop a chemosensor for the sensing of the Glutathione and the Caspase-3 enzyme. 
One of the most important topics in nanomedicine is represented by luminescent 
chemosensors, able to monitor in vitro and in vivo biologically relevant analytes. A 
luminescent chemosensor is the combination of different components: (i) a recognition site 
(receptor) able to recognize the analyte; (ii) a signaling unit (luminophore)  apt to signal the 
binding event, and (iii), in most cases, a linker between the receptor and the luminophore 
(Figure 6.1).  
 
 
Figure 6.1 Schematic representation of a luminescent chemosensor. 
 
To investigate the functions and the possible alterations of target analytes in living 
systems, these probes can take advantage of the high sensitivity and spatio-temporal 
resolution provided by fluorescence techniques.1-4 In addition to a high signal-to-noise ratio 
and selectivity, the ideal chemosensor should also avoid the perturbation of the cellular 
methabolism, descreasing, for instance, the concentration of analytes such as metal ions.5  
Among the available nanostructures, that include Quantum Dots (QDs)6-10 and gold 
nanoparticles,11-15 DSNPs play a promising role,16-18 circumventing several restrictions of 
conventional chemosensors.2,19-25 One of the unique advantages that SNPs can offer in 
the field of sensing is signal amplification and to lower the detection limits using energy- 
and electron-transfer processes. Indeed, because of their collective nature, it is very 
challenging to obtain these functions following a supramolecular approach, with a 
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receptor-linker(s)-luminophore(s) structure.1 In this context, the group of Prodi and co-
workers developed SNPs doped with a chemosensor having the dansil-polyamine as 
fluorophore-receptor couple; this system was used to quench 13 fluorescent units upon the 
complexation of a single copper ion.26 To amplify the quenching luminescence response to 
the presence of Cu (II) ions, Tonellato et al. proposed an alternative approach based on 
the assembly of fluorescent dyes and receptors on the SNPs surface; due to their 
proximity, the dye-receptor couple was able to allow intercomponent photoinduced 
processes, with the need of a direct covalent bond.27,28  
The previous example revealed that the amplification of the luminescence signal is an 
important objective for SNPs-based chemosensors. An example was shown by using a 6-
methoxy-8-p-toluensulfonamidequinoline (TSQ) derivative as a probe for Zn (II) ions:29 
short distances for homo- and hetero-energy transfer processes - that produced the 
amplified enhancement of the luminescence signal - were obtained by grafting the different 
components on the nanoparticles surface (Figure 6.2).30  
 
Figure 6.2 Schematization of functionalized SNPs and  triethoxysilane TSQ derivative as 
in reference 29. A) In the absence of zinc ions, TSQ excited states deactivate mostly in a 
nonradiative way (black dashed arrows), because the radiative path (red arrows) is 
inefficient. B) At low zinc concentration, [TSQ2Zn] complexes are formed and the 
fluorescence of the complexed units is switched on (green arrows): as a result of energy 
transfer processes (ET), the excitation energy absorbed is funneled towards the 
fluorescent excited states. 
 
More recently, our group proposed a new, very efficient strategy to monitor Cu(I) ions in 
biological samples, achieving both signal amplification and affinity increase.31 A bodipy-
based chemosensor32 was added to a water solution of DSNPs doped with a coumarin 
derivative. The doping fluorescent units were chosen in order to have an efficient energy 
transfer process between the dyes inside the nanoparticles and the bodipy derivative when 
hosted by the nanostructutre. The chemosensor, due to its lipophilic nature, in fact, was 
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able to be hosted by the SNPs. The signal transduction mechanism of this nanosensor 
was based on the modulation of the energy transfer efficiency by the Cu(I) complexation 
(Figure 6.3). This system also showed additional benefits: (i) the increase in separation 
between the excitation and emission wavelengths, leading to the enhancement of the 
signal-to-noise ratio and (ii) the use of water insoluble chemosensors in aqueous media, 
which is a general advantage of using DSNPs in sensing. Indeed, this approach was later  
exploited also with various chemosensors for sensing Hg (II) ions in different milieu.33,34 
 
 
Figure 6.3 Schematization of the transduction mechanism in the sensing system for Cu(I) 
ions as in reference 31. 
 
The previous examples showed the two main advantages for sensing applications 
provided by DSNPs: versatility and multi-functionality. In this work, these features will be 
exploited for the design of a chemosensor for the Caspase-3 enzyme (Cas-3) and the 
Glutathione (GSH). 
 
6.2 Results and discussion 
6.2.1 Design of biosensor for Cas-3 based on DSNPs 
Apoptosis - the programmed cell death - is a highly regulated process which occurs in 
multicellular organisms.35-40 This essential physiological process has an astonishing role in 
the development of multicellular organisms, regulation of the immune system, and 
+ 
- 
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clearance of abnormal cells. Shortcomings in cell death regulation may compromise 
homeostasis causing several diseases such as neurodegenerative disorders, cancer, 
autoimmune diseases, atherosclerosis and myocardial infarction. Consequently, 
monitoring apoptosis is crucial to the early identification of therapy efficiency and the 
assessment of disease progression.41-45 
Caspases are a family of ubiquitously expressed cysteine proteases involved in the 
initiation and execution of apoptosis, which are present in cells as inactive zymogens. Pro-
apoptotic signals activate initiator caspases, which cleave downstream effector caspases, 
causing a proteolytic cascade that leads to cell death.46-53 
The activation of Caspase-3 (Cas-3) is essential for the neural cells apoptosis, since it is 
the key activator in the self-propagation of positive feedback cycle composed by other 
caspases in the apoptotic pathway. However, there is the need for sensors with high 
specificity to detect Cas-3 in vitro or in vivo, as its activation mechanism is not completely 
understood.53-58  
As Cas-3 recognizes and cleaves with high specificity the N-terminus of the tetra-peptide 
sequence Asp-Glu-Val-Asp (DEVD), it is possible to use this sequence for Cas-3 
detection. DEVD-containing peptides have been combined with nanomaterials such as 
quantum dots (QDs),59,60 graphene oxide,61 carbon nanotubes,62 manganese oxide63 and 
gold nanoparticles.64,65 In this work NPs doped with a triethoxysilane derivative of 
Rhodamine B (RhodB-Si, Figure 6.5) were covalently linked to a DEVD-containing peptide 
(G-DEVD-Pra, Figure 6.4), which was functionalized with a nonfluorescent quencher 
(Black Hole Quencher, BHQ) derivative. This peptide was close enough to the DSNPs 
core to enable an energy transfer process between the rhodamines and the BHQ. After 
proteolitic cleavage, rhodamine dyes and quencher were separated, resulting in an 
increased fluorescent signal (Figure 6.5). 
 
 
Figure 6.4 Molecular structure of G-DEVD-Pra (DEVD) peptide synthesized for the 
present work. Abbreviations were used for amino acids: G=glycine; D=aspartic acid; 
E=glutamic acid; Pra=propargyl glycine.  
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Figure 6.5 Schematization of the main components of the Cas-3 sensor based on DSNPs. 
 
6.2.2 Design of biosensor for GSH based on DSNPs 
In this work we have also designed a sensor for the detection of the Glutathione (GSH) 
based on DSNPs. 
GSH is a thiolated tripeptide that is the main redox buffering system of the cell (Figure 
6.6). It is present at concentrations up to 10 mM in the cellular environment, with several 
functions, such as the regulation of intracellular redox activity, the protection of DNA and 
RNA from free radicals and the maintenance of xenobiotic metabolism and gene 
regulation.66-68 
 
 
Figure 6.6 Molecular structure of Glutathione (GSH). 
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Abnormal levels of GSH can cause serious diseases, including liver damage, Alzheimer’s 
disease, autism, cancer and AIDS.69 As a consequence, the development of luminescent 
biosensors for detection of GSH has special importance to understand its vital functions 
and has become a crucial topic of current chemical research,70-73 involving nanomaterials 
such as carbon nanodots,74 QDs,69,75,76 upconversion nanoparticles (UCPs)77 and 
manganese oxide,78,79 gold80 and silver nanoparticles.81    
In the present study, we used a system very similar to the one previously described for 
Cas-3 detection to achieve the sensor for GSH; in this case the nucleophilic GS- was able 
to attack one of the two sulfur atoms of disulfide bond (S-S) which was positioned between 
the DSNP and the BHQ derivative, leading to the increase in the fluorescent signal (Figure 
6.7). 
 
 
Figure 6.7 Schematization of the main components of the GSH sensor based on DSNPs. 
 
6.2.3 Synthesis of F127-BHQ derivatives 
Non-fluorescent BHQ-2 quenchers are widely used to achieve FRET-based bioprobes,82-86 
as they exhibit a broad absorption spectrum which covers the blue-red - ca. 400-600 nm - 
part of the visible spectrum (according to the solvent and substitution pattern of the 
aniline).87,88 
80 
 
Four different BHQ-2 derivatives (Figure 6.8) were synthesized to carry out the quenching 
of the rhodamines loaded within the DSNPs (Fig. 6.5 and 6.7). Sulfonate (BHQ-sul), 
alcohol (BHQ-alc) and PEG (BHQ-PEG) moieties were used to decrease their lipophilic 
nature - due to the aromatic bis-diazo scaffold - and to increase their water solubility up to 
a concentration range compatible with bio-applications involving FRET probes (µm to mm). 
 
 
Figure 6.8 Molecular structure of BHQ-PEG, BHQ-alc, BHQ-sul and BHQ-car derivatives. 
 
As can be seen from Figure 6.8, BHQ-PEG, -alc and -sul derivatives were functionalized 
with an alkyne group to perform azide-alkyne cycloaddition reactions (“click” reactions)89 
with the “clickable” F127-SS-azide, allowing the covalent linking of quenchers to the 
surfactant Pluronic F127 (Figure 6.9). The resulting F127 derivatives (F127-SS-BHQ-PEG, 
-sul and –alc) were used to develop a sensing system for GSH based on SNPs. 
The click approach has also been used for the reaction between the GDP-BHQ-PEG and 
the F127-azide derivative, leading to the BHQ-derivatized surfactant F127-D-BHQ-PEG 
which was involved in the synthesis of SNPs suitable for the detection of Cas-3 enzyme 
(Figure 6.10). 
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Figure 6.9 Schematization of the synthesis of F127-SS-BHQ-PEG, -alc and –sul 
derivatives. Reagents and conditions: i) Na ascorbate, Cu(II) sulfate pentahydrate, 1,4-
Dioxane/H2O, room temperature, 8 h. 
 
 
Figure 6.10 Schematization of the synthesis of F127-D-BHQ-PEG derivative. Reagents 
and conditions: i) DIPEA, DMF, room temperature, 16 h; ii) F127-azide, Na ascorbate, 
Cu(II) sulfate pentahydrate, DMF, room temperature, 8 h. 
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6.2.4 Synthesis and characterization of SNPs 
On the basis of a one pot synthetic approach that we have recently developed (Section 
8.9),90-92 we designed a family of SNPs by using suitably derivatized surfactant, F127-SS-
BHQ-PEG, -sul, -alc (Figure 6.9) and F127-D-BHQ-PEG (Figure 6.10 and Table 6.1). In 
this way, the outer shells of the nanoparticles were decorated with SS-BHQ-PEG, alcohol, 
sulfonate and D-BHQ-PEG moieties yielding NPGP, NPGa, NPGs and NPDP, as 
schematically represented in Figure 6.11. Different SNPs preparatives were synthesized 
by using increasing amounts of derivatized surfactant (NP-16 and NP-32); furthermore, 
non-derivatized SNPs (NP-PEG, see Section 3.2.1) were prepared and used in the 
fluorescence experiments for comparison (Table 6.1). All SNPs were covalently doped 
with the triethoxysilane derivative of Rhodamine B (RhodB-Si, Fig 6.6, 6.7, 6.11 and Table 
6.1). 
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Figure 6.11 Schematic representation of the synthetic procedure and the main 
components of derivatized NPGa, NPGs, NPGP and NPDP.  
 
Table 6.1 Quantities of F127 surfactant and RhodB-Si used in SNPs preparations. RhodB-
Si was introduced in the reaction mixtures using pristine methanol solutions. 
 
 
Morphological characterization by TEM images (Figure 6.12) showed that the silica core 
(dc) was very similar for all samples, with values ranging from 10 to 12 nm. The 
hydrodynamic diameter (dH) measured by dynamic light scattering (DLS) (Figure 6.13) was 
very similar for NP-PEG, NPGP-16, NPGP-32 and NPGs-16 (dH = 24, 26, 26 and 27 nm, 
respectively) with a very low polydispersity index (PdI = 0.02, 0.03, 0.06 and 0.09, 
respectively). Slight aggregation among particles was instead observed in the case of 
NPGa-16 and NPGa-32 (dH = 38 and 34 nm; PdI = 0.25 and 0.30, respectively) and for 
NPGs-32, NPDP-16 and NPDP-32 (dH = 65, 83 and 86 nm; PdI = 0.28, 0.49 and 0.23, 
respectively) , probably due to H-bonding interactions among the SNPs (Table 6.2). 
 
Table 6.2 Mean silica core  (dc ± SD) determined by TEM analysis and DLS hydrodynamic 
values (dH  ± SD) for the SNPs described in this work. Standard deviation was calculated 
on five different measurements. 
NPs sample F127  
(mg) 
  Derivatized F127       (mg) RhodB-Si 
(mg) 
NP-PEG 100 - 1.45 
NPGP-16 84 F127-SS-BHQ-PEG     16 1.45 
NPGP-32 68 F127-SS-BHQ-PEG     32 1.45 
NPGs-16 84 F127-SS-BHQ-sul        16 1.45 
NPGs-32 68 F127-SS-BHQ-sul        32 1.45 
NPGa-16 84 F127-SS-BHQ-alc        16 1.45 
NPGa-32 68 F127-SS-BHQ-alc        32 1.45 
NPDP-16 84 F127-D-BHQ-PEG       16 1.45 
NPDP-32 68 F127-D-BHQ-PEG       32 1.45 
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Sample (dc ± SD) / nm (dH ± SD) / nm PdI 
NP-PEG 10 ± 1    24 ± 3 0.02 
NPGP-16 11 ± 3    26 ± 4  0.03 
NPGP-32 10 ± 2    26 ± 6  0.06 
NPGs-16 11 ± 2    27 ± 8 0.09 
NPGs-32 11 ± 2      65 ± 30  0.28 
NPGa-16 12 ± 3      38 ± 20  0.25 
NPGa-32 11 ± 2      34 ± 20  0.30 
NPDP-16 12 ± 2      83 ± 60  0.49 
NPDP-32 11 ± 3      86 ± 40  0.23 
 
 
 
 
Figure 6.12 TEM images and silica core size distribution of: A) NPGP-16 (dc = 11 ± 3 nm); 
B) NPGs-32 (dc = 11 ± 2 nm); C) NPGa-16 (dc = 12 ± 3 nm); D) NPDP-32 (dc = 11 ± 3 nm).  
For clarity, only results of experiments done with NPGP-16, NPGs-32, NPGa-16 and 
NPDP-32 are shown. 
 
 
A B 
C D 
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Figure 6.13 DLS diameter distribution by volume and undersize curve for: A) NPGP-16 (dH 
= 26 ± 4 nm); B) NPGs-32 (dH = 65 ± 30 nm); C) NPGa-16 (dH = 38 ± 20 nm); D) NPDP-32 
(dH = 86 ± 40 nm).  For clarity, only results of experiments done with NPGP-16, NPGs-32, 
NPGa-16 and NPDP-32 are shown. 
 
6.2.5 Evaluation of quenching efficiency 
Fluorescence spectra were recorded to evaluate the decrease of emission intensity of 
NPGP, NPGs, NPGa and NPDP samples with respect to the unquenched NP-PEG. 
Interestingly, normalized integral emission intensities of SNPs-16 (Figure 6.14) revealed 
that BHQ-2 quenchers were efficient at quenching RhodB-Si with a general value of nearly 
80% for NPG samples (NPGP-16 = 82%; NPGs-16 = 81%; NPGa-16 = 78%) and 66% for 
NPDP-16.  
SNPs-32 provided an increase in quenching efficiency, with NPDP-32 exhibiting the best 
results - 90 % - with respect to the other nanoparticles (NPGP-32 = 87%; NPGs-32 = 89%; 
NPGa-32 = 84%, Table 6.3). Subsequently, NPGP-32, NPGs-32 and NPGa-32 were 
treated with Tris(2-CarboxyEthyl)Phosphine (TCEP), able to reduce organic disulfides to 
thiols in water.93-95 Interestingly, the quenching effect due to BHQ was removed in about 
an hour, leading to a complete restoration of the NPs fluorescence (Figure 6.15). 
FRET-based sensors are widely used in bioassay sensors.96,97 Taken together, our 
quenching data - that indicated the increase in SNPs quenching efficiency up to 90% - 
represent a promising starting point for potential in vitro and in vivo detection of the Cas-3 
and GSH. 
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Figure 6.14 Decrease of emission intensity of derivatized NPGa, NPGs, NPGP and NPDP 
with respect to the unquenched NP-PEG. A) NPGP-16 and NPGP-32; B) NPGs-16 and 
NPGP-32; C) NPGa-16 and NPGa-32; D) NPDP-16 and NPDP-32. 
 
Table 6.3 Quenching efficiency % of derivatized NPGa, NPGs, NPGP and NPDP with 
respect to the unquenched NP-PEG (NP-PEG = 100%). λex = 530 nm. [SNPs] = 0.1 µM.  
Sample Quenching 
efficiency % 
NP-PEG - 
NPGP-16 82 
NPGP-32 87 
NPGs-16 81 
NPGs-32 89 
NPGa-16 78 
NPGa-32 84 
NPDP-16 66 
NPDP-32 90 
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Figure 6.15 Fluorescence recovery of (A) NPGa-32, (B) NPGs-32, (C) NPGP-32 in water 
after the addition of TCEP (D). [NPs] = 13 nM; [TCEP] = 14 mM. 
 
6.3 Conclusions 
In the present work we displayed a synthetic strategy based on the development of silica-
core PEG-shell nanoparticles covalently doped with a triethoxysilane derivative of 
Rhodamine B. The resulting SNPs were highly bright and monodisperse, displaying high 
stability under physiological conditions.91,98 
These SNPs were covalently linked to a DEVD-containing peptide that was functionalized 
with a nonfluorescent quencher (GPD-BHQ-PEG), to obtain FRET-based nanoplatforms 
suitable for the detection of Cas-3 (NPGP, NPGs and NPGa). By using a system similar to 
the one described for Cas-3 detection, it was possible to synthesize a sensor for the 
detection of GSH based on SNPs (NPDP). BHQ-2 quenchers were very efficient at 
quenching RhodB-Si, yielding quenching efficiency values up to 90%.  
These results are very encouraging in view of the next steps planned for this study, 
namely (i) the analysis of photophysical parameters to determine the nature of the 
quenching and (ii) the in vitro and in vivo detection of the Cas-3 and GSH. 
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Chapter 7 
Silica nanoparticles for drug delivery 
 
7.1 Introduction 
In this study luminescent silica-core/PEG-shell nanoparticles (DSNps) were designed to 
assess their potential application in drug delivery. 
Nanotechnology is a discipline in rapid and continuous evolution, as it seeks to offer 
solutions to current social, environmental and health problems. In this regard, one of its 
most important applications is to develop multifunctional platforms suitable for cancer 
treatment, within a broader context concerning theranostics, i.e., the simultaneous 
diagnosis and therapy.  
Particularly, we believe that DSNPs offers very appealing solutions in this field for several 
reasons. Firstly, luminescence measurements are very sensitive (down to single molecule 
detection), easily performed, and versatile, offering submicron spatial resolution and sub 
millisecond temporal resolution.1 This enables, in general, low detection limits (and thus, 
early diagnosis), and could permit the tracking of biological events to reveal the origin and 
growth of different pathologies, including cancer. Secondly, compared to magnetic 
resonance imaging (MRI), optical imaging is much easier to use and more cost-effective, 
and can be applied to cancer diagnosis with high resolution.2 This could lead to direct 
visualization of tumour tissues in real-time during the surgical process, providing direct 
guidance to surgeons for effective and complete tumour resection.3 Finally, since optical 
fibres are currently used in the investigation of some tumours (such as colorectal cancer), 
near infrared (NIR) imaging can be quickly and easily introduced into clinical practice.4 
There are many different nanocolloids that could offer a valuable alternative to SNPs, such 
as dye-doped latex nanoparticles5-7 or intrinsically luminescent nanomaterials, such as the 
so-called quantum dots (QDs).3,8,9 However, in our opinion, silica is the only one capable of 
offering all the required features for effective diagnostic and theranostic applications.3,8,10-16 
Silica is intrinsically not toxic, although more in-depth investigations are under way to 
completely rule out possible hazards related to the tiny dimensions of nanoparticles. 
Preliminary experiments point in favour of their benign nature, even supporting their use 
for in vivo imaging and therapy.3,4,8,11 Silica nanoparticles constitute a robust domain also 
under different external stimuli, providing increased mechanical strength and chemical 
stability to the loaded species, as well as protection against enzymatic degradation, an 
enhanced resistance to photobleaching and an almost constant chemical environment.17,18 
Since silica is photophysically inert, it is transparent to visible light and is not involved in 
energy- and electron-transfer processes that may quench the luminescence of the dyes 
linked to the matrix. In addition, each silica nanoparticle can contain many active species, 
which can induce collective effects to increase the brightness and the signal-to-noise ratio. 
Moreover, the great versatility offered by the different synthetic strategies, typically 
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requiring inexpensive reagents and mild conditions, is an extremely valuable characteristic 
since it opens up the possibility to adapt these materials for a large number of 
applications.4,11  
While some nanomedicine-based drug/dye delivery systems have already been marketed 
and others are in clinical trials, most remain in the stage of preclinical development. 
Mesoporous silica nanoparticles have been highlighted as an interesting drug delivery 
platform, due to their flexibility and high drug load potential, and have therefore been 
extensively investigated as delivery systems. In spite of considerable interest in the 
biomedical applications of such nanoparticles, the knowledge of their in vivo 
biocompatibility, toxicity and bio-distribution remains limited, which has delayed the onset 
of human clinical trials. 
Within this context, in the present study we have evaluated the possible application of dye-
doped silica-core/PEG-shell nanoparticles (DSNPs) as drug delivery systems, by using 
Dasa-10 (Dasa), i.e., an anticancer drug that belongs to the family of substituted N,N’-
diarylsulfonamides (Figure 7.1).19 The synthesis of such a drug, as well as that of the 
DSNPs, will be analyzed in the next section. 
 
 
Figure 7.1 Molecular structure of Dasa. 
 
7.2 Results and discussion 
7.2.1 Dasa: synthesis and preliminary study of loading 
Dasa is a promising anticancer agent because it is a pharmacological activator20-23 of the 
tumor cell specific pyruvate kinase isozyme that is known as PKM2.19,24-27 To understand 
the importance of this activator, it is necessary to analyze the differences in metabolic 
requirements of differentiated and proliferative tissues (Figure 7.2). 
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Figure 7.2 Schematic representation of the differences between oxidative 
phosphorylation, anaerobic glycolysis, and aerobic glycolysis (Warburg effect). 
 
In the presence of oxygen, differentiated tissues first metabolize glucose to pyruvate via 
glycolysis and then completely oxidize most of that pyruvate in the mitochondria to CO2 
during the process of oxidative phosphorylation. Oxygen is essential for this process 
because it is required as the final electron acceptor to completely oxidize the glucose. 
When oxygen is limiting, cells can redirect the pyruvate generated by glycolysis away from 
mitochondrial oxidative phosphorylation by generating lactate in a process called 
anaerobic glycolysis. This generation of lactate during anaerobic glycolysis allows 
glycolysis to continue. Warburg observed that cancer cells - and normal proliferative 
tissues - have increased rates of lactate production even in the presence of oxygen 
(aerobic glycolysis).28-32 This altered metabolism is thought to give tumor cells a selective 
growth advantage compared to normal cells.  
PKM2 is usually inactive in tumor cells. Substituted N,N’-diarylsulfonamides, such as 
Dasa, are pharmacological activators of PKM2, directing glucose towards oxidative 
metabolism; in this way it is possible to alter the Warburg effect, yielding a therapeutic 
potential in the treatment of cancer and other metabolic diseases.19  
Dasa was synthesized by using a strategy based on an efficient sequence of coupling 
reaction, deprotection, and a second coupling reaction as detailed in Figure 7.3.19  
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Figure 7.3 Schematization of the synthesis of Dasa. Reagents and conditions: i) and iii) 
TEA, DCM, 0°C, 1 h; ii) TFA, DCM, 0°C, 1 h; iv) SnCl2.2H2O, EtOH, 70°C, 50 min. 
 
In particular, the monoboc protected diazepine (2) was coupled to aryl sulfonyl chloride (1) 
to provide the corresponding boc-protected N-arylsulfonamide (3). These intermediate was 
deprotected and subsequently coupled to the second aryl sulfonyl chloride (5) to provide 
the N,N’-diarylsulfonamide derivative (6) that was reduced to yield Dasa (for more details 
see Section 8.3).  
On the basis of a one-pot synthetic approach that our group recently developed,33-35 we 
designed SNPs covalently doped with the triethoxysilane derivative of Rhodamine B 
(RhodB-Si), which allows visualization by both fluorescence microscopy and flow-
cytometry.36 Multifunctional NPs were realized by adding Dasa in the same synthetic step, 
to be confined - due to its lipophilic nature - within the apolar silica core of NPs; indeed, in 
view of a potential application of the above-mentioned nanoparticles in the field of drug 
delivery, it was necessary that Dasa was simply physically entrapped in the SNP structure. 
The non-covalent entrapment of the drug, however, increases the likelihood of leaching 
from the particle; for this reason, a high Dasa : NP doping ratio (50 : 1) was chosen for a 
preliminary study, yielding NPT-1-D50. (Table 7.1 and Figure 7.4). 
 
 
Figure 7.4 Schematic representation of the synthetic procedure and the main components 
of NPT-1-D50. 
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Table 7.1 Doping characteristics of the SNPs sample presented in this study. 
SNPs 
sample 
Doping 
ratioa 
SNPs 
µmol 
TEOS 
mmol 
RhodB-Sib 
µmol 
Dasa 
µmol 
NPT-50 50 0.2  1.6 2  10 
aDoping ratio= [mol(drug)/mol(NP)]. bRhobB-Si was introduced in the reaction mixture 
using pristine dichloromethane solutions. 
 
By means of absorbance measurements of NPT-50 (εDasa = 5.65 x 103 M-1 cm-1 at λmax = 
292 nm) and considering the NP concentration obtained with this synthetic method,37 we 
found that the loading of Dasa inside the silica matrix (5 molecules of Dasa per NP) was 
lower than expected; this was probably due to a difficulty of entrapment of the drug in the 
silica matrix, which led quickly to leaching of Dasa from the particle.  
 
7.2.2 Synthesis and characterization of SNPs  
In light of the results of this preliminary test, we decided to design different NPs with 
improved properties using three different silica precursors (Figure 7.5) with the following 
objectives: (i) the synthesis of SNPs that had increased lipophilic nature on their silica core 
by using the derivative BTSE; indeed, as can be seen from Fig. 7.5, the presence of an 
ethylene moiety makes this derivative more apolar than TEOS. BTSE was utilized either in 
combination with TEOS (NPB-1, NPB-2 and NPB-3) at three different BTSE : TEOS 
molecular ratios (1 : 3, 1 : 1 and 3 : 1) or alone (NPB-4) (Table 7.2); (ii) the synthesis of 
SNPs capable of establishing H-bonding interactions between their silica core and the 
hosted molecule by using the derivative BUPS, which had an ureidic moiety suitable for 
this purpose. BUPS was employed in combination with TEOS (NPU-1 and NPU-2) at two 
different BUPS : TEOS molecular ratios (1 : 3 and 1 : 9). Non derivatized SNPs were also 
prepared and used in subsequent experiments for comparison (NPT-1) (Figure 7.5 and 
Table 7.2). 
 
 
Figure 7.5 Molecular structure of silica precursors TEOS, BTSE and BUPS. 
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Table 7.2 Doping characteristics, mean silica core - dc ± SD - determined by TEM analysis 
and DLS hydrodynamic values (dH ± SD) for the SNPs described in this work. Standard 
deviation was calculated on five different measurements 
SNPs 
sample 
TEOS BTSE BUPS (dc ± SD) 
 / nm 
(dH ± SD)  
/ nm 
PdI 
mmol % mmol % mmol %    
NPT-1 1.6 100 - - - - 11 ± 2 20 ± 4 0.04 
NPB-1 1.2 75 0.2 25 - - 11 ± 4 23 ± 9 0.15 
NPB-2 0.8 50 0.4 50 - - 10 ± 3 25 ± 12 0.22 
NPB-3 0.4 25 0.6 75 - - 11 ± 4 35 ± 12 0.12 
NPB-4 - - 0.8 100 - - 11 ± 4 35 ± 24 0.48 
NPU-1 1.2 75 - - 0.2 25 11 ± 3 17 ± 8 0.21 
NPU-2 1.44 90 - - 0.08 10 12 ± 4 23 ± 12 0.26 
 
Morphological characterization by TEM images showed that all SNPs shared a low 
polydispersion index (PdI) and that the dimensions of the silica core (ca. 12 nm) were not 
influenced by the silica precursor used (Table 7.2, Figure 7.6). The hydrodynamic diameter 
(dH), measured by dynamic light scattering (DLS), was similar for all samples, with values 
ranging between 17 and 35 nm (Table 7.2, Figure 7.7). These data confirmed the 
possibility of applying such nanoplatforms to evaluate if the possibility to tune the polarity 
of their silica core could increase the loading and retention of Dasa within the particles. 
 
 
  Figure 7.6 TEM images and silica core size distribution of: A) NPT-1 (dc = 12 ± 4 nm); B) 
NPB-4 (dc = 11 ± 4 nm). For clarity, only results of experiments done with NPT-1 and NPB-
4 are shown. 
 
 
A B 
A B 
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Figure 7.7 DLS diameter distribution by volume and undersize curve for: A) NPT-1 (dH = 
20 ± 4 nm); B) NPB-4 (dH = 35 ± 24 nm). For clarity, only results of experiments done with 
NPT-1 and NPB-4 are shown. 
 
7.2.3 Synthesis and characterization of DSNPs with Dasa 
A selection of the samples shown previously, NPT-1, NPB-2, NPB-4 and NPU-1 was 
chosen to synthesize DSNPs covalently doped with RhodB-Si; drug loading was carried 
out by using increasing Dasa : NP doping ratio (50 : 1, 100 : 1 and 300 :1), yielding NP-
D50, NP-D100 and NP-D300 preparatives (Table 7.3 and Figure 7.8).   
 
Table 7.3 Doping characteristics of the SNPs sample presented in this study. 
SNPs 
sample 
TEOS BTSE BUPS Rhod
B-Sia 
Dasa 
initial 
d. ratiob 
Dasa 
final 
d. ratioc mmol % mmol % mmol % µmol 
NPT-1-D50 1.6 100 - - - - 2 50 5 
NPT-1-D100 1.6 100 - - - - 2 100 9 
NPT-1-D300 1.6 100 - - - - 2 300 11 
NPB-2-D50 0.8 50 0.4 50 - - 2 50 2 
NPB-2-D100 0.8 50 0.4 50 - - 2 100 4 
NPB-2-D300 0.8 50 0.4 50 - - 2 300 17 
NPB-4-D50 - - 0.8 100 - - 2 50 7 
NPB-4-D100 - - 0.8 100 - - 2 100 8 
NPB-4-D300 - - 0.8 100 - - 2 300 23 
NPU-1-D50 1.2 75 - - 0.2 25 2 50 4 
NPU-1-D100 1.2 75 - - 0.2 25 2 100 8 
NPU-1-D300 1.2 75 - - 0.2 25 2 300 33 
aRhobB-Si was introduced in the reaction mixture using pristine dichloromethane solutions. 
bInitial Doping ratio=[mol(drug)/mol(NP)]; cFinal doping ratio=[mol(drug)/mol(NP)] after the 
purification step by means of size-exclusion chromatography (see Section 8.1.2). 
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Figure 7.8 Schematic representation of the synthetic procedure and the main components 
of NPT-1, NPB-2, NPB-4 and NPU-1 loaded with Dasa. 
 
The results obtained clearly demonstrated that the loading of Dasa within the 
nanoparticles increased in a nonlinear way upon increasing the initial Dasa : NP molecular 
ratio; the lack of linearity was probably due to the saturation of the porous sites present in 
the silica core and to the differences in release rate of the drug at different loading level. 
Finally, the analysis of data relating to particles having the highest initial doping ratio (NPT-
1-D300, NPB-2-D300, NPB-4-D300 and NPU-1-D300) revealed that the increase of the 
apolarity detected by employing a mixed system TEOS/BTSE in place of the one 
containing the only TEOS could almost double the units of drug per particle. The best 
loading of Dasa was found in sample NPU-1-D300, due to the presence of a precursor 
containing an ureidic moiety capable of giving H-bonding interactions between the silica 
core and the hosted molecule. 
 
7.3 Conclusions  
Fluorescence imaging techniques are becoming essential in biomedical applications and 
the research of suitable tools for in vitro and in vivo measurements is gaining increasing 
attention. Nanotechnology is supplying many solutions for present limitations in the field 
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and, in particular, luminescent nanoparticles are one of the most promising materials 
proposed for future diagnostic implementations. 
In this contribution we have focused our attention on dye doped silica nanoparticles, since 
they are able to merge different materials to combine various functionalities. That is, to act 
as a basis for multifunctional medicine dedicate nanoplatforms, enabling multimodal 
imaging and simultaneous diagnosis and therapy. 
In particular, we tested the ability of the particles to load biologically active molecules such 
as Dasa, an anti cancer drug capable of altering the Warburg effect, yielding a therapeutic 
potential in the treatment of cancer and other metabolic diseases. DSNPs were 
synthesized in increasing degree of lipophilicity and ability to establish hydrogen bond 
interactions in their silica core, resulting in an increased loading capacity of the drug within 
the silica core. However, this step, that is crucial for pratical applications, is only the first 
one towards a potential application of these systems in clinical trials. Therefore, this study 
will continue in the coming months in order to synthesize novel silica derivatives and 
multimodal/multifunctional nanoparticles suitable for theranostics. 
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Chapter 8 
Experimental section 
 
8.1 Materials and methods 
8.1.1 Chemicals 
1-Iodopropane (99%), Malonaldehyde bis(phenylimine) monohydrochloride (97%), Acetic 
anhydride (≥ 99%), 6-Bromohexanoic acid (97%), Dimethylformamide (DMF ≥ 99.8%, over 
molecular sieve, H2O ≤ 0.01%), Pyridine (≥ 99.8%), 1-[Bis(dimethylamino)methylene]-1H-
1,2,3-triazolo[4,5-b]pyridinium3-oxidhexafluorophosphate (HATU, 97%), 1-
Hydroxybenzotriazole hydrate (HOBt ≥ 99%)  IR-813 perchlorate (80%), (3-
Mercaptopropyl)triethoxysilane (≥ 80%), Acetonitrile (MeCN, 99.8%), Diethyl ether (Et2O, ≥ 
99.8%), Methanol (MeOH, ≥ 99.8%), Magnesium sulfate (≥ 99.5%), Dichloromethane 
(DCM, ≥ 99.8%), Ethyl acetate (EtOAc, ≥ 99.5%), Sodium hydroxide (≥ 98%), Piperidine (≥ 
99.5%), Pluronic F127, Tetraethyl orthosilicate (TEOS, 99.99%), Copper(II) sulfate 
pentahydrate (≥ 98%), N,N-Diisopropylethylamine (≥ 99%), Chlorotrimethylsilane (TMSCl, 
≥ 98%), Acetic acid (HOAc, ≥ 99.7 %), HCl (≥ 37 %), 4-(Dimethylamino)pyridine (DMAP, ≥ 
99%), HBTU (≥ 98%), N,N’-Disuccinimidyl carbonate, Propargyl bromide solution (80 wt. 
% in toluene),  DSC ( ≥ 98%), 1,6-Diaminohexane (98%), Tin(II) chloride dehydrate (98%), 
Trifluoroacetic acid (TFA, 99%), N-(2-Hydroxyethyl)aniline (98%), Sodium bicarbonate (≥ 
99.7%), sodium sulfate (≥ 99%), 1,4-Dioxane (≥ 99%), reagent grade Ethanol (EtOH), 
DMF, Et2O, DCM, Thionyl chloride, Acetone, Dimethyl sulfoxide (DMSO), Cyclohexane, 
Chloroform, Heptane were purchased from Sigma-Aldrich. 
Triisopropylsilane (TIS, 99%), 3-Azido-1-propanol (97%) 3-(Triethoxysilyl)propyl 
isocyanate (95%), 1,2-Bis(triethoxysilyl)ethane (96%), 3-Nitrobenzenesulfonyl chloride 
(97%), 1,4-Benzodioxan-6-sulfonyl chloride (95%), 1-Boc-hexahydro-1,4-diazepine (98%), 
Fmoc-tBu-Gly-OH (≥ 98%), Fmoc-Glu(OtBu)-OH (≥ 98%),  Fmoc-Val-OH (98%), Fmoc-
Asp(OtBu)-OH (≥ 98%), Sulfur trioxide triethylamine complex (≥ 95%), Propargylamine 
(98%), 4-Nitrophenyl chloroformate (96%), 1,1′-Carbonyldiimidazole (≥ 97%), 3-Bromo-1-
propanol (97%), Sodium azide (≥ 99%) and Methanesulfonyl chloride (98%) were 
purchased from Aldrich. 
Lithium chloride (≥ 99%), Sodium phosphate monobasic (≥ 98 %), Fluorescamine (≥ 98 %) 
and Sodium ascorbate (≥ 99%) was purchased from Sigma. 
Octaethylene glycol monomethyl ether (≥ 96%) was purchased from TCI. 
(Fmoc-Pra-OH) was purchased from ChemPep Inc. 
Cystamine dihydrochloride (≥ 98 %), Methoxypolyethylene glycol amine (PEG-NH2, MW 
750 g/mol), (3-Aminopropyl)triethoxysilane (APTES, ≥ 98%), Fast Black K salt, N,N-
Diisopropylethylamine (DIPEA, ≥ 98%), Triethylamine (TEA, ≥  99.5%), NaCl and Silica on  
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Reference Cy5.5 commercial dye (Cy5.5 GE) was purchased from GE Healthcare 
(Amersham FluoroLinkTM Cy5.5 Monofunctional dye, Code: PA25501). 
Resin Rink amide AM was purchased from Activotec 
 
8.1.2 Purifications 
Dialysis was performed vs. water at room temperature under gentle stirring with 
regenerated cellulose dialysis tubing (Sigma, mol wt. cut-off > 12 KDa, avg. diameter 33 
mm). 
After dialysis, all luminescent nanoparticles samples were passed through hydrophilic 
Durapore membrane filters (0.45, 0.22 and 0.1 µm pore size) purchased from Millipore. 
Size-Exclusion Chromatography (SEC) was performed on Sephadex G-25 (nanoparticles 
for drug delivery, see Chapter 7), or Sephadex LH-20, that were purchased  from Sigma. 
Flash chromatography was performed on silica gel 60, 230-400 and 35-70 mesh. Thin 
layer chromatography was carried out on silica gel supported on aluminum foils, containing 
a fluorescent indicator at 254 nm. These products were purchased from Fluka. 
Semipreparative HPLC chromatography was performed on SunFire C18 column (5 µm, 19 
× 150 mm) on Gilson PLC2020. 
 
8.1.3 NMR measurements 
Unless otherwise specified, NMR measurements were recorded at 25 °C, in CDCl3, on a 
Varian Mercury Plus 200, 300 and 400 MHz spectrometer. Chemical shifts are reported in 
δ from Me4Si (δ = 0.00 ppm) or from CDCl3 (δ = 7.27 ppm for 1H-Nmr or δ = 77.0 ppm for 
13C-NMR). Multiplicities are reported using the following abbreviations: s (singlet); d 
(doublet); t (triplet); q (quartet), m (multiplet); br (broad), or a suitable combination. All 
coupling constants J are expressed in Hz. In case of uncertainty or ambiguity, proton 
assignments were determined by means of two-dimensional 1H,1H-Cosy experiments. 
 
8.1.4 Photophysical measurements 
UV-VIS absorption spectra were recorded at 25°C by means of Perkin-Elmer Lambda 45 
spectrophotometer. The fluorescence spectra were recorded with a Perkin-Elmer Lambda 
LS 55 fluorimeter and with a modular UV-VIS-NIR spectrofluorimeter Edinburgh 
Instruments FLS920 equipped with a photomultiplier Hamamatsu R928P. The latter 
instrument connected to a PCS900 PC card was used for the Time Correlated Single 
Photon Counting (TCSPC) experiments.  
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Chapter 4 and 5 - Corrected fluorescence emission and excitation spectra (450 W Xe 
lamp) were obtained with the same instrument equipped with both a Hamamatsu R928P P 
photomultiplier tube (for the 500-850 nm spectral range) and an Edinburgh Instruments Ge 
detector (for the 800-1600 nm spectral range).  
Quartz cuvettes with optical path length of 1 cm were used for both absorbance and 
emission measurements.  
Nanoparticles solutions were diluted with Milli-Q® water.  
Luminescence quantum yields (uncertainty ± 15%) were recorded on air-equilibrated 
solutions (absorbance < 0.1 in the whole spectral region to avoid auto-absorption), with 
rhodamine 101 in ethanol (Φ = 0.1) and cyanine IR-125 (from Acros Organics) in ethanol 
(Φ = 0.05) as a reference.1 Corrections for instrumental response, inner filter effects and 
phototube sensitivity were performed.2  
All fluorescence anisotropy measurements were performed on an Edinburgh FLS920 
equipped with Glan-Thompson polarizers. Anisotropy measurements were collected using 
an L-format configuration, and all data were corrected for polarization bias using the G-
factor. Four different spectra were acquired for each sample combining different 
orientation of the excitation and emission polarizers: IVV, IVH, IHH, IHV (where V stands for 
vertical and H for horizontal; the first subscript refers to the excitation polarizer and the 
second subscript refers to the emission one). The spectra were used to calculate the G-
factor and the anisotropy r: G = IHV/IHH, r = (IVV - GIVH)/(IVV + 2GIVH). 
 
8.1.5 Trasmission Electron Microscopy 
A Philips CM 100 transmission electron microscope operating at 80 kV was used. For TEM 
investigations a 3.05 mm copper grid (400 mesh) covered by a Formvar support film was 
dried up under vacuum after deposition of a drop of nanoparticles solution diluted with 
water (1:50). The SiNP TEM images show that only the silica cores present sufficient 
contrast to appear in the images. The size distribution was obtained analyzing images with 
a block of several hundred nanoparticles. The obtained histogram was fitted according to a 
Gaussian distribution obtaining the average diameter for the silica nanoparticles core. 
 
8.1.6 Dynamic Light Scattering  
Chapter 3, 6 and 7 - SNP hydrodynamic diameter (dH) distributions determination was 
carried out through Dynamic Light Scattering measurements with a Malvern Nano ZS 
instrument equipped with a 633 nm laser diode. Samples were housed in disposable 
polystyrene cuvettes of 1 cm optical path length, using water as solvent.  
Chapter 4 and 5 - SNP hydrodynamic diameter (dH) distributions determination was carried 
out at 25°C through Dynamic Light Scattering measurements using a NICOMP Model 370 
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Submicron Particle Sizer (Nicomp International, Orlando, FL) equipped with a 488 nm 
Argon laser. This laser source and equipment was used to minimize interferences due to 
absorption-emission processes during the DLS measurements. 
Samples were housed in small disposable glass test tubes, using water as solvent.  
The width of DLS hydrodynamic diameter distribution is indicated by the standard 
deviation of five different measurement. The Polydispersion Index values (in case of 
monomodal distribution PdI=(σ/Zavg)2, where σ is the width of the distribution and Zavg is 
average diameter of the particles population respectively) are also reported. 
 
8.1.7 ζ-Potential experiments  
SNPs ζ-Potential values were determined using a Malvern Nano ZS instrument. Samples 
were housed in disposable polycarbonate folded capillary cell (750 µL, 4 mm optical path 
length). Electrophoretic determination of ζ-Potential was made under Smoluchowski 
approximation in acqueous media at moderate electrolyte concentration. 
 
8.1.8 Cells 
Chapter 3 - Blood samples were collected in heparin-coated tubes from 6 healthy blood 
donors following informed consent, in accordance with the Declaration of Helsinki and in 
agreement with institutional guidelines. Peripheral blood mononuclear cells (PBMC) from 
healthy donors were isolated by gradient centrifugation with lymphocyte cell separation 
medium (Cedarlane Laboratories, Hornby, ON) and were routinely cultured in RPMI-1640 
medium containing 10% FBS, L-glutamine and Penicillin/Streptomycin (all from Gibco, Life 
Technologies Corporation, Paisley, UK). The JVM-2 B leukemic line was purchased from 
DSMZ (Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH, 
Braunschweig, Germany) and cultured, as previously described3 in RPMI-1640 medium 
containing 15% FBS, L-glutamine, Penicillin/Streptomycin, supplemented with glucose 4.5 
g/L, sodium pyruvate 1 mM, sodium bicarbonate 1.5 g/L, HEPES 10 mM (Gibco). Huh7 
hepatocellular-carcinoma cell line (European Collection of Cell Cultures, Salisbury, UK) 
was cultured in Dulbecco’s Modified Eagle Medium (DMEM) containing 10% FBS, L-
glutamine and penicillin/streptomycin (Gibco). Human umbilical vein endothelial cells 
(HUVEC) were purchased from BioWhittaker (Lonza, Walkersville, MD), grown in EGM2 
medium (Lonza) on tissue culture plates coated with 1µg/cm2 of human fibronectin (BD, 
Becton Dickinson, San Jose, CA) and used between the 3rd and 5th passage in vitro, as 
previously described.4  
Chapter 4 - JVM-2 B leukemic cell line was purchased from DSMZ (Deutsche Sammlung 
von Mikroorganismen und Zellkulturen GmbH, Braunschweig, Germany) and cultured in 
RPMI-1640 medium containing 15% FBS, L-glutamine, penicillin/streptomycin, 
supplemented with glucose 4.5 gL-1, sodium pyruvate 1 mM, sodium bicarbonate 1.5 gL-
1, HEPES 10 mM (Gibco, Grand Island, NY). Human bone marrow-derived mesenchymal 
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stromal cells (MSC) were isolated as previously reported.5 MSC cell preparations were 
homogenously CD105+, CD90+, CD34-, CD45-, CD14-, which is a typical MSC surface 
antigen profile, and were routinely cultured in MSC-Growth Medium (MSC-GM; Lonza, 
Walkersville, MD).  
 
8.1.9 Assessment of cell viability 
At different time points (24-96 hours) post treatment with SNPs used at different 
concentrations (range 1-100 nM), cell survival was evaluated by Trypan blue dye 
exclusion, as previously described.6,7 Moreover, the degree of apoptosis was evaluated by 
double-staining with PI and FITC-conjugated Annexin V (Alexis Biochemical, Enzo Life 
Sciences, Lausen, Switzerland,) according to the manufacturer’s instructions and analyzed 
by flow cytometry as previously detailed.8,9 These assays were performed on 0.5 ml of 
cells suspension, for PBMC and JMV-2 cultures. For cells growing in adhesion (HUVEC, 
Huh7 and MSC), adherent cells were recovered with 0.25% trypsin-EDTA (Gibco) and 
pooled with floating cells to analyze the degree of cell death and apoptosis in the entire 
cell population.10 In addition, for adherent cell types (HUVEC and Huh7), cell proliferation 
was analyzed by using the DP version of the xCELLigence real time cell analyzer RTCA, 
(Roche Diagnostics, Mannheim, Germany), which records changes in impedance 
(reported as Cell Index) over a prolonged time course in a non-invasive system. All data 
were then analyzed using the xCELLigence software (version 1.2.1). Briefly, the 
background impedance of RTCA DP E-Plates 16 was performed using a standard protocol 
provided in the software with 100 µL of cell culture medium (pre-coating with fibronectin 
was performed for HUVEC). Cells were seeded at a pre-defined optimal concentration in a 
final volume of 200 µL in quadruplicate before treatment with SNP preparations or, in 
some experiments, with Sorafenib 10µM as positive control of cellular cytotoxicity.11 Cell 
cultures treated in parallel in normal 96 well plates were analyzed for cell shape and 
growth changes and phase-contrast images were recorded with EVOS digital inverted 
microscope (Advanced Microscopy Group, Bothel, WA).  
 
8.1.10 Flow cytometric analysis  
Chapter 3 - The binding efficiency of SNPs to the cell surface membrane was investigated 
by flow cytometry (FACSCalibur Analyzer, BD), as previously described.12 JVM-2 cells, 
seeded at 106/mL, were incubated with Rhodamine-labeled SNPs (10-100 nM) for 45 min 
at 4°C, washed three times in ice-cold PBS, suspended in fresh medium and placed at 
37°C, 5% CO2. At different time points, cells were analyzed for the evaluation of 
Rhodamine signal persistence. SNP entry on adherent cell types (HUVEC and Huh7) was 
evaluated on cells treated as described above with Rhodamine-labeled SNPs. Flow 
cytometry analysis was performed following incubation of cells with 0.25% trypsin-EDTA to 
remove eventual residue of SNPs still attached to the outside of cells and to detach cells 
from the flask.13 In some experiments, cells were treated with the endocytosis inhibitor 
Genistein (0.4 mM, Sigma-Aldrich, Saint Luis, MO) starting from 2 hours before addition of 
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Rhodamine-labeled SNPs.14 Nonspecific fluorescence was evaluated on not-treated cells. 
Data files were collected and analyzed using the CellQuest Pro software. 
Chapter 4 - Cell labeling performance and/or efficiency of the single and m-NIR-SNPs was 
quantitatively evaluated by flow cytometry using a FACSCalibur Analyzer (Becton-
Dickinson, San Jose, CA) equipped with a 488 nm laser and a 635 nm laser, spatially 
separated. The filters used in our FACSCalibur provide the measurement of green (515-
545 nm; FL1), yellow (564-606 nm; FL2), red (> 670 nm; FL3) fluorescences excited at 
488 nm. The FL4 filter (653-669 nm) is used to measure the red fluorescence excited at 
635 nm. This is possible because of the particular hardware/elettronic setting, which allows 
the detection by the FL4 detector of the signals that have been exited by the 635 nm laser. 
For labeling of JVM-2, cells were seeded at 106 mL-1 in fresh medium before the addition 
of SNPs (10 nM). JVM-2 cultures were then placed at 37°C, 5% CO2, for 18 hours. For cell 
labeling of adherent MSC cultures, SNPs were directly added to the medium of sub-
confluent cell layer. Cultures were then kept at 37°C, 5% CO2 for 18 hours. After 18 hours 
of incubation, cells were washed with PBS and incubated with 0.25% trypsin–EDTA (to 
remove any eventual residue of SNPs attached to the outside of cells and/or to detach 
MSC cells from the flask) and analyzed by flow cytometry. For multiparametric analysis, 
JVM-2 and MSC cultures, either left untreated or labeled with siNPs, were then incubated 
with the following monoclonal antibodies (Ab) recognizing cell-type specific surface 
antigens: FITC-conjugated anti-human-CD19 and PE-conjugated anti-human-CD105 
(Immunotech; Marseille, France), FITC-conjugated anti-human-CD90 (Miltenyi Biotech, 
Auburn, CA). For cell surface staining, 5×105 cells were resuspended in 200 µL of PBS 
containing 1% BSA (Sigma-Aldrich, St Louis, MO) and incubated 30 minutes at 4°C with 
the conjugated monoclonal Ab (CD19 for the JVM-2 B cells; CD90 and CD105 for the 
MSC). Non-specific fluorescence was assessed by incubation of cells with isotype-
matched conjugated Ab (Becton-Dickinson). Data files were collected and analysed using 
the CellQuest Pro software and displayed as single histograms and as two-colours dot 
plots to measure the proportion of double-positive cells. 
 
8.1.11 Fluorescence microscopy 
For fluorescence microscopy observation, Huh-7 adherent cells were seeded over night at 
1.5x105/well on 6 well plates containing glass coverslips and treated with Rhodamine-
labeled SNPs (100-300 nM). At different time points, cells were fixed in paraformaldehyde 
4%, permeabilized with 0.1% Triton X-100 and stained with FITC-conjugated Phalloidin (all 
from Sigma-Aldrich) to mark intracellular actin.15 Cells were then mounted on slides with 
anti-fading and anti-photobleaching solution Vectashield Mounting Medium (Vector 
Laboratories, Burlingame, CA). Cells were examined using an inverted Swept Field Nikon 
(Nikon Corporation, Tokyo, Japan) confocal microscope equipped with 60x plan apoVC 
objective and Andor DU885 EM-CCD camera (Andor Technology Ltd, Belfast, Northen 
Ireland). Images were captured with Nikon NIS Elements software and analyzed using the 
Image-J 1.43m software (NIH, Bethesda, MA). In parallel, additional images were taken 
using the Xcellence® Olympus imaging platform (Olympus, Vienna, Austria) equipped with 
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Hamamatsu ORCA CCD camera and 60x oil immersion objective. For each field 21 planes 
of 0.5 µm each were acquired. Z-stacks were then visualized using the extended slice 
function on Bitplane Imaris 4.0 software (Bitplane AG, Zurich, Switzerland). 
 
8.1.12 In vivo experiments 
Chapter 3 - Female SCID mice (5 weeks-old) were purchased from Charles River 
Laboratories (Hollister, CA) and were maintained in accordance with the guide for the care 
and use of laboratory animals at the animal facility of the University of Ferrara. Mice were 
housed in vented cabinet with food and water ad libitum. The procedures involving animals 
and their care were approved by the institutional animal ethical care committee (CEASA) 
of the University of Ferrara and by the Italian Ministry of Health. JVM-2 (5x106) cells were 
treated for 24 hours with Rhodamine-labeled SNPs (100 nM), harvested, washed and 
suspended in PBS before intravenous injection (in a volume of 100 µL of PBS) into the 
lateral tail vein of adult mice. Controls were represented by mice injected with JVM-2 not 
loaded with SNPs. Twentyfour hours post inoculations, peripheral blood of mice was taken 
by intracardiac puncture performed under deep anesthesia followed by euthanasia of 
animals. Clot of blood was inhibited by addition of 10mg/ml EDTA. Before flow-cytometry 
analysis on mouse whole blood and evaluation of Rodamine-positive cells, red cells were 
lysed in lysing buffer (BD) following vendor’s instructions. 
Chapter 4 - Female BALB/c and SCID mice (4-6 weeks old) were purchased from Harlan 
(Italy) and maintained under pathogen-free conditions with ad libitum food and water, in 
accordance with the guide for the care and use of laboratory animals. All the experimental 
procedures were performed in compliance with the guidelines of European (86/609/EEC) 
and Italian (D.L.116/1992) laws and were approved by the institutional animal ethical care 
committee of the University of Trieste and by the Italian Ministry of Health. BALB/c mice 
were used for the biodistribution analysis of the m-NIR-SNPs in normal (healthy) settings, 
by i.v. injection of m-NIR-SNPs (1 nmol in 150 µL PBS, corresponded to 4.2 nmol of 
Cy5.5-Si). SCID mice were used to establish xenograft tumor models by subcutaneous 
(s.c.) inoculation on the left flank of 107 human leukemic cells (JVM-2) resuspended in 100 
µL of PBS. Explanted subcutaneous tumor masses, after ex vivo imaging acquisitions, 
were fixed in 10% buffered-formalin solution and embedded in paraffin for histological 
analysis. 
 
8.1.13 Optical imaging assessment  
Equimolar aliquots (20 µM) of the fluorescent single or m-NIR-SNPs preparatives were 
placed on a paper substrate and comparatively analyzed with a time-domain fluorescence 
imager Optix MX2 preclinical NIRF-imager (Advanced Research Technologies, Montreal, 
CA). The same equipment was adopted for the acquisition of in vivo data in mouse 
models, as previously described.16 Briefly, mice were shaved prior to the scanning 
procedure in order to reduce scattering of the signal from fur. Throughout all imaging 
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sessions, mice were anesthetized with vaporized isoflurane at 1.8-2.0 volume % (Sigma). 
The anesthetized mice were placed inside the acquisition system and gently fixed on a 
heated block (37°C) for the entire duration of data acquisition. Two-dimensional regions of 
interest (ROIs) were selected, and laser power, integration time (repetition time of the 
excitation per raster point) and scan step size were optimized according to the emitted 
signal. Prior to injection of the contrast agent (either m-NIR-SNPs or m-NIR-SNPs-labeled 
cells), mice were scanned to obtain background images. The background signal intensity, 
recorded with the baseline image for each animal, was subtracted from each post injection 
image. For ex vivo optical imaging, the last in vivo whole-body imaging session was 
followed by euthanasia of animals. The organs were explanted and imaged with the same 
Optix system. For each explanted organ, the average fluorescence intensity was 
calculated within a region of interest covering the whole sample and subtracted by the 
average fluorescence intensity within a region of the same area in the corresponding 
explanted organ of a control mouse (uninjected mouse). For selected mice, explanted 
organs were snap-frozen in isopentane and cooled at -80°C for tissue analysis.  
Optical imaging results were analyzed by reporting fluorescence intensity values in 
normalized counts (NC) representing the photon count for unit excitation laser power and 
unit exposure time, allowing comparison among different images. Fluorescence lifetime 
results were obtained by fitting every fluorescence decay curve corresponding to each 
pixel measured by Optix using the Levenberg Marquet least squares method.17 
 
8.1.14 Tissue analysis  
For fluorescence microscopy, sections of 7- and 12-µm thickness were cut from frozen 
organs with a cryostat at -20°C. Glass slides were kept at 4°C at dark and Vectashield 
Mounting Medium with DAPI (Vector Laboratories, Burlingame, CA), diluted 1:1 with PBS, 
was used to stain cell nuclei. Fluorescent images were acquired by using an inverted 
microscope with a CCD camera (DVC-1412AM monochrome digital camera QE > 62% at 
550nm) and the objectives lens 10x, 40x and 63x (NA 1.63) immersion oil.  
For histological analysis, 5 µm thick sections were cut from paraffin blocks and stained 
with haematoxylin-eosin. Immunohistochemistry was performed by using the primary Ab 
for human CD20 (clone L26; NovocastraTM; Leica Biosystems Newcastle Ltd, Newcastle 
Upon Tyne, UK), associated to the NovoLinkTM Polymer Detection System (Novocastra), 
which was used for the visualization of the primary Ab, following manufacturer’s 
instruction. After staining, the slides were examined under a Leica DM2000 optical 
microscope and microphotographs were taken using a Leica DFC320 digital camera. 
 
8.1.15 Statistical analysis  
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Results from at least three independent experiments are reported as the means ± SD and 
analyzed for statistical significance by the two-tail Student's t-test and Mann-Witney rank-
sum test. Differences were considered significant when p value was < 0.05. 
 
8.1.16 Photoacoustic measurements 
In vitro photoacoustic experiments were carried out by Vevo LZ250 transducer (Vevo® 
LAZR Photoacoustic Imaging System). Axial resolution: 75 µm. Broadband frequency: 13 
MHz-24 MHz.  
 
8.2 Synthesis and characterization of dyes 
8.2.1 Cy 7 derivative  
 
Figure 8.1 Schematization of the synthesis of the triethoxysilane derivative of Cy 7 dye 
(Cy7-Si) 
 
2-[2-[2-Thio-[3-(triethoxysilyl)propyl]-3-[2-(1,3-dihydro-1,1,3-trimethyl-2H-benzo[e]-indol-2-
ylidene)-ethylidene]-1-cyclohexen-1-yl]-ethenyl]-1,1,3-trimethyl-1H-benzo[e]indolium 
perchlorate Cy7-Si: this compound was synthesized adapting reported procedures.18 In a 
flamed 25 mL round bottom flask dried under vacuum, to a solution of 2-[2-[2-Chloro-3-[2-
(1,3-dihydro-1,1,3-trimethyl-2H-benzo[e]-indol-2-ylidene)-ethylidene]-1-cyclohexen-1-yl]-
ethenyl]-1,1,3-trimethyl-1H-benzo[e]indolium perchlorate (IR-813 perchlorate, 0.064 g, 94 
µmol) in DMF (6 mL) was added N,N-Diisopropylethylamine (DIPEA, 20 µL, 113 µmol) and 
(3-Mercaptopropyl)triethoxysilane (1) (68 µL, 282 µmol) and the reaction mixture was 
stirred at room temperature for 72 h. The reaction mixture was then diluted with Brine and 
extracted three times with DCM. The combined organic phases are dried over Sodium 
sulfate, concentrated with the rotary evaporator and desiccated in vacuum, affording a 
green solid substance. Purification was carried out by silica gel chromatography eluting 
with EtOAc/MeOH (9:1-1:9) to give the compound Cy7-Si as a dark green solid (0.053 g, 
yield 64 %). 
• Chemical formula: C49H61ClN2O7SSi; 
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• Molecular Weight: 885.6; 
• 
1H-NMR (400 MHz, CDCl3, 25°C): δ = 8.91 (2H, d, J = 16 Hz, CH), 8.11 (2H, d, J = 
8 Hz, ar. CH), 7.93 (4H, d, J = 8 Hz, ar. CH), 7.47-7.43 (2H, m, ar. CH), 7.41 (2H, d, 
J = 8 Hz, ar. CH), 6.23 (2H, d, J = 12 Hz, CH), 3.77 (6H, q, J = 6.7 Hz, -OCH2CH3), 
3.77 (6H, s, N-CH3) overlapped, 2.83 (2H, t, J = 8 Hz, -SCH2-), 2.68 (4H, t, J = 8 Hz, 
-CH2CH2CH2-), 2.03 (12H, s, -CH3), 1.96-1.92 (2H, m, -SCH2CH2CH2-), 1.81-1.74 
(2H, q, -CH2CH2CH2-), 1.17 (9H, t, J = 6 Hz, -OCH2CH3), 0.75-0.70 (2H, m, -
CH2CH2CH2Si); 
• 
13C-NMR (100 MHz, CDCl3, 25°C): δ = 139.8, 139.2, 135.7, 132.5, 131.5, 128.1, 
125.6, 124.9, 124.5, 123.1, 105.0, 70.0, 64.5, 57.4, 30.7, 29.3, 27.14, 27.13, 27.0, 
17.6, 7.9; 
• ESI-MS: m/z calculated for C49H61N2O3SSi+ is 785.4; obs: 786.4. 
 
8.2.2 Cy 5.5 derivative 
 
 
Figure 8.2 Schematization of the synthesis of (Cy5.5-Si). 
 
3-propyl-1,1,2-trimethyl-1H-benz[e]indolium iodide salt 2: this compound was synthesized 
adapting reported procedures.19 In a 100 mL flamed round bottom flask dried under 
vacuum, to a solution of 1,1,2-Trimethylbenz[e]indole (1) (1.0 g, 4.8 mmol) in MeCN (36 
mL) was added 1-Iodopropane (1) (702 µL, 7.2 mmol) and the reaction mixture was 
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heated under reflux for two days. After cooling down to room temperature, the reaction 
mixture was concentrated in vacuo and the resulting oil was washed several times with 
Et2O to obtain compound 2 as dark brown solid (1.34 g, yield 97 %). 
• Chemical formula: C18H22IN; 
• Molecular Weight: 379.3; 
• 
1H-NMR (400 MHz, CDCl3, 25°C): δ = 8.08 (2H, t, J = 8 Hz, ar. CH) and 8.04 (1H, d, 
J = 8 Hz, ar. CH) part. overlapped, 7.92 (1H, d, J = 8 Hz, ar. CH), 7.83 (1H, d, J = 8 
Hz, ar. CH), 7.66 (1H, t, J = 8 Hz, ar. CH), 4.80 (2H, t, J = 8 Hz, -NCH2-), 3.20 (3H, 
s, -CH3), 2.11-2.02 (2H, m, -NCH2CH2CH2), 1.87 (6H, s, -CH3), 1.11 (3H, t, J = 8 
Hz, -NCH2CH2CH3); 
• 
13C-NMR (100 MHz, CDCl3, 25°C): δ = 195.3, 189.7, 150.1, 138.5, 138.0, 136.9, 
133.5, 132.1, 131.2, 130.0, 127.3, 55.8, 55.2, 22.6, 21.6, 16.8, 11.2; 
• ESI-MS: m/z calculated for C18H22N+ is 252.2; obs: 253.2. 
 
2-[4-(N-Phenyl-N-acetylamino)1,3-pentadienyl]-1,1-dimethyl-3-propyl-1H-benz[e]indolium 
iodide salt 3: this compound was synthesized adapting reported procedures.19,20 In a 
flamed 50 mL round bottom flask dried under vacuum, a suspension of compound (2) (1.0 
g, 3.5 mmol) and malonaldehyde bis(phenylimine) monohydrochloride (7) (906 mg, 3.5 
mmol) in Acetic anhydride (17 mL) was heated at 100°C for 2 h. After cooling down to 
room temperature, the reaction mixture was poured into 190 mL Et2O. The dark brown 
precipitate 3 (1.51 g, yield 79 %) was then filtered and used in the next step without further 
purification. 
• Chemical formula: C29H31IN2O; 
• Molecular Weight: 550.5; 
• ESI-MS: m/z calculated for C29H31N2O+ is 423.2; obs: 423.2. 
 
1,1,2-Trimethyl-3-(6-carboxylatohexyl)benz[e]indolium bromide salt 4: this compound was 
synthesized adapting reported procedures.19,20 In a flamed 100 mL round bottom flask 
dried under vacuum, to a solution of compound (1) (1.0 g, 4.8 mmol) in MeCN (40 mL) was 
added 6-Bromohexanoic acid (8) (1.21 g, 6.2 mmol) and the reaction mixture was heated 
under reflux for four days. After cooling down to room temperature, the reaction mixture 
was poured into 150 mL of Et2O and kept in fridge overnight. The obtained solid was 
filtered and washed three times with diethyl ether to obtain the compound 4 as blue-green 
solid (0.522 g, yield 34 %). 
• Chemical formula: C21H26NO2+; 
• Molecular Weight: 324.4; 
• 
1H-NMR (400 MHz, CDCl3, 25°C): δ = 8.33 (1H, d, J = 8 Hz, ar. CH), 8.25 (1H, d, J 
= 8 Hz, ar. CH), 8.17 (1H, d, J = 8 Hz, ar. CH), 8.01 (1H, d, J = 8 Hz, ar. CH), 7.83-
7.79 (1H, m, ar. CH), 7.75-7.71 (1H, m, ar. CH), 4.64 (2H, t, J = 8 Hz, -NCH2-), 2.36 
(2H, t, J = 6 Hz, -CH2COOH), 2.10-2.01 (2H, m, -NCH2CH2), 1.85 (6H, s, -CH3), 
1.79-1.76 (2H, m, -CH2CH2COOH), 1.62-1.54 (2H, m, -CH2CH2CH2-); 
114 
 
• 
13C-NMR (100 MHz, CDCl3, 25°C): δ = 197.7, 175.8, 139.9, 138.9, 135.4, 132.6, 
131.2, 129.9, 129.29, 128.93, 124.57, 113.92, 57.5, 34.52, 34.41, 28.9, 27.21, 
27.16, 25.58, 25.55, 22.5;  
• ESI-MS m/z calculated for C21H26NO2+ is 324.2; obs.: 324.2. 
 
2-[7-(1,3-Dihydro-1,1-dimethyl-3-propylbenz[e]indolin-2-ylidene)-1,3,5-pentatrienyl]-1,1-
dimethyl-3-(6-carboxylatohexyl)-1H-benz[e]indolium inner salt 5: this compound was 
synthesized adapting reported procedures.19,20 In a flamed 10 mL round bottom flask 
dried under vacuum, to a solution of compound (4) (0.150 g, 0.46 mmol) in Pyridine (3 
mL) was added compound (3) (0.255 g, 0.46 mmol) and the reaction mixture was 
heated at 40°C for 30 min. After cooling down to room temperature, the reaction 
mixture was concentrated in vacuo and the residue was purified by silica gel 
chromatography eluting with DCM/MeOH (99:1-90:10) to give the compound 5 as a 
blue solid (0.147 g, yield 49 %). 
• Chemical formula: C42H46N2O2; 
• Molecular Weight: 610.8; 
• 
1H-NMR (400 MHz, CDCl3, 25°C): δ = 8.33-8.11 (4H, m, ar. CH), 7.90 (4H, d, J = 8 
Hz, ar. CH), 7.59 (2H, q, J = 6.7 Hz, ar. CH), 7.45 (2H, q, J = 6.7 Hz, ar. CH), 7.32 
(2H, t, J = 8 Hz, CH), 6.99 (1H, t, J = 12 Hz, CH), 6.54 (1H, d, J = 12 Hz, CH), 6.37 
(1H, d, J = 16 Hz, CH), 4.19 (2H, t, J = 8 Hz, -NCH2-) and 4.15 (2H, t, J = 8 Hz, -
NCH2-) par. overlapped, 2.15 (2H, t, J = 8 Hz, -CH2COOH), 2.05-2.03 (12H, d, -
CH3), 1.93-1.86 (4H, m, -NCH2CH2CH2 and -CH2CH2COOH), 1.80-1.76 (2H, m, -
NCH2CH2), 1.61-1.57 (2H, m, -CH2CH2CH2-), 1.08 (3H, t, J = 8 Hz, -NCH2CH2CH3); 
• 
13C-NMR (100 MHz, CDCl3, 25°C): δ =  202.0, 173.9, 152.2, 135.9, 130.9, 130.8, 
130.3, 129.2, 128.1, 127.0, 125.4, 125.3, 125.2, 124.5, 123.6, 122.5, 122.4, 120.1, 
110.9, 110.8, 110.6, 104.4, 103.7, 58.6, 51.4, 51.2, 46.3, 44.6, 34.1, 28.1, 26.4, 
24.3, 21.5, 15.1, 11.7;  
• ESI-MS m/z calculated for C42H47N2O2+ is 611.4; obs.: 611.2.  
 
2-[7-(1,3-Dihydro-1,1-dimethyl-3-propylbenz[e]indolin-2-ylidene)-1,3,5-pentatrienyl]-1,1-
dimethyl-3-[6-[N-(3-(triethoxysilyl)propyl]hexanamide]-1H-benz[e]indolium iodide salt 
Cy5.5-Si: this compound was synthesized adapting reported procedures.19 In a flamed 
25 mL round bottom flask dried under vacuum, to a solution of compound (5) (0.118 g, 
0.19 mmol) in DCM (12 mL) was added 1-[Bis(dimethylamino)methylene]-1H-1,2,3-
triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate (HATU) (0.087 g, 0.24 mmol), (3-
Aminopropyl)triethoxysilane (9) (0.049 mL, 0.21 mmol) and TEA (0.053 mL, 0.38 mmol) 
and the reaction mixture was stirred at room temperature for 2 h. The reaction mixture 
was concentrated in vacuo and the residue was purified by silica gel chromatography 
eluting with EtOAc/MeOH (95:5-80:20) to give the compound Cy5.5-Si as blue solid 
(0.102 g, yield 66 %). 
• Chemical formula: C51H68IN3O4Si; 
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• Molecular Weight: 942.1; 
• 
1H-NMR (400 MHz, CDCl3, 25°C): δ = 8.33-8.11 (4H, m, ar. CH), 7.90 (4H, d, J = 8 
Hz, ar. CH), 7.59 (2H, q, J = 6.7 Hz, ar. CH), 7.45 (2H, q, J = 6.7 Hz, ar. CH), 7.32 
(2H, t, J = 8 Hz, CH), 6.99 (1H, t, J = 12 Hz, CH), 6.54 (1H, d, J = 12 Hz, CH), 6.37 
(1H, d, J = 16 Hz, CH), 4.19 (2H, t, J = 8 Hz, -NCH2-) and 4.15 (2H, t, J = 8 Hz, -
NCH2-) par. overlapped, 3.77 (6H, q, J = 6.7 Hz, -OCH2CH3) - (6H, s, N-CH3) 
overlapped, 2.15 (2H, t, J = 8 Hz, -CH2COOH), 2.05-2.03 (12H, d, -CH3), 1.96-1.92 
(2H, m, -NHCH2CH2CH2-) and 1.93-1.86 (4H, m, -NCH2CH2CH2 and -
CH2CH2COOH) overlapped, 1.80-1.76 (2H, m, -NCH2CH2), 1.81-1.74 (2H, q, -
CH2CH2CH2-), 1.61-1.57 (2H, m, -CH2CH2CH2-),  1.17 (9H, t, J = 6 Hz, -OCH2CH3), 
1.08 (3H, t, J = 8 Hz, -NCH2CH2CH3), 0.75-0.70 (2H, m, -CH2CH2CH2Si); 
• 
13C-NMR (100 MHz, CDCl3, 25°C): δ = 12.1, 13.9, 18.5, 21.6, 23.5, 24.4, 25.0, 25.3, 
27.5, 27.7, 34.3, 43.1, 49.4, 49.7, 52.8, 53.3, 58.4, 104.5, 104.8, 113.7, 117.6, 
121.0, 122.0, 124.9, 125.5, 125.6, 125.8, 126.1, 126.3, 126.5,  126.9, 127.0, 128.6, 
130.4, 132.5, 132.6, 133.5, 137.4, 143.1, 148.4, 170.7, 172.8;  
• ESI-MS m/z calculated for C51H68N3O4Si+ is 814.5; obs.: 816.4. 
 
The triethoxysilane derivative of Rhodamine B, RhodB-Si, was synthesized following 
reported procedures.21 
 
8.3 Synthesis and characterization of Dasa 
 
Figure 8.3 Schematization of the synthesis of Dasa. 
 
1-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)sulfonyl)-4-((3-nitrophenyl)sulfonyl)-1,4-diazepane 
6 was synthesized adapting reported procedures.22  In a flamed 25 mL round bottom flask 
dried under vacuum, compound (4) (0.287 g, 0.697 mmol) was dissolved in DCM (4 mL) 
and cooled in an ice bath. TEA (0.810 mL, 2.93 mmol) was added followed by portionwise 
addition of 3-Nitrobenzenesulfonyl chloride (5) (0.173 g, 0.8 mmol) and the reaction 
mixture was stirred at 0°C for 1 h. The reaction was quenched with saturated aqueous 
Ammonium chloride (6 mL). The organic layer was washed twice with saturated 
116 
 
Ammonium chloride, once with Brine, dried over Sodium sulfate and concentrated in vacuo 
and the residue was purified by silica gel chromatography eluting with Cyclohexane/EtOAc 
(1:1-1:9) to give the compound 6 as a white solid (0.256 g, yield 76 %). 
• Chemical formula: C19H21N3O8S2; 
• Molecular Weight: 483.5; 
• 
1H-NMR (400 MHz, CDCl3, 25°C): δ = 8.62 (1H, s, ar. CH), 8.45 (1H, d, J = 8.0 Hz, 
ar. CH), 8.11 (1H, d, J = 7.6 Hz, ar. CH), 7.76 (1H, t, J = 8.0 Hz, ar. CH), 7.28 (1H, 
s, ar. CH), 7.24 (1H, s, ar. CH), 6.95 (1H, d, J = 8.0 Hz, ar. CH), 4.31 (4H, s, -OCH2-
), 3.35 (8H, m, -NCH2CH2-), 1.95 (2H, m, -CH2CH2CH2-); 
 
3-((4-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)sulfonyl)-1,4-diazepan-1-yl)sulfonyl)aniline 
DASA was synthesized adapting reported procedures.23 In a 50 mL flamed round bottom 
flask dried under vacuum, to a solution of compound (6) (0.256 g, 0.53 mmol) in EtOH (15 
mL) was added SnCl2 . 2H2O (0.597 g, 2.64 mmol) and the reaction mixture was heated at 
70°C for 50 min. After cooling down to room temperature, the reaction mixture was 
quenched with NaOH 0.2 M and extracted three times with DCM. The combined organic 
phases were dried over Sodium sulfate, concentrated in vacuo and the residue was 
purified by silica gel chromatography eluting with Cyclohexane/EtOAc (7:3-5:5) to give the 
compound DASA as a white solid (0.166 g, yield 69 %). 
• Chemical formula: C19H23N3O6S2; 
• Molecular Weight: 453.5; 
• 
1H-NMR (400 MHz, CDCl3, 25°C): δ = 7.43 (1H, d, J = 8.4, ar. CH), 7.37 (2H, m, ar. 
CH), 7.25 (2H, m, ar. CH), 7.19 (1H, d, J = 7.6 Hz, ar. CH), 6.95 (1H, d, J = 8.0 Hz, 
ar. CH), 4.31 (4H, s, -OCH2-), 3.96 (2H, br, -NH2), 3.37 (8H, m, -NCH2CH2-), 1.95 
(2H, m, -CH2CH2CH2-);  
• 
13C-NMR (100 MHz, CDCl3, 25°C): δ = 147.4, 147.0, 143.6, 140.0, 131.3, 130.1, 
120.5, 119.0, 117.8, 116.5, 116.4, 112.7, 64.5, 64.1, 50.9, 50.8, 47.2, 29.0; 
• ESI-MS m/z calculated for C19H23N3O6S2+ is 453.1; obs.: 454.1. 
 
tert-butyl-4-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)sulfonyl)-1,4-diazepane-1-carboxylate 3 
and 4-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)sulfonyl)-1,4-diazepan-1-ium 2,2,2-
trifluoroacetate 4 were synthesized following reported procedures.22  
 
8.4 Synthesis and characterization of BUPS 
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Figure 8.4 Schematization of the synthesis of BUPS. 
 
1,3-bis(3-(triethoxysilyl)propyl)urea BUPS: in a flamed 25 mL round bottom flask dried 
under vacuum, 3-(Triethoxysilyl)propyl isocyanate (1) (0.469 mL, 2 mmol) was dissolved in 
DCM (5 mL) and cooled in an ice bath. 3-(Aminopropyl)triethoxysilane (2) (0.457 mL, 2 
mmol) was added and the reaction mixture was stirred at 0°C for 1 h. The reaction was 
concentrated in vacuo to give the compound BUPS as a white solid (0.906 g, yield 97 %). 
• Chemical formula: C19H44N2O7Si2; 
• Molecular Weight: 468.7; 
• 
1H-NMR (400 MHz, CDCl3, 25°C): δ = 6.00 (2H, s, -NH), 3.81 (12H, dd, J = 7.2 and 
14 Hz, -OCH2), 3.17 (4H, t, J = 6.8, -NCH2-), 1.63 (4H, t, J = 7.6 Hz, -CH2CH2CH2-), 
1.24 (18H, dd, J = 7.2 and 14.0 Hz, -CH2CH3), 0.64 (4H, t, J = 7.6 Hz, -SiCH2-); 
• 
13C-NMR (100 MHz, CDCl3, 25°C): δ = 158.2, 58.4, 43.0, 23.6, 18.3, 7.6. 
• ESI-MS m/z calculated for C19H44N2O7Si2+ is 468.2; obs.: 469.1. 
 
8.5 Synthesis and characterization of DEVD 
 
Figure 8.5 Molecular structure of DEVD peptide. 
 
(3S,6S,9S,12S,15S)-3-(2-aminoacetamido)-15-carbamoyl-6-(2-carboxyethyl)-12-
(carboxymethyl)-9-isopropyl-4,7,10,13-tetraoxo-5,8,11,14-tetraazaoctadec-17-ynoic acid 
DEVD: this peptide was synthesized manually on a Rink Amide AM resin using the Fmoc-
based strategy. Solid-phase reactions were performed in polypropylene tubes equipped 
with polyethylene frits and polypropylene caps using an orbital agitator shaking device. 
The overall yields for the solid-phase syntheses were calculated based on the initial 
loading provided by the supplier (0.58 mmol/g). The initial amount of resin was 1g. Amino 
118 
 
acids were introduced protected in the following order: Fmoc-Pra-OH, Fmoc-Asp(OtBu)-
OH, Fmoc-Val-OH, Fmoc-Glu(OtBu)-OH, Fmoc-Asp(OtBu)-OH and Fmoc-Gly-OH. The 
cleavages of Fmoc protecting groups were performed in 20% piperidine/DMF (2 times for 
15 min). The completion of couplings and Fmoc cleavages was monitored with the color 
Kaiser test. Coupling reactions of Fmoc amino acids were performed for 2 h in DMF (7 mL) 
under gentle stirring using a molar ratio of amino acid/HBTU/HOBt/DIEA/resin (5:5:5:5:1). 
Boc and resin cleavage was carried out by a mixture consisting of 95% TFA:2.5% 
H2O:2.5% TIS (7 mL) for 2 h under gentle stirring. The reaction mixture was then 
concentrated in vacuo. Et2O was added (10 mL), the resulting precipitate was filtered and 
washed three times with Et2O to obtain DEVD as a transparent gel (0.280 g, yield 77 %).  
• Chemical formula: C25H37N7O12; 
• Molecular Weight: 627.6; 
• ESI-MS m/z calculated for C25H37N7O12+ is 627.2; obs.: 628.2. 
 
8.6 Synthesis and characterization of BHQ derivatives 
8.6.1 BHQ-alc 
 
 
Figure 8.6 Schematization of the synthesis of the alcoholic derivative of BHQ (BHQ-alc). 
 
2-(phenyl(prop-2-yn-1-yl)amino)ethan-1-ol 2: in a flamed 250 mL round bottom flask dried 
under vacuum, to a solution of N-(2-Hydroxyethyl)aniline (1) (5 g, 36.45 mmol) in Dimethyl 
sulfoxide (DMSO) (40 mL) was added Propargyl bromide (3) (solution 80 wt. % in toluene) 
(4.8 mL, 43.10 mmol) and Sodium bicarbonate (6.13 g, 73 mmol) and the reaction mixture 
was stirred at room temperature for 15 h. The reaction mixture was then diluted with H2O 
(40 mL) and extracted four times with EtOAc. The combinated organic phases were 
washed two times with H2O and one time with Brine, dried over Sodium sulfate and 
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concentrated in vacuo to give the title compound 2 as a yellow-brown oil (6.219 g, yield 98 
%). 
• Chemical formula: C11H13NO; 
• Molecular Weight: 175.2; 
• 
1H-NMR (400 MHz, CDCl3, 25°C): δ = 7.31 (2H, t, J = 8.2 Hz, ar. CH), 6.95 (2H, d, J 
= 8.0 Hz, ar. CH), 6.87 (1H, t, J = 7.3 Hz, ar. CH), 4.11 (2H, s, -NCH2-), 3.86 (2H, t, 
J = 5.3 Hz, -NCH2CH2-), 3.59 (2H, t, J = 5.5 Hz, -CH2CH2OH), 2.28 (1H, s, -CCH); 
• 
13C-NMR (100 MHz, CDCl3, 25°C): δ = 148.3, 129.4, 119.0, 114.8, 80.1, 72.6, 60.2, 
54.0, 41.1;  
• ESI-MS m/z calculated for C11H13NO+ is 175.1; obs.: 176.1. 
 
 
2-((4-((E)-(2,5-dimethoxy-4-((E)-(4-nitrophenyl)diazenyl)phenyl)diazenyl)phenyl)(prop-2-
yn-1-yl)amino)ethan-1-ol BHQ-alc: in a flamed 1 L round bottom flask dried under vacuum, 
the compound (2) (5.077 g, 29 mmol) was solubilized with 100 mL of 1,4-Dioxane. Fast 
Black K salt (5) (30% dye content, 20.4 g, 14.64 mmol) was solubilized in a mixture 1,4-
Dioxane/H2O (7/3, 400 mL) and added to the previous solution,  and the reaction mixture 
was stirred at room temperature for 72 h. 1,4-Dioxane was then removed in vacuo; a black 
solid was attached to the flask, and the water was discarded. The residue was purified by 
silica gel chromatography eluting with EtOAc/Heptane (5:5-9:1) to give the compound 
BHQ-alc as a purple solid (1.417 g, yield 10 %). 
• Chemical formula: C25H24N6O5; 
• Molecular Weight: 488.5; 
• 
1H-NMR (400 MHz, CDCl3, 25°C): δ = 8.39 (2H, d, J = 8.9 Hz, ar. CH), 8.06 (2H, d, 
J = 8.8 Hz, ar. CH), 7.99 (2H, d, J = 8.9 Hz, ar. CH), 7.48 (1H, s, ar. CH), 7.45 (1H, 
s, ar. CH), 6.99 (2H, d, J = 9.7 Hz, ar. CH), 4.25 (2H, s, -NCH2C-), 4.10 (3H, s, -
OCH3), 4.06 (3H, s, -OCH3), 3.95 (2H, t, J = 5.3 Hz, -NCH2CH2OH), 3.74 (2H, t, J = 
5.3 Hz, -CH2CH2OH), 2.34 (1H, s, -CCH); 
• 
13C-NMR (100 MHz, CDCl3, 25°C): δ = 156.6, 153.7, 151.3, 151.0, 148.6, 146.6, 
145.7, 142.6, 126.0, 124.9, 123.8, 113.1, 101.3, 100.3, 79.5, 73.0, 60.6, 57.0, 56.9, 
53.9, 41.3; 
• ESI-MS m/z calculated for C25H24N6O5+ is 488.2; obs.: 489.2. 
 
8.6.2 BHQ-sul 
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Figure 8.7 Schematization of the synthesis of the sulfonic derivative of BHQ (BHQ-sul). 
 
2-((4-((E)-(2,5-dimethoxy-4-((E)-(4-nitrophenyl)diazenyl)phenyl)diazenyl)phenyl)(prop-2-
yn-1-yl)amino)ethyl sulfate BHQ-sul: in a flamed 50 mL round bottom flask dried under 
vacuum, to a solution of (BHQ-alc) (0.2 g, 0.41 mmol) in DMF (15 mL) was added Sulfur 
trioxide triethylamine complex (1) (0.8 g, 4.4 mmol) and the reaction mixture was heated at 
55°C for 18 h. After cooling down to room temperature, the reaction mixture was then 
concentrated in vacuo and the residue was purified by silica gel chromatography eluting 
with DCM/MeOH (9:1-8:2) to give the compound BHQ-sul as a purple solid (0.202 g, yield 
87 %). 
• Chemical formula: C25H23N6O8S-; 
• Molecular Weight: 567.5; 
• 
1H-NMR (400 MHz, CDCl3, 25°C): δ = 8.38 (2H, d, J = 8.9 Hz, ar. CH), 8.05 (2H, d, 
J = 9.0 Hz, ar. CH), 7.95 (2H, d, J = 9.1 Hz, ar. CH), 7.51 (1H, s, ar. CH), 7.46 (1H, 
s, ar. CH), 6.96 (2H, d, J = 9.2 Hz, ar. CH), 4.34 (2H, t, J = 6.2 Hz, -CH2CH2OS-), 
4.25 (2H, s, -NCH2C-), 4.10 (3H, s, -OCH3), 4.05 (3H, s, -OCH3), 3.87 (2H, t, J = 5.3 
Hz, -NCH2CH2OS-), 2.26 (1H, s, -CCH); 
• 
13C-NMR (100 MHz, CDCl3, 25°C): δ = 156.4, 153.5, 151.0, 148.4, 146.5, 145.1, 
142.3, 132.3, 125.8, 124.7, 123.6, 112.7, 101.1, 100.2, 72.4, 64.8, 56.8, 50.5, 46.1; 
• ESI-MS m/z calculated for C25H23N6O8S+ is 567.1; obs.: 568.1. 
 
8.6.3 BHQ-PEG 
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Figure 8.8 Schematization of the synthesis of the PEGylated derivative of BHQ (BHQ-
PEG). 
 
25-chloro-2,5,8,11,14,17,20,23-octaoxapentacosane 3: in a flamed 25 mL round bottom 
flask dried under vacuum, to a solution of Octaethylene glycol monomethyl ether (1) (0.5 g, 
1.3 mmol) in Chloroform (CHCl3, 5 mL) was added Pyridine (0.105 mL, 1.3 mmol) and 
Thionyl chloride (2) (0.142 mL, 1.95 mmol) and the reaction mixture was heated at 60°C 
for 1 h. After cooling down to room temperature, the reaction mixture was then 
concentrated in vacuo to give the compound 3 as a yellow oil (0.445 g, yield 85 %). 
• Chemical formula: C17H35ClO8; 
• Molecular Weight: 402.9; 
• 
1H-NMR (400 MHz, CDCl3, 25°C): δ = 3.76 (2H, t, J = 6.0 Hz, -CH2Cl), 3.69-3.64 
(28H, m, -OCH2CH2O-), 3.55 (2H, t, J = 4.9 Hz, -CH2CH2Cl), 3.38 (3H, s, -OCH3); 
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• 
13C-NMR (100 MHz, CDCl3, 25°C): δ = 71.7, 71.1, 70.4, 70.3, 70.2, 58.8, 42.6;  
• ESI-MS m/z calculated for C17H35ClO8+ is 402.2; obs.:403.2. 
 
25-azido-2,5,8,11,14,17,20,23-octaoxapentacosane 4: in a flamed 25 mL round bottom 
flask dried under vacuum, to a solution of (3) (0.969 g, 2.4 mmol) in DMF (9.5 mL) was 
added Sodium azide (7) (0.313 g, 4.8 mmol) and the reaction mixture was heated at 80°C 
for 18 h. After cooling down to room temperature, the reaction mixture was then 
concentrated in vacuo and the obtained residue was redisperded with 5 mL of H2O and 
extracted four times with DCM. The combinated organic phases were dried over Sodium 
sulfate and concentrated in vacuo to give the compound 4 as a yellow oil (0.908 g, yield 93 
%). 
• Chemical formula: C17H35N3O8; 
• Molecular Weight: 409.5; 
• 
1H-NMR (400 MHz, CDCl3, 25°C): δ = 3.66 (30H, t, J = 2.8 Hz, -OCH2CH2O-), 3.55 
(2H, t, J = 4.3 Hz, -CH2N3), 3.38 (3H, s, -OCH3); 
• 
13C-NMR (100 MHz, CDCl3, 25°C): δ = 71.2, 70.6, 69.9, 69.8, 69.7, 69.3, 56.2, 49.9, 
42.1;  
• ESI-MS m/z calculated for C17H35N3O8+ is 409.2; obs.:427.3 (M+NH4)+. 
 
2-(((1-(2,5,8,11,14,17,20,23-octaoxapentacosan-25-yl)-1H-1,2,3-triazol-4-yl)methyl)(4-
((E)-(2,5-dimethoxy-4-((E)-(4-
nitrophenyl)diazenyl)phenyl)diazenyl)phenyl)amino)ethan-1-ol BHQ-alc-PEG: in a 
flamed 250 mL round bottom flask dried under vacuum, (BHQ-alc) (0.709 g, 1.45 
mmol) and the compound (4) (0.714 g, 1.74 mmol) were solubilized with 65 mL of 1,4-
Dioxane. Copper(II) sulfate pentahydrate (0.181 g, 0.73 mmol) and Sodium ascorbate 
(0.201 mg, 1.02 mmol) were solubilized with 3 mL of H2O and added to the previous 
solution, and the reaction mixture was stirred at room temperature for 30 min. The 
reaction mixture was then concentrated in vacuo and the residue was purified by silica 
gel chromatography eluting with DCM/MeOH (9:1) to give the compound BHQ-alc-
PEG as a purple solid (0.975 g, yield 75 %). 
• Chemical formula: C42H59N9O13; 
• Molecular Weight: 898.0; 
• 
1H-NMR (400 MHz, CDCl3, 25°C): δ = 8.36 (2H, d, J = 9.0 Hz, ar. CH), 8.03 (2H, d, 
J = 9.1 Hz, ar. CH), 7.89 (2H, d, J = 9.0 Hz, ar. CH) - 7.87 (1H, s, -NCH) 
overlapped, 7.47 (1H, s, ar. CH), 7.43 (1H, s, ar. CH) 6.92 (2H, d, J = 7.4 Hz, ar. 
CH), 4.82 (2H, s, -NCH2C-), 4.52 (2H, t, J = 5.0 Hz, -NCH2CH2O-), 4.06 (3H, s, -
OCH3), 4.02 (3H, s, -OCH3), 3.95 (2H, t, J = 4.6 Hz, -NCH2CH2OH), 3.83 (2H, t, J = 
4.8 Hz, -CH2CH2OH), 3.64-3.60 (30H, m, -OCH2CH2O-), 3.35 (3H, s, -CH2OCH3); 
• 
13C-NMR (100 MHz, CDCl3, 25°C): δ = 156.6, 153.7, 151.2, 151.1, 148.6, 146.8, 
145.1, 145.0, 142.4, 126.0, 124.9, 123.7, 123.6, 112.4, 101.2, 100.3, 72.1, 71.5, 
70.8, 70.7, 69.5, 60.7, 59.2, 57.0, 55.8, 50.7, 47.7, 42.9;  
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• ESI-MS m/z calculated for C42H59N9O13+ is 897.4; obs.:898.4. 
 
2-(((1-(2,5,8,11,14,17,20,23-octaoxapentacosan-25-yl)-1H-1,2,3-triazol-4-yl)methyl)(4-((E)-
(2,5-dimethoxy-4-((E)-(4-nitrophenyl)diazenyl)phenyl)diazenyl)phenyl)amino)ethyl (4-
nitrophenyl) carbonate BHQ-car: in a flamed 100 mL round bottom flask dried under 
vacuum, (BHQ-alc-PEG) (0.975 g, 1.09 mmol), Pyridine (0.264 mL, 3.27 mmol) and 4-
Nitrophenyl chloroformate (5) (0.659 g, 3.27 mmol) were solubilized with 36 mL of DCM 
and the reaction mixture was stirred at room temperature for 18 h. The reaction mixture 
was then concentrated in vacuo and the residue was purified by silica gel chromatography 
eluting with EtOAc/Acetone (1:1) to give the compound BHQ-car as a purple oil (0.819 g, 
yield 71 %). 
• Chemical formula: C49H62N10O17; 
• Molecular Weight: 1063.1; 
• 
1H-NMR (400 MHz, CDCl3, 25°C): δ = 8.36 (2H, d, J = 9.1 Hz, ar. CH), 8.25 (2H, d, 
J = 9.1 Hz, ar. CH), 8.03 (2H, d, J = 9.0 Hz, ar. CH), 7.94 (2H, d, J = 8.8 Hz, ar. 
CH), 7.69 (1H, s, -NCH), 7.51 (1H, s, ar. CH), 7.51 (1H, s, ar. CH), 7.33 (2H, d, J = 
9.2 Hz, ar. CH), 6.98 (2H, d, J = 8.9 Hz, ar. CH), 4.85 (2H, s, -NCH2C-), 4.58 (2H, t, 
J = 5.6 Hz, -OCH2CH2N-), 4.53 (2H, t, J = 4.9 Hz, -NCH2CH2O-), 4.10 (3H, s, -
OCH3), 4.06 (3H, s, -OCH3), 4.0 (2H, t, J = 5.1 Hz, -NCH2CH2O-), 3.65-3.54 (30H, 
m, -OCH2CH2O-), 3.38 (3H, s, -CH2OCH3); 
• 
13C-NMR (100 MHz, CDCl3, 25°C): δ = 158.0, 156.1, 153.4, 150.9, 151.0, 148.4, 
148.1, 146.3, 145.7, 145.5, 144.4, 142.9, 126.2, 125.2, 125.1, 124.4, 123.1, 123.0, 
122.3, 121.9, 110.4, 101.8, 101.2, 71.4, 70.6, 69.6, 66.3, 59.1, 56.8, 50.7, 49.4, 
48.8, 42.9, 29.7;  
• ESI-MS m/z calculated for C49H62N10O17+ is 1062.4; obs.:1063.4. 
 
2-(((1-(2,5,8,11,14,17,20,23-octaoxapentacosan-25-yl)-1H-1,2,3-triazol-4-yl)methyl)(4-((E)-
(2,5-dimethoxy-4-((E)-(4-nitrophenyl)diazenyl)phenyl)diazenyl)phenyl)amino)ethyl prop-2-
yn-1-ylcarbamate BHQ-PEG: in a flamed 25 mL round bottom flask dried under vacuum, 
to a solution of (BHQ-car) (0.1 g, 0.094 mmol) in DMF (5 mL) was added DIEA (0.065 mL, 
0.376 mmol) and Propargylamine (6) (0.024 mL, 0.376 mmol) and the reaction mixture 
was stirred at room temperature for 18 h. The reaction mixture was then diluted with H2O 
(5 mL) and extracted three times with DCM. The combinated organic phases were washed 
three times with a saturated solution of Sodium bicarbonate, dried over Sodium sulfate and 
concentrated in vacuo to give the compound BHQ-PEG as a purple oil (0.074 g, yield 81 
%). 
• Chemical formula: C46H62N10O14; 
• Molecular Weight: 979.1; 
• 
1H-NMR (400 MHz, CDCl3, 25°C): δ = 8.39 (2H, d, J = 9.1 Hz, ar. CH), 8.06 (2H, d, 
J = 9.0 Hz, ar. CH), 7.93 (2H, d, J = 9.1 Hz, ar. CH), 7.62 (1H, s, -NCH), 7.50 (1H, 
s, ar. CH), 7.45 (1H, s, ar. CH), 6.91 (2H, d, J = 8.9 Hz, ar. CH), 4.81 (2H, s, -
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NCH2C-), 4.52 (2H, t, J = 4.8 Hz, -OCH2CH2N-), 4.36 (2H, t, J = 5.2 Hz, -
NCH2CH2O-), 4.10 (3H, s, -OCH3), 4.05 (3H, s, -OCH3), 3.97 (2H, t, J = 5.2 Hz, -
NCH2CH2O-), 3.86 (2H, s, NHCH2C-), 3.65-3.53 (30H, m, -OCH2CH2O-) + (1H, s, 
CCH) overlapped, 3.38 (3H, s, -CH2OCH3); 
• 
13C-NMR (100 MHz, CDCl3, 25°C): δ = 156.4, 155.8, 153.5, 151.1, 150.9, 148.4, 
146.4, 145.1, 144.5, 142.3, 126.0, 124.7, 123.5, 123.1, 112.2, 101.0, 100.1, 79.8, 
71.9, 71.7, 71.4, 70.7, 70.6, 70.5, 70.4, 69.4, 62.4, 59.0, 56.8, 50.3, 47.3, 42.7, 
30.8, 29.7;  
• ESI-MS m/z calculated for C46H62N10O14+ is 978.4; obs.: 979.4. 
 
8.6.4 GDP-BHQ-PEG 
 
Figure 8.9 Schematization of the synthesis of the GDO-BHQ-PEG derivative. 
(11S,14S,17S,20S)-1-(1-(2,5,8,11,14,17,20,23-octaoxapentacosan-25-yl)-1H-1,2,3-triazol-
4-yl)-20-(((S)-1-amino-1-oxopent-4-yn-2-yl)carbamoyl)-14-(2-carboxyethyl)-11-
(carboxymethyl)-2-(4-((E)-(2,5-dimethoxy-4-((E)-(4-
nitrophenyl)diazenyl)phenyl)diazenyl)phenyl)-17-isopropyl-6,9,12,15,18-pentaoxo-5-oxa-
2,7,10,13,16,19-hexaazadocosan-22-oic acid GDP-BHQ-PEG: in a flamed 25 mL round 
bottom flask dried under vacuum, to a solution of (BHQ-car) (0.531 g, 0.5 mmol) in DMF 
(5 mL) was added DIEA (0.017 mL, 0.1 mmol) and (DEVD) (6) (0.024 mL, 0.376 mmol) 
and the reaction mixture was stirred at room temperature for 16 h. The reaction mixture 
was then concentrated in vacuo and the residue was purified by semi-preparative HPLC 
chromatography eluted with solvent B in solvent A: 20% for 5 min, then from 20% to 60% 
in 25 min to give the compound BHQ-PEG as a purple solid (0.066 g, yield 39 %). Solvent 
B (0.1% TFA in MeCN, v/v); solvent A (0.1% TFA in H2O, v/v). 
• Chemical formula: C68H94N16O26; 
• Molecular Weight: 1551.6; 
• ESI-MS m/z calculated for C68H94N16O26+ is 1550.6; obs.: 1551.6. 
 
8.7 Synthesis and characterization of F127 derivatives 
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8.7.1 F127-amino 
 
Figure 8.10 Schematization of the synthesis of F127-amino. 
Pluronic F127 N-disuccinimydil carbonate F127-carbonate was synthesized adapting 
reported procedures.24 A toluene solution of Pluronic F127 (4.01 g, 0.32 mmol, 1.0 eq, 100 
mL) was distilled under reduced pressure at 50-60°C in a 250 mL round bottom flask. The 
residue was dried under vacuum and finally solubilized with 15 mL of dry THF. N,N’- 
disuccinimidyl carbonate (2) (0.80 g, 3.1 mmol), solubilized in 7.0 mL of acetone was 
added. DMAP (0.41 g, 3.32 mmol) was then slowly added at room temperature under 
stirring by a dropping funnel. After 12 hours, F127-carbonate was precipitated with Et2O 
and recovered by centrifugation (25 minutes, 5000 rpm). The precipitate was resuspended 
and centrifugated several times with acetone (20 mL), until no trace of the excess reagent 
(TLC, chloroform-methanol 5:1) was present. The product was finally dried under vacuum 
and directly used for amine functionalization. 
 
Pluronic F127-di-yl bis ((6-aminoesyl)carbamate) F127-amino was synthesized adapting 
reported procedures.24 In a flamed 100 mL round bottom flask dried under vacuum, 1,6-
Diaminohexane (3) (1.908 g, 16.4 mmol) was solubilized with 10 mL of dry DCM. A 10 mL 
DCM solution of (F127-carbonate) (2.0 g, 0.16 mmol) was then slowly added under 
stirring at room temperature. After 3 hours the reaction mixture was distilled under reduced 
pressure and the residue was solubilized with 20 mL of water. The resulting solution was 
dialyzed vs. Milli-Q water (regenerated cellulose, 12 KDa) for about 20 h under gentle 
stirring. The dialyzed solution was evaporated under reduced pressure and finally dried 
under vacuum, obtaining 0.84 g of white solid (yield 42%). 
• 
1H-NMR (300 MHz, CDCl3, 25°C): δ = 8.21 (2H, s, -NHCO-), 5.09 (4H, s, -NH2), 
4.14 (4H, s, -CH2OCO-), 3.76-3.75 (4H, m, -CH2CH2OH), 3.58 (s, -OCH2CH2O-) +  
3.51-3.42 (m, -OCH2CCH3) + 3.33 (m, -OCH2CHCH3) ~1000H, 3.09 (4H, s, -
CH2NH2), 1.45 (8H, s, -NHCH2CH2CH2CH2CH2CH2NH2), 1.25−1.24 (8H, s, -
NHCH2CH2CH2CH2CH2CH2NH2), 1.08 (s, -OCH2CHCH3) ~195H; 
• 
13C-NMR (100 MHz, CDCl3, 25°C): δ = 75.7, 75.6, 75.4, 75.3, 73.6, 73.5, 72.2-73.0 
(m), 70.0, 17.7, 17.5. 
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The dicarboxylic acid derivative of Pluronic F127 F127-carbo was synthesized following 
reported procedures.25 
 
8.7.2 F127-SS-azide 
 
Figure 8.11 Schematization of the synthesis of F127-SS-azide. 
 
3-azidopropyl (2-((2-aminoethyl)disulfanyl)ethyl)carbamate 5 was syntyesized adapting 
reported procedures.26,27 Cystamine dihydrochloride was neutralized by 4 M NaOH and 
extracted  three times with DCM to yield cystamine (4). In a flamed 50 mL round bottom 
flask dried under vacuum, to a solution of (4) (1.267 g, 8.3 mmol) in DCM (20 mL) was 
added 3-azidopropyl 1H-imidazole-1-carboxylate (3) and the reaction mixture was stirred 
at room temperature for 24 h. The reaction mixture was concentrated in vacuo, and the 
residue was treated with NaH2PO4 (50 mL, 1.0 M) and extracted three times with Et2O. 
The reaction mixture was then concentrated in vacuo to give the compound 5 as a yellow 
solid (0.412 g, yield 22 %). 
• Chemical formula: C8H17N5O2S2; 
• Molecular Weight: 279.4; 
• 
1H-NMR (400 MHz, CDCl3, 25°C): δ = 4.14 (2H, t, J = 6.0 Hz, -OCH2CH2-), 3.52-
3.47 (2H, m, CH2N3), 3.36 (2H, t, J = 6.6 Hz, -OCNHCH2-), 3.01 (2H, t, J = 6.2 Hz, -
CH2NH2), 2.78-2.74 (4H, m, -CH2SSCH2-), 1.90-1.84 (2H, m, -CH2CH2CH2-); 
• 
13C-NMR (100 MHz, CDCl3, 25°C): δ = 156.4, 134.9, 121.4, 61.4, 47.7, 41.1, 41.0, 
39.7, 39.5, 37.5, 28.1; 
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• ESI-MS m/z calculated for C8H17N5O2S2+ is 279.1; obs.: 280.1. 
 
• Dicarbamate derivative of Pluronic F127 7: in a flamed 100 mL round bottom flask 
dried under vacuum, (F127) (6.3 g, 0.5 mmol), Pyridine (0.242 mL, 3 mmol) and 4-
Nitrophenyl chloroformate (6) (0.605 g, 3 mmol) were solubilized with 30 mL of 
DCM and the reaction mixture was stirred at room temperature for 18 h. The 
reaction mixture was then concentrated in vacuo, then the residue was redispersed 
with HCl 0.1 M and extracted five times with DCM. The combined organic phases 
were dried over Sodium sulfate, concentrated in vacuo to give the compound 7 as a 
white solid (5.85 g, yield 91 %). 
• 
1H-NMR (400 MHz, CDCl3, 25°C): δ = 8.25 (2H, d, J = 9.1 Hz, ar. CH), 8.06 (2H, d, 
J = 9.1 Hz, ar. CH), 7.36 (2H, d, J = 9.2 Hz, ar. CH), 6.88 (2H, d, J = 9.1 Hz, ar. 
CH), 4.42-4.39 (4H, m, -CH2COO-), 3.79-3.77 (4H, m, -CH2CH2COO-), 3.63-3.59 (-
OCH2CH2O-) + 3.57-3.49 (m, -OCH2CH-) + 3.41-3.39 (m, -CHCH3) ~1000H, 1.12-
1.09 (~195H, m, -CHCH3); 
• 
13C-NMR (100 MHz, CDCl3, 25°C): δ = 166.2, 155.5, 152.4, 145.3, 139.1, 126.2, 
125.2, 121.8, 116.3, 75.5, 75.3, 75.1, 73.3, 72.9, 70.5, 68.5, 68.3, 17.4, 17.3. 
 
 
• Disulfide-azide derivative of Pluronic F127 F127-SS-azide: in a flamed 100 mL 
round bottom flask dried under vacuum, compound (7) (1.75 g, 0.135 mmol), DIPEA 
(0.092 mL, 0.54 mmol) and compound (5) (0.151 g, 0.54 mmol) were solubilized 
with 20 mL of MeCN and the reaction mixture was stirred at room temperature for 
18 h. The reaction mixture was concentrated in vacuo, then the residue was 
redispersed with water and purification was carried out by means of dialysis against 
water (72 h) to give the compound F127-SS-azide as a yellow solid (1.075 g, yield 
61 %). 
• 
1H-NMR (400 MHz, CDCl3, 25°C): δ = 4.24-4.12 (8H, m, -CH2OOCNH-), 3.80 (4H, t, 
J = 4.3 Hz, -NHCOOCH2CH2O-), 3.63-3.61 (m, (-OCH2CH2O-) + 3.57-3.46 (m, -
OCH2CH-) + 3.52-3.47 (4H, m, CH2N3) + 3.41-3.35 (m, -CHCH3) + 3.36 (8H, m, -
OCNHCH2-) ~1000H, 2.80 (8H, t, J = 6.0 Hz, -CH2SSCH2-), 1.93-1.86 (4H, m, -
CH2CH2CH2N3), 1.13-1.10 (~195H, m, -CHCH3) ; 
• 
13C-NMR (100 MHz, CDCl3, 25°C): δ = 156.3, 155.4, 75.4, 75.2, 75.0, 73.2, 72.8, 
72.7, 70.7, 69.5, 69.4, 68.5, 68.2, 61.7, 48.1, 39.7, 39.6, 38.0, 17.3, 17.2.  
 
Diazidic derivative of Pluronic F127) F127-azide was synthesized following reported 
procedures (see Section 6.2.2).28 
3-azidopropyl 1H-imidazole-1-carboxylate 3 was synthesized following reported 
procedures.26 
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8.8 Synthesis and characterization of F127-BHQ derivatives 
8.8.1 F127-SS-BHQ derivatives 
 
Figure 8.12 Schematization of the general procedure for F127-BHQ derivatives. 
 
General procedure: in a flamed 20 mL round bottom flask dried under vacuum, (F127-SS-
azide) (1 eq., 0.012 mmol) was solubilized with 3 mL of Dioxane. Copper(II) sulfate 
pentahydrate (5 eq.) and Sodium ascorbate (7 eq.) were solubilized with 1 mL of H2O and 
added to the previous solution, and the reaction mixture was stirred at room temperature 
for 8 h. The reaction mixture was concentrated in vacuo, then the residue was purificated 
by means of Size-exclusion chromatography (LH-20) eluting with DCM/MeOH (1:1) to 
obtain the desired compound. 
 
 
Figure 8.13 Molecular structure of F127-SS-BHQ-alc. 
Di-BHQ-alcohol derivative of F127 F127-SS-BHQ-alc (yield 68 %). 
• 
1H-NMR (400 MHz, CDCl3, 25°C): δ = 8.37 (4H, d, J = 8.9 Hz, ar. CH), 8.04 (4H, d, 
J = 8.9 Hz, ar. CH), 7.87 (4H, d, J = 8.9 Hz, ar. CH), 7.61 (2H, s, -CCH-), 7.48 (2H, 
s, ar. CH), 7.42 (2H, s, ar. CH), 6.82 (4H, d, J = 8.9 Hz, ar. CH), 4.81 (4H, s, -
NCH2C-), 4.34 (4H, t, J = 6.0 Hz, -NCH2CH2CH2-), 4.22-4.18 (8H, m, -CH2OOCNH-
), 4.07 (6H, s, -OCH3-), 4.03 (6H, s, -OCH3-), 3.96-3.94 (4H, m, -NCH2CH2OH), 
3.82-3.80 (4H, m, -NCH2CH2OH) + (4H, m, -NHCOOCH2CH2O-) overlapped, 3.64-
3.62 (m, -CH2OCH2-) + 3.57-3.49 (m, -OCH2CH-) + 3.41-3.39 (m, -CHCH3) + 3.36 
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(8H, m, -OCNHCH2-) ~1000H, 2.83 (8H, t, J = 6.3 Hz, -CH2SSCH2-), 2.17-2.16 (4H, 
m, -NCH2CH2CH2O-), 1.14-1.12 (~195H, m, -CHCH3) ; 
• 
13C-NMR (100 MHz, CDCl3, 25°C): δ = 177.3, 168.1, 164.4, 158.0, 156.3, 156.2, 
151.8, 146.6, 143.3, 125.9, 125.8, 125.7, 125.6, 123.5, 123.4, 112.9, 112.0, 100.9, 
97.2, 73.2, 72.8, 72.7, 70.4, 685, 68.4, 68.1, 63.9, 63.5, 61.5, 56.7, 39.7, 38.0, 17.3, 
17.2.  
 
 
Figure 8.14 Molecular structure of F127-SS-BHQ-sul. For clarity, only molecular structure 
of F127-SS-BHQ-sul and F127-SS-BHQ-alc are shown.  
 
 Di-BHQ-sulfonate derivative of Pluronic F127  F127-SS-BHQ-sul (yield 68 %) 
• 
1H-NMR (400 MHz, CDCl3, 25°C): δ = 8.40 (4H, d, J = 8.4 Hz, ar. CH), 8.04 (4H, d, 
J = 8.8 Hz, ar. CH), 7.86 (4H, d, J = 7.6 Hz, ar. CH), 7.49-7.43 (2H, s, -CCH-) + (2H, 
s, ar. CH) + (2H, s, ar. CH) overlapped, 6.93 (4H, d, J = 8.4 Hz, ar. CH), 4.84 (4H, 
s, -NCH2C-), 4.45-4.40 (4H, m, -CH2OS-), 4.35-4.30 (4H, m, -NCH2CH2CH2-), 4.24-
4.19 (8H, m, -CH2OOCNH-), 4.08 (6H, s, -OCH3-), 4.03 (6H, s, -OCH3-), 3.96-3.91 
(4H, m, -NCH2CH2OS), 3.83-3.79 (4H, m, -NHCOOCH2CH2O-), 3.64-3.62 (m, -
CH2OCH2-) + 3.57-3.49 (m, -OCH2CH-) + 3.41-3.39 (m, -CHCH3) + 3.36 (8H, m, -
OCNHCH2-) ~1000H, 2.89-2.79 (8H, m -CH2SSCH2-), 2.18-2.16 (4H, m, -
NCH2CH2CH2O-) 1.15-1.12 (~195H, m, -CHCH3); 
• 
13C-NMR (100 MHz, CDCl3, 25°C): δ = 169.4, 168.9, 166.9, 157.2, 156.5, 154.5, 
153.6, 148.6, 146.7, 142.8, 140.5, 132.4, 126.5, 126.1, 125.9, 124.8, 123.5, 121.6, 
100.2, 82.3, 81.6, 75.5, 75.5, 75.1, 73.3, 72.9, 72.8, 70.8, 63.6, 61.5, 56.8, 40.8, 
39.8, 17.4, 17.3.  
 
 Di-BHQ-PEG derivative of F127 F127-SS-BHQ-PEG (yield 87 %) 
• 
1H-NMR (400 MHz, CDCl3, 25°C): δ = 8.38 (4H, d, J = 8.9 Hz, ar. CH), 8.06 (4H, d, 
J = 8.8 Hz, ar. CH), 7.93-7.90 (4H, m, ar. CH), 7.70-7.61 (4H, s, -CCH-), 7.50 (2H, 
s, ar. CH), 7.45 (2H, s, ar. CH), 6.90 (4H, d, J = 8.7 Hz, ar. CH), 4.81-4.79 (4H, s, -
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NCH2C-), 4.54-4.48 (8H, m, -NNNCH2-), 4.46-4.31 (12H, m, -CH2OOCNH-), 4.10 
(6H, s, -OCH3-), 4.04 (6H, s, -OCH3-), 3.98-3.94 (4H, m, -NCH2CH2O-), 3.88-3.81 
(4H, m, -OOCNHCH2C-) + (4H, m, -NHCOOCH2CH2O-), 3.65-3.54 (30H, m, -
OCH2CH2O-), 3.64-3.62 (m, -CH2OCH2-) + 3.57-3.49 (m, -OCH2CH-) + 3.41-3.39 
(m, -CHCH3) + 3.36 (8H, m, -OCNHCH2-) ~1000H, 3.04-2.97 (8H, m -CH2SSCH2-), 
2.29-2.28 (4H, m, -NCH2CH2CH2O-), 1.16-1.13 (~195H, m, -CHCH3); 
• 
13C-NMR (100 MHz, CDCl3, 25°C): δ = 169.9, 156.1, 153.3, 150.9, 150.8, 150.7, 
148.2, 146.2, 144.9, 142.1, 125.8, 124.5, 123.6, 123.0, 122.9, 112.0, 104.9, 101.1, 
100.8, 100.0, 75.3, 75.2, 74.9, 73.1, 2.8, 72.4, 71.7, 70.3, 61.4, 58.8, 56.6, 50.1, 
29.5, 17.2, 17.1. 
 
8.8.2 F127-D-BHQ-PEG 
 
Figure 8.15 Schematization of the synthesis of F127-D-BHQ-PEG 
 
Di-BHQ-Pegylated DEVD derivative of F127 F127-D-BHQ-PEG (yield 52 %). Synthetic 
procedure and purification identical to the previous case, with DMF in place of 
Dioxane/Water.  
 
8.9 Nanoparticles synthesis 
The preparation of core-shell silica-PEG dye doped nanoparticles was obtained adapting 
existing procedures.29,30 For the preparation, 200 mg of Pluronic F127 and the desired 
amount of alkoxysilane dye(s) (or drug) were solubilized with a small amount (~1.0 mL) of 
dichloromethane in a 20 mL glass scintillation vial. The solvent was then evaporated from 
the homogeneous solution under vacuum at room temperature. NaCl (137 mg) was added 
to the solid residue and the mixture was solubilized at 25°C under magnetic stirring with 
1560 µL of acetic acid 1.0 M. TEOS (360 µL, 1.6 mmol) was then added to the resulting 
aqueous homogeneous solution followed by TMSCl (20 µL, 0.16 mmol) after 180 min. The 
mixture was kept under stirring for 48 hours at 25°C before dialysis treatments. The 
dialysis purification steps were carried out versus water on a precise amount of 
nanoparticles solution (3000 µL) finally diluted to a total volume of 10.0 mL with water (For 
the purification of nanoparticles for drug delivery, see Section 8.1. 
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